



US012390135B2

(12) **United States Patent**
Hayter et al.

(10) **Patent No.:** US 12,390,135 B2
(45) **Date of Patent:** Aug. 19, 2025

(54) **METHOD AND APPARATUS FOR PROVIDING DATA PROCESSING AND CONTROL IN A MEDICAL COMMUNICATION SYSTEM**

(71) Applicant: **ABBOTT DIABETES CARE INC.**, Alameda, CA (US)

(72) Inventors: **Gary Alan Hayter**, Oakland, CA (US); **Geoffrey V. McGarraugh**, Bodega Bay, CA (US); **Kenneth J. Doniger**, Menlo Park, CA (US)

(73) Assignee: **ABBOTT DIABETES CARE INC.**, Alameda, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 956 days.

(21) Appl. No.: **17/392,209**

(22) Filed: **Aug. 2, 2021**

(65) **Prior Publication Data**

US 2021/0361196 A1 Nov. 25, 2021

Related U.S. Application Data

(63) Continuation of application No. 15/681,345, filed on Aug. 19, 2017, now Pat. No. 11,076,785, which is a (Continued)

(51) **Int. Cl.**

A61B 5/1486 (2006.01)
A61B 5/00 (2006.01)

(Continued)

(52) **U.S. Cl.**

CPC **A61B 5/1486** (2013.01); **A61B 5/0008** (2013.01); **A61B 5/002** (2013.01); (Continued)

(58) **Field of Classification Search**

CPC A61B 5/1486; A61B 5/0008; A61B 5/002; A61B 5/0022; A61B 5/145; A61B 5/14532; A61B 5/14546; A61B 5/1473; A61B 5/7275; A61B 2560/0223; A61B 2560/0276; A61B 5/7221

See application file for complete search history.

(56)

References Cited

U.S. PATENT DOCUMENTS

3,581,062 A 5/1971 Aston
3,926,760 A 12/1975 Allen et al.
(Continued)

FOREIGN PATENT DOCUMENTS

CA 2143172 7/2005
CA 2396613 3/2008

(Continued)

OTHER PUBLICATIONS

About Dexcom—Continuous Glucose Monitoring Company, 12 pages (2021).

(Continued)

Primary Examiner — Jason M Sims


Assistant Examiner — Kyle W. Kretzer

(74) *Attorney, Agent, or Firm* — WORKMAN NYDEGGER

(57) **ABSTRACT**

Methods and apparatus for providing data processing and control for use in a medical communication system are provided.

34 Claims, 20 Drawing Sheets



Related U.S. Application Data

continuation of application No. 14/741,457, filed on Jun. 17, 2015, now Pat. No. 9,737,249, which is a continuation of application No. 14/106,000, filed on Dec. 13, 2013, now Pat. No. 9,060,719, which is a continuation of application No. 13/599,847, filed on Aug. 30, 2012, now Pat. No. 8,612,163, which is a continuation of application No. 12/152,636, filed on May 14, 2008, now Pat. No. 8,260,558.	5,051,688 A 5,055,171 A 5,068,536 A 5,082,550 A 5,106,365 A 5,122,925 A 5,135,004 A 5,165,407 A 5,202,261 A 5,204,264 A 5,210,778 A 5,228,449 A 5,231,988 A 5,243,696 A 5,246,867 A 5,251,126 A 5,262,035 A 5,262,305 A 5,264,104 A 5,264,105 A 5,279,294 A 5,285,792 A 5,293,877 A 5,299,571 A 5,320,725 A 5,322,063 A 5,330,634 A 5,340,722 A 5,342,789 A 5,356,786 A 5,360,404 A 5,372,427 A 5,379,238 A 5,384,547 A 5,390,671 A 5,391,250 A 5,408,999 A 5,410,326 A 5,411,647 A 5,425,868 A 5,429,602 A 5,431,160 A 5,431,921 A 5,438,983 A 5,462,645 A 5,472,317 A 5,489,414 A 5,497,772 A 5,505,828 A 5,507,288 A 5,509,410 A 5,514,718 A 5,531,878 A 5,532,686 A 5,552,997 A 5,555,190 A 5,564,434 A 5,568,400 A 5,568,806 A 5,569,186 A 5,582,184 A 5,586,553 A 5,593,852 A 5,601,435 A 5,609,575 A 5,628,310 A 5,634,468 A 5,653,239 A 5,660,163 A 5,665,222 A 5,707,502 A 5,711,001 A 5,711,861 A 5,724,030 A 5,726,646 A 5,733,259 A 5,735,285 A 5,748,103 A 5,749,907 A	9/1991 Murase et al. 10/1991 Peck 11/1991 Rosenthal 1/1992 Rishpon et al. 4/1992 Hernandez 6/1992 Inpyn 8/1992 Adams et al. 11/1992 Wilson et al. 4/1993 Musho et al. 4/1993 Kaminer et al. 5/1993 Massart 7/1993 Christ et al. 8/1993 Wernicke et al. 9/1993 Carr et al. 9/1993 Lakowicz et al. 10/1993 Kahn et al. 11/1993 Gregg et al. 11/1993 Heller et al. 11/1993 Gregg et al. 11/1993 Gregg et al. 1/1994 Anderson et al. 2/1994 Sjoquist et al. 3/1994 O'Hara et al. 4/1994 Mastrototaro 6/1994 Gregg et al. 6/1994 Allen et al. 7/1994 Wong et al. 8/1994 Wolfbeis et al. 8/1994 Chick et al. 10/1994 Heller et al. 11/1994 Novacek et al. 12/1994 Padovani et al. 1/1995 Stark 1/1995 Lynk et al. 2/1995 Lord et al. 2/1995 Cheney, II et al. 4/1995 Singh et al. 4/1995 Goldstein 5/1995 Johnson et al. 6/1995 Pedersen 7/1995 Hauser 7/1995 Wilkins 7/1995 Thombre 8/1995 Falcone 10/1995 Albery et al. 12/1995 Field et al. 2/1996 Schreiber et al. 3/1996 Schulman et al. 4/1996 Wong et al. 4/1996 Bocker et al. 4/1996 Hill et al. 5/1996 Lewis et al. 7/1996 Vadgama et al. 7/1996 Urbas et al. 9/1996 Massart 9/1996 Derby et al. 10/1996 Halperin et al. 10/1996 Stark et al. 10/1996 Cheney, II et al. 10/1996 Lord et al. 12/1996 Erickson et al. 12/1996 Halili et al. 1/1997 Heller et al. 2/1997 Quy 3/1997 Larson et al. 5/1997 Rao et al. 6/1997 Platt et al. 8/1997 Pompei et al. 8/1997 Schulman et al. 9/1997 Heller et al. 1/1998 McCaffrey et al. 1/1998 Bussan et al. 1/1998 Ward et al. 3/1998 Urbas et al. 3/1998 Bane et al. 3/1998 Valcke et al. 4/1998 Albert et al. 5/1998 Flach et al. 5/1998 Mann
(60) Provisional application No. 60/917,889, filed on May 14, 2007.		
(51) Int. Cl.		
<i>A61B 5/145</i> (2006.01)		
<i>A61B 5/1473</i> (2006.01)		
<i>G16H 40/63</i> (2018.01)		
<i>G16H 15/00</i> (2018.01)		
(52) U.S. Cl.		
CPC <i>A61B 5/0022</i> (2013.01); <i>A61B 5/1451</i> (2013.01); <i>A61B 5/1452</i> (2013.01); <i>A61B 5/1454</i> (2013.01); <i>A61B 5/1473</i> (2013.01); <i>A61B 5/4845</i> (2013.01); <i>A61B 5/7275</i> (2013.01); <i>G16H 40/63</i> (2018.01); <i>A61B 2560/0223</i> (2013.01); <i>A61B 2560/0242</i> (2013.01); <i>A61B 2560/0276</i> (2013.01); <i>G16H 15/00</i> (2018.01)		
(56) References Cited		
U.S. PATENT DOCUMENTS		
3,949,388 A 4/1976 Fuller		
3,960,497 A 6/1976 Acord et al.		
4,033,330 A 7/1977 Willis et al.		
4,036,749 A 7/1977 Anderson		
4,055,175 A 10/1977 Clemens et al.		
4,129,128 A 12/1978 McFarlane		
4,245,634 A 1/1981 Albisser et al.		
4,327,725 A 5/1982 Cortese et al.		
4,344,438 A 8/1982 Schultz		
4,349,728 A 9/1982 Phillips et al.		
4,373,527 A 2/1983 Fischell		
4,392,849 A 7/1983 Petre et al.		
4,425,920 A 1/1984 Bourland et al.		
4,431,004 A 2/1984 Bessman et al.		
4,441,968 A 4/1984 Emmer et al.		
4,464,170 A 8/1984 Clemens et al.		
4,478,976 A 10/1984 Goertz et al.		
4,494,950 A 1/1985 Fischell		
4,509,531 A 4/1985 Ward		
4,527,240 A 7/1985 Kvitash		
4,538,616 A 9/1985 Rogoff		
4,619,793 A 10/1986 Lee		
4,671,288 A 6/1987 Gough		
4,703,756 A 11/1987 Gough et al.		
4,731,726 A 3/1988 Allen, III		
4,749,985 A 6/1988 Corsberg		
4,757,022 A 7/1988 Shultz et al.		
4,777,953 A 10/1988 Ash et al.		
4,779,618 A 10/1988 Mund et al.		
4,847,785 A 7/1989 Stephens		
4,854,322 A 8/1989 Ash et al.		
4,871,351 A 10/1989 Feingold		
4,890,620 A 1/1990 Gough		
4,925,268 A 5/1990 Iyer et al.		
4,953,552 A 9/1990 DeMarzo		
4,986,271 A 1/1991 Wilkins		
4,995,402 A 2/1991 Smith et al.		
5,000,180 A 3/1991 Kuypers et al.		
5,002,054 A 3/1991 Ash et al.		
5,019,974 A 5/1991 Beckers		
5,050,612 A 9/1991 Matsumura		

US 12,390,135 B2

Page 3

(56)

References Cited

U.S. PATENT DOCUMENTS

5,772,586 A	6/1998	Heinonen et al.	6,387,048 B1	5/2002	Schulman et al.	
5,791,344 A	8/1998	Schulman et al.	6,400,974 B1	6/2002	Lesho	
5,804,047 A	9/1998	Karube et al.	6,405,066 B1	6/2002	Essenpreis et al.	
5,833,603 A	11/1998	Kovacs et al.	6,413,393 B1	7/2002	Van Antwerp et al.	
5,842,189 A	11/1998	Keeler et al.	6,416,471 B1	7/2002	Kumar et al.	
5,891,049 A	4/1999	Cyrus et al.	6,418,346 B1	7/2002	Nelson et al.	
5,899,855 A	5/1999	Brown	6,424,847 B1	7/2002	Mastrototaro et al.	
5,914,026 A	6/1999	Blubaugh, Jr. et al.	6,427,088 B1	7/2002	Bowman, IV et al.	
5,919,141 A	7/1999	Money et al.	6,440,068 B1	8/2002	Brown et al.	
5,925,021 A	7/1999	Castellano et al.	6,446,729 B2	10/2002	Say et al.	
5,935,224 A	8/1999	Svancarek et al.	6,493,069 B1	12/2002	Nagashimada et al.	
5,942,979 A	8/1999	Luppino	6,496,729 B2	12/2002	Thompson	
5,951,485 A	9/1999	Cyrus et al.	6,497,655 B1	12/2002	Linberg et al.	
5,957,854 A	9/1999	Besson et al.	6,498,043 B1	12/2002	Schulman et al.	
5,961,451 A	10/1999	Reber et al.	6,514,718 B2	2/2003	Heller et al.	
5,964,993 A	10/1999	Blubaugh, Jr. et al.	6,520,326 B2	2/2003	McIvor et al.	
5,965,380 A	10/1999	Heller et al.	6,544,212 B2	4/2003	Galley et al.	
5,971,922 A	10/1999	Arita et al.	6,546,268 B1	4/2003	Ishikawa et al.	
5,980,708 A	11/1999	Champagne et al.	6,549,796 B2	4/2003	Sohrab	
5,995,860 A	11/1999	Sun et al.	6,551,494 B1	4/2003	Feldman et al.	
6,001,067 A	12/1999	Shults et al.	6,554,798 B1	4/2003	Mann et al.	
6,024,699 A	2/2000	Surwit et al.	6,558,320 B1	5/2003	Causey, III et al.	
6,028,413 A	2/2000	Brockmann	6,558,321 B1	5/2003	Burd et al.	
6,049,727 A	4/2000	Crothall	6,558,351 B1	5/2003	Steil et al.	
6,052,565 A	4/2000	Ishikura et al.	6,560,471 B1	5/2003	Heller et al.	
6,066,243 A	5/2000	Anderson et al.	6,561,975 B1	5/2003	Pool et al.	
6,083,710 A	7/2000	Heller et al.	6,561,978 B1	5/2003	Conn et al.	
6,088,608 A	7/2000	Schulman et al.	6,562,001 B2	5/2003	Lebel et al.	
6,091,976 A	7/2000	Pfeiffer et al.	6,564,105 B2	5/2003	Starkweather et al.	
6,091,987 A	7/2000	Thompson	6,565,509 B1	5/2003	Say et al.	
6,093,172 A	7/2000	Funderburk et al.	6,571,128 B2	5/2003	Lebel et al.	
6,096,364 A	8/2000	Bok et al.	6,572,545 B2	6/2003	Knobbe et al.	
6,103,033 A	8/2000	Say et al.	6,574,490 B2	6/2003	Abbink et al.	
6,117,290 A	9/2000	Say et al.	6,574,510 B2	6/2003	Von Arx et al.	
6,119,028 A	9/2000	Schulman et al.	6,576,101 B1	6/2003	Heller et al.	
6,120,676 A	9/2000	Heller et al.	6,577,899 B2	6/2003	Lebel et al.	
6,121,009 A	9/2000	Heller et al.	6,579,231 B1	6/2003	Phipps	
6,121,611 A	9/2000	Lindsay et al.	6,579,690 B1	6/2003	Bonnecaze et al.	
6,122,351 A	9/2000	Schlueter, Jr. et al.	6,585,644 B2	7/2003	Lebel et al.	
6,130,623 A	10/2000	MacLellan et al.	6,591,125 B1	7/2003	Buse et al.	
6,134,461 A	10/2000	Say et al.	6,595,919 B2	7/2003	Berner et al.	
6,143,164 A	11/2000	Heller et al.	6,605,200 B1	8/2003	Mao et al.	
6,144,871 A	11/2000	Saito et al.	6,605,201 B1	8/2003	Mao et al.	
6,157,850 A	12/2000	Diab et al.	6,607,509 B2	8/2003	Bobroff et al.	
6,159,147 A	12/2000	Lichter et al.	6,610,012 B2	8/2003	Mault	
6,162,611 A	12/2000	Heller et al.	6,631,281 B1	10/2003	Kastle	
6,175,752 B1 *	1/2001	Say	A61B 5/1495 128/903	6,633,772 B2	10/2003	Ford et al.
				6,635,014 B2	10/2003	Starkweather et al.
				6,635,167 B1	10/2003	Batman et al.
				6,641,533 B2	11/2003	Causey, III et al.
6,200,265 B1	3/2001	Walsh et al.	6,648,821 B2	11/2003	Lebel et al.	
6,212,416 B1	4/2001	Ward et al.	6,654,625 B1	11/2003	Say et al.	
6,219,574 B1	4/2001	Cormier et al.	6,656,114 B1	12/2003	Poulsen et al.	
6,223,283 B1	4/2001	Chaiken et al.	6,658,396 B1	12/2003	Tang et al.	
6,233,471 B1	5/2001	Berner et al.	6,659,948 B2	12/2003	Lebel et al.	
6,248,067 B1	6/2001	Causey, III et al.	6,668,196 B1	12/2003	Villegas et al.	
6,254,586 B1	7/2001	Mann et al.	6,675,030 B2	1/2004	Ciurczak et al.	
6,270,455 B1	8/2001	Brown	6,676,816 B2	1/2004	Mao et al.	
6,275,717 B1	8/2001	Gross et al.	6,687,546 B2	2/2004	Lebel et al.	
6,283,761 B1	9/2001	Joa	6,689,056 B1	2/2004	Kilcoyne et al.	
6,284,478 B1	9/2001	Heller et al.	6,694,191 B2	2/2004	Starkweather et al.	
6,291,200 B1	9/2001	LeJeune et al.	6,695,860 B1	2/2004	Ward et al.	
6,293,925 B1	9/2001	Safabash et al.	6,698,269 B2	3/2004	Baber et al.	
6,294,997 B1	9/2001	Paratore et al.	6,702,857 B2	3/2004	Brauker et al.	
6,295,506 B1	9/2001	Heinonen et al.	6,721,582 B2	4/2004	Trepagnier et al.	
6,299,347 B1	10/2001	Pompei	6,730,025 B1	5/2004	Platt	
6,306,104 B1	10/2001	Cunningham et al.	6,731,976 B2	5/2004	Penn et al.	
6,309,884 B1	10/2001	Cooper et al.	6,733,446 B2	5/2004	Lebel et al.	
6,314,317 B1	11/2001	Willis	6,735,183 B2	5/2004	O'Toole et al.	
6,329,161 B1	12/2001	Heller et al.	6,740,075 B2	5/2004	Lebel et al.	
6,348,640 B1	2/2002	Navot et al.	6,740,518 B1	5/2004	Duong et al.	
6,359,270 B1	3/2002	Bridson	6,741,877 B1	5/2004	Shults et al.	
6,359,444 B1	3/2002	Grimes	6,746,582 B2	6/2004	Heller et al.	
6,360,888 B1	3/2002	McIvor et al.	6,758,810 B2	7/2004	Lebel et al.	
6,366,794 B1	4/2002	Moussy et al.	6,770,030 B1	8/2004	Schaupp et al.	
6,377,828 B1	4/2002	Chaiken et al.	6,789,195 B1	9/2004	Prihoda et al.	
6,379,301 B1	4/2002	Worthington et al.	6,790,178 B1	9/2004	Mault et al.	

US 12,390,135 B2

Page 4

(56)

References Cited

U.S. PATENT DOCUMENTS

6,804,558 B2	10/2004	Haller et al.	7,155,729 B1	12/2006	Andrew et al.
6,809,653 B1	10/2004	Mann et al.	7,167,818 B2	1/2007	Brown
6,810,290 B2	10/2004	Lebel et al.	7,171,274 B2	1/2007	Starkweather et al.
6,811,533 B2	11/2004	Lebel et al.	7,179,226 B2	2/2007	Crothall et al.
6,811,534 B2	11/2004	Bowman, IV et al.	7,183,102 B2	2/2007	Monfre et al.
6,813,519 B2	11/2004	Lebel et al.	7,190,988 B2	3/2007	Say et al.
6,850,790 B2	2/2005	Berner et al.	7,192,450 B2	3/2007	Brauker et al.
6,862,465 B2	3/2005	Shults et al.	7,226,442 B2	6/2007	Sheppard et al.
6,865,407 B2	3/2005	Kimball et al.	7,226,978 B2	6/2007	Tapsak et al.
6,873,268 B2	3/2005	Lebel et al.	7,228,182 B2	6/2007	Healy et al.
6,878,112 B2	4/2005	Linberg et al.	7,237,712 B2	7/2007	DeRocco et al.
6,881,551 B2	4/2005	Heller et al.	7,258,673 B2	8/2007	Racchini et al.
6,882,940 B2	4/2005	Potts et al.	7,267,665 B2	9/2007	Steil et al.
6,892,085 B2	5/2005	McIvor et al.	7,276,029 B2	10/2007	Goode, Jr. et al.
6,895,263 B2	5/2005	Shin et al.	7,278,983 B2	10/2007	Ireland et al.
6,895,265 B2	5/2005	Silver	7,286,894 B1	10/2007	Grant et al.
6,923,763 B1	8/2005	Kovatchev et al.	7,295,867 B2	11/2007	Berner et al.
6,923,764 B2	8/2005	Aceti et al.	7,299,082 B2	11/2007	Feldman et al.
6,931,327 B2	8/2005	Goode, Jr. et al.	7,301,463 B1	11/2007	Paterno
6,932,894 B2	8/2005	Mao et al.	7,310,544 B2	12/2007	Brister et al.
6,936,006 B2	8/2005	Sabra	7,317,938 B2	1/2008	Lorenz et al.
6,940,403 B2	9/2005	Kail, IV	7,318,816 B2	1/2008	Bobroff et al.
6,941,163 B2	9/2005	Ford et al.	7,324,850 B2	1/2008	Perse et al.
6,942,518 B2	9/2005	Liamos et al.	7,335,294 B2	2/2008	Heller et al.
6,950,708 B2	9/2005	Bowman IV et al.	7,344,500 B2	3/2008	Talbot et al.
6,954,662 B2	10/2005	Freger et al.	7,347,819 B2	3/2008	Lebel et al.
6,958,705 B2	10/2005	Lebel et al.	7,354,420 B2	4/2008	Steil et al.
6,968,294 B2	11/2005	Gutta et al.	7,364,592 B2	4/2008	Carr-Brendel et al.
6,971,274 B2	12/2005	Olin	7,366,556 B2	4/2008	Brister et al.
6,974,437 B2	12/2005	Lebel et al.	7,379,765 B2	5/2008	Petisce et al.
6,983,176 B2	1/2006	Gardner et al.	7,384,397 B2	6/2008	Zhang et al.
6,990,366 B2	1/2006	Say et al.	7,387,010 B2	6/2008	Sunshine et al.
6,997,907 B2	2/2006	Safabash et al.	7,399,277 B2	7/2008	Saidara et al.
6,998,247 B2	2/2006	Monfre et al.	7,402,153 B2	7/2008	Steil et al.
6,999,854 B2	2/2006	Roth	7,404,796 B2	7/2008	Ginsberg
7,003,336 B2	2/2006	Holker et al.	7,419,573 B2	9/2008	Gundel
7,003,340 B2	2/2006	Say et al.	7,424,318 B2	9/2008	Brister et al.
7,003,341 B2	2/2006	Say et al.	7,460,898 B2	12/2008	Brister et al.
7,009,511 B2	3/2006	Mazar et al.	7,467,003 B2	12/2008	Brister et al.
7,011,630 B2	3/2006	Desai et al.	7,468,125 B2	12/2008	Kraft et al.
7,015,817 B2	3/2006	Copley et al.	7,471,972 B2	12/2008	Rhodes et al.
7,016,713 B2	3/2006	Gardner et al.	7,474,992 B2	1/2009	Ariyur
7,020,508 B2	3/2006	Stivoric et al.	7,492,254 B2	2/2009	Bandy et al.
7,022,072 B2	4/2006	Fox et al.	7,494,465 B2	2/2009	Brister et al.
7,022,219 B2	4/2006	Mansouri et al.	7,497,827 B2	3/2009	Brister et al.
7,024,236 B2	4/2006	Ford et al.	7,519,408 B2	4/2009	Rasdal et al.
7,024,245 B2	4/2006	Lebel et al.	7,519,478 B2	4/2009	Bartkowiak et al.
7,025,425 B2	4/2006	Kovatchev et al.	7,523,004 B2	4/2009	Bartkowiak et al.
7,027,848 B2	4/2006	Robinson et al.	7,547,281 B2	6/2009	Hayes et al.
7,027,931 B1	4/2006	Jones et al.	7,565,197 B2	7/2009	Haubrich et al.
7,029,444 B2	4/2006	Shin et al.	7,569,030 B2	8/2009	Lebel et al.
7,041,068 B2	5/2006	Freeman et al.	7,574,266 B2	8/2009	Dudding et al.
7,041,468 B2	5/2006	Drucker et al.	7,583,990 B2	9/2009	Goode, Jr. et al.
7,043,305 B2	5/2006	KenKnight et al.	7,591,801 B2	9/2009	Brauker et al.
7,046,153 B2	5/2006	Oja et al.	7,599,726 B2	10/2009	Goode, Jr. et al.
7,052,472 B1	5/2006	Miller et al.	7,602,310 B2	10/2009	Mann et al.
7,052,483 B2	5/2006	Wojcik	7,604,178 B2	10/2009	Stewart
7,056,302 B2	6/2006	Douglas	7,613,491 B2	11/2009	Boock et al.
7,058,453 B2	6/2006	Nelson et al.	7,615,007 B2	11/2009	Shults et al.
7,060,031 B2	6/2006	Webb et al.	7,618,369 B2	11/2009	Hayter et al.
7,074,307 B2	7/2006	Simpson et al.	7,630,748 B2	12/2009	Budiman
7,081,195 B2	7/2006	Simpson et al.	7,632,228 B2	12/2009	Brauker et al.
7,082,334 B2	7/2006	Boute et al.	7,635,594 B2	12/2009	Holmes et al.
7,092,891 B2	8/2006	Maus et al.	7,637,868 B2	12/2009	Saint et al.
7,098,803 B2	8/2006	Mann et al.	7,640,048 B2	12/2009	Dobbles et al.
7,108,778 B2	9/2006	Simpson et al.	7,643,798 B2	1/2010	Ljung
7,110,803 B2	9/2006	Shults et al.	7,651,596 B2	1/2010	Petisce et al.
7,113,821 B1	9/2006	Sun et al.	7,651,845 B2	1/2010	Doyle, III et al.
7,118,667 B2	10/2006	Lee	7,653,425 B2	1/2010	Hayter et al.
7,123,950 B2	10/2006	Mannheimer	7,654,956 B2	2/2010	Brister et al.
7,125,382 B2	10/2006	Zhou et al.	7,657,297 B2	2/2010	Simpson et al.
7,134,999 B2	11/2006	Brauker et al.	7,659,823 B1	2/2010	Killian et al.
7,136,689 B2	11/2006	Shults et al.	7,668,596 B2	2/2010	Von Arx et al.
7,153,265 B2	12/2006	Vachon	7,699,775 B2	4/2010	Desai et al.
7,155,290 B2	12/2006	Von Arx et al.	7,699,964 B2	4/2010	Feldman et al.

(56)	References Cited				
U.S. PATENT DOCUMENTS					
7,711,402 B2	5/2010 Shults et al.	8,130,093 B2	3/2012 Mazar et al.		
7,711,493 B2	5/2010 Bartkowiak et al.	8,131,351 B2	3/2012 Kalgren et al.		
7,713,574 B2	5/2010 Brister et al.	8,131,365 B2	3/2012 Zhang et al.		
7,715,893 B2	5/2010 Kamath et al.	8,131,565 B2	3/2012 Dicks et al.		
7,736,310 B2	6/2010 Taub et al.	8,132,037 B2	3/2012 Fehr et al.		
7,741,734 B2	6/2010 Joannopoulos et al.	8,135,352 B2	3/2012 Langsweirdt et al.		
7,751,864 B2	7/2010 Buck, Jr.	8,136,735 B2	3/2012 Arai et al.		
7,766,829 B2	8/2010 Sloan et al.	8,138,925 B2	3/2012 Downie et al.		
7,768,386 B2	8/2010 Hayter et al.	8,140,160 B2	3/2012 Pless et al.		
7,768,387 B2	8/2010 Fennell	8,140,168 B2	3/2012 Olson et al.		
7,771,352 B2	8/2010 Shults et al.	8,140,299 B2	3/2012 Siess		
7,774,145 B2	8/2010 Brauker et al.	8,140,312 B2	3/2012 Hayter et al.		
7,778,680 B2	8/2010 Goode, Jr. et al.	8,150,321 B2	4/2012 Winter et al.		
7,779,332 B2	8/2010 Karr et al.	8,150,516 B2	4/2012 Levine et al.		
7,782,192 B2	8/2010 Jeckelmann et al.	8,170,803 B2	5/2012 Kamath et al.		
7,783,333 B2	8/2010 Brister et al.	8,179,266 B2	5/2012 Hermle		
7,791,467 B2	9/2010 Mazar et al.	8,192,394 B2	6/2012 Estes et al.		
7,792,562 B2	9/2010 Shults et al.	8,216,138 B1	7/2012 McGarraugh et al.		
7,811,231 B2	10/2010 Jin et al.	8,239,166 B2	8/2012 Hayter et al.		
7,813,809 B2	10/2010 Strother et al.	8,255,026 B1	8/2012 Al-Ali		
7,826,382 B2	11/2010 Sicurello et al.	8,260,558 B2	9/2012 Hayter et al.		
7,826,981 B2	11/2010 Goode, Jr. et al.	8,282,549 B2	10/2012 Brauker et al.		
7,831,310 B2	11/2010 Lebel et al.	8,374,668 B1	2/2013 Hayter et al.		
7,857,760 B2	12/2010 Brister et al.	8,376,945 B2	2/2013 Hayter et al.		
7,860,574 B2	12/2010 Von Arx et al.	8,377,271 B2	2/2013 Mao et al.		
7,882,611 B2	2/2011 Shah et al.	8,409,093 B2	4/2013 Bugler		
7,885,697 B2	2/2011 Brister et al.	8,444,560 B2	5/2013 Hayter et al.		
7,889,069 B2	2/2011 Fifolt et al.	8,461,985 B2	6/2013 Fennell et al.		
7,899,511 B2	3/2011 Shults et al.	8,484,005 B2	7/2013 Hayter et al.		
7,899,545 B2	3/2011 John	8,543,354 B2	9/2013 Luo et al.		
7,905,833 B2	3/2011 Brister et al.	8,560,038 B2	10/2013 Hayter et al.		
7,912,674 B2	3/2011 Killoren Clark et al.	8,571,808 B2	10/2013 Hayter		
7,914,450 B2	3/2011 Goode, Jr. et al.	8,583,205 B2	11/2013 Budiman et al.		
7,916,013 B2	3/2011 Stevenson	8,597,570 B2	12/2013 Terashima et al.		
7,920,906 B2	4/2011 Goode et al.	8,600,681 B2	12/2013 Hayter et al.		
7,928,850 B2	4/2011 Hayter et al.	8,612,163 B2	12/2013 Hayter et al.		
7,938,797 B2	5/2011 Estes	8,657,746 B2	2/2014 Roy		
7,941,200 B2	5/2011 Weinert et al.	8,682,615 B2	3/2014 Hayter et al.		
7,946,984 B2	5/2011 Brister et al.	8,710,993 B2	4/2014 Hayter et al.		
7,946,985 B2	5/2011 Mastrototaro et al.	8,834,366 B2	9/2014 Hayter et al.		
7,955,258 B2	6/2011 Goscha et al.	8,845,536 B2	9/2014 Brauker et al.		
7,970,448 B2	6/2011 Shults et al.	9,000,914 B2	4/2015 Baker et al.		
7,972,296 B2	7/2011 Braig et al.	9,060,719 B2	6/2015 Hayter et al.		
7,974,672 B2	7/2011 Shults et al.	9,289,179 B2	3/2016 Hayter et al.		
7,976,466 B2	7/2011 Ward et al.	9,398,872 B2	7/2016 Hayter et al.		
7,978,063 B2	7/2011 Baldus et al.	9,408,566 B2	8/2016 Hayter et al.		
7,996,158 B2	8/2011 Hayter et al.	9,439,586 B2	9/2016 Bugler		
7,999,674 B2	8/2011 Kamen	9,483,608 B2	11/2016 Hayter et al.		
8,005,524 B2	8/2011 Brauker et al.	9,558,325 B2	1/2017 Hayter et al.		
8,010,174 B2	8/2011 Goode et al.	9,743,872 B2	8/2017 Hayter et al.		
8,010,256 B2	8/2011 Oowada	9,980,140 B1	5/2018 Spencer et al.		
8,060,173 B2	11/2011 Goode, Jr. et al.	10,375,222 B2	8/2019 Mandapaka et al.		
8,072,310 B1	12/2011 Everhart	10,855,788 B2	12/2020 Arabo et al.		
8,090,445 B2	1/2012 Ginggen	11,076,785 B2 *	8/2021 Hayter A61B 5/1473		
8,093,991 B2	1/2012 Stevenson et al.	2001/0037366 A1	11/2001 Webb et al.		
8,094,009 B2	1/2012 Allen et al.	2002/0016534 A1	2/2002 Trepagnier et al.		
8,098,159 B2	1/2012 Batra et al.	2002/0019022 A1	2/2002 Dunn et al.		
8,098,160 B2	1/2012 Howarth et al.	2002/0042090 A1	4/2002 Heller et al.		
8,098,161 B2	1/2012 Lavedas	2002/0054320 A1	5/2002 Ogino		
8,098,201 B2	1/2012 Choi et al.	2002/0065454 A1	5/2002 Lebel et al.		
8,098,208 B2	1/2012 Ficker et al.	2002/0068860 A1	6/2002 Clark		
8,102,021 B2	1/2012 Degani	2002/0072784 A1	6/2002 Sheppard et al.		
8,102,154 B2	1/2012 Bishop et al.	2002/0095076 A1	7/2002 Krausman et al.		
8,102,263 B2	1/2012 Yeo et al.	2002/0103499 A1	8/2002 Perez et al.		
8,102,789 B2	1/2012 Rosar et al.	2002/0106709 A1	8/2002 Potts et al.		
8,103,241 B2	1/2012 Young et al.	2002/0117639 A1	8/2002 Paolini et al.		
8,103,325 B2	1/2012 Swedlow et al.	2002/0120186 A1	8/2002 Keimel		
8,103,471 B2	1/2012 Hayter	2002/0128594 A1	9/2002 Das et al.		
8,111,042 B2	2/2012 Bennett	2002/0147135 A1	10/2002 Schnell		
8,115,488 B2	2/2012 McDowell	2002/0150959 A1	10/2002 Lejeune et al.		
8,116,681 B2	2/2012 Baarman	2002/0161288 A1	10/2002 Shin et al.		
8,116,683 B2	2/2012 Baarman	2002/0169635 A1	11/2002 Shillingburg		
8,117,481 B2	2/2012 Anselmi et al.	2003/0004403 A1	1/2003 Drinan et al.		
8,120,493 B2	2/2012 Burr	2003/0023317 A1	1/2003 Brauker et al.		
8,124,452 B2	2/2012 Sheats	2003/0023461 A1	1/2003 Quintanilla et al.		
		2003/0028089 A1	2/2003 Galley et al.		
		2003/0028184 A1	2/2003 Lebel et al.		
		2003/0032077 A1	2/2003 Itoh et al.		
		2003/0032867 A1	2/2003 Crothall et al.		

(56)	References Cited					
U.S. PATENT DOCUMENTS						
2003/0032874 A1	2/2003	Rhodes et al.	2005/0004439 A1	1/2005	Shin et al.	
2003/0042137 A1	3/2003	Mao et al.	2005/0004494 A1	1/2005	Perez et al.	
2003/0050546 A1	3/2003	Desai et al.	2005/0010269 A1	1/2005	Lebel et al.	
2003/0054428 A1	3/2003	Monfre et al.	2005/0017864 A1	1/2005	Tsoukalis	
2003/0060692 A1	3/2003	Ruchti et al.	2005/0027177 A1	2/2005	Shin et al.	
2003/0060753 A1	3/2003	Starkweather et al.	2005/0027180 A1	2/2005	Goode et al.	
2003/0065308 A1	4/2003	Lebel et al.	2005/0027181 A1	2/2005	Goode et al.	
2003/0100040 A1	5/2003	Bonnecaze et al.	2005/0027182 A1	2/2005	Siddiqui et al.	
2003/0100821 A1	5/2003	Heller et al.	2005/0027462 A1	2/2005	Goode et al.	
2003/0114897 A1	6/2003	Von Arx et al.	2005/0027463 A1	2/2005	Goode et al.	
2003/0125612 A1	7/2003	Fox et al.	2005/0031689 A1	2/2005	Shults et al.	
2003/0130616 A1	7/2003	Steil et al.	2005/0038332 A1	2/2005	Saidara et al.	
2003/0134347 A1	7/2003	Heller et al.	2005/0043598 A1	2/2005	Goode, Jr. et al.	
2003/0147515 A1	8/2003	Kai et al.	2005/0049179 A1	3/2005	Davidson et al.	
2003/0168338 A1	9/2003	Gao et al.	2005/0049473 A1	3/2005	Desai et al.	
2003/0176933 A1	9/2003	Lebel et al.	2005/0070774 A1	3/2005	Addison et al.	
2003/0187338 A1	10/2003	Say et al.	2005/0070777 A1	3/2005	Cho et al.	
2003/0191377 A1	10/2003	Robinson et al.	2005/0090607 A1	4/2005	Tapsak et al.	
2003/0199744 A1	10/2003	Buse et al.	2005/0096511 A1	5/2005	Fox et al.	
2003/0199790 A1	10/2003	Boecker et al.	2005/0096512 A1	5/2005	Fox et al.	
2003/0208113 A1	11/2003	Mault et al.	2005/0096516 A1	5/2005	Soykan et al.	
2003/0212317 A1	11/2003	Kovatchev et al.	2005/0112169 A1	5/2005	Brauker et al.	
2003/0212379 A1	11/2003	Bylund et al.	2005/0113648 A1	5/2005	Yang et al.	
2003/0216630 A1	11/2003	Jersey-Willuhn et al.	2005/0113653 A1	5/2005	Fox et al.	
2003/0217966 A1	11/2003	Tapsak et al.	2005/0121322 A1	6/2005	Say et al.	
2003/0235817 A1	12/2003	Bartkowiak et al.	2005/0131346 A1	6/2005	Douglas	
2004/0010186 A1	1/2004	Kimball et al.	2005/0134731 A1	6/2005	Lee et al.	
2004/0010207 A1	1/2004	Flaherty et al.	2005/0137530 A1	6/2005	Campbell et al.	
2004/0011671 A1	1/2004	Shults et al.	2005/0143635 A1	6/2005	Kamath et al.	
2004/0024553 A1	2/2004	Monfre et al.	2005/0148890 A1	7/2005	Hastings	
2004/0039298 A1	2/2004	Abreu	2005/0154271 A1	7/2005	Rasdal et al.	
2004/0040840 A1	3/2004	Mao et al.	2005/0176136 A1	8/2005	Burd et al.	
2004/0041749 A1	3/2004	Dixon	2005/0177398 A1	8/2005	Watanabe et al.	
2004/0045879 A1	3/2004	Shults et al.	2005/0182306 A1	8/2005	Sloan	
2004/0054263 A1	3/2004	Moerman et al.	2005/0187442 A1	8/2005	Cho et al.	
2004/0063435 A1	4/2004	Sakamoto et al.	2005/0187720 A1	8/2005	Goode, Jr. et al.	
2004/0064068 A1	4/2004	DeNuzzio et al.	2005/0192494 A1	9/2005	Ginsberg	
2004/0099529 A1	5/2004	Mao et al.	2005/0192557 A1	9/2005	Brauker et al.	
2004/0106858 A1	6/2004	Say et al.	2005/0195930 A1	9/2005	Spital et al.	
2004/0111017 A1	6/2004	Say et al.	2005/0196821 A1	9/2005	Monfre et al.	
2004/0117204 A1	6/2004	Mazar et al.	2005/0197793 A1	9/2005	Baker, Jr.	
2004/0122353 A1	6/2004	Shahmirian et al.	2005/0199494 A1	9/2005	Say et al.	
2004/0133164 A1	7/2004	Funderburk et al.	2005/0203360 A1	9/2005	Brauker et al.	
2004/0133390 A1	7/2004	Osorio et al.	2005/0204134 A1	9/2005	Von Arx et al.	
2004/0135571 A1	7/2004	Uutela et al.	2005/0209515 A1	9/2005	Hockersmith et al.	
2004/0135684 A1	7/2004	Steinthal et al.	2005/0214892 A1	9/2005	Kovatchev et al.	
2004/0138588 A1	7/2004	Saikley et al.	2005/0239154 A1	10/2005	Feldman et al.	
2004/0142403 A1	7/2004	Hetzell et al.	2005/0239156 A1	10/2005	Drucker et al.	
2004/0146909 A1	7/2004	Duong et al.	2005/0241957 A1	11/2005	Mao et al.	
2004/0147872 A1	7/2004	Thompson	2005/0245795 A1	11/2005	Goode, Jr. et al.	
2004/0152622 A1	8/2004	Keith et al.	2005/0245799 A1	11/2005	Brauker et al.	
2004/0162678 A1	8/2004	Hetzell et al.	2005/0245839 A1	11/2005	Stivoric et al.	
2004/0167464 A1	8/2004	Ireland et al.	2005/0245904 A1	11/2005	Estes et al.	
2004/0167801 A1	8/2004	Say et al.	2005/0251033 A1	11/2005	Scarantino et al.	
2004/0171921 A1	9/2004	Say et al.	2005/0272985 A1	12/2005	Kotulla et al.	
2004/0176672 A1	9/2004	Silver et al.	2005/0277164 A1	12/2005	Drucker et al.	
2004/0186362 A1	9/2004	Brauker et al.	2005/0277912 A1	12/2005	John	
2004/0186365 A1	9/2004	Jin et al.	2005/0283208 A1	12/2005	Von Arx et al.	
2004/0193020 A1	9/2004	Chiba et al.	2005/0287620 A1	12/2005	Heller et al.	
2004/0193025 A1	9/2004	Steil et al.	2006/0001538 A1	1/2006	Kraft et al.	
2004/0193090 A1	9/2004	Lebel et al.	2006/0001551 A1	1/2006	Kraft et al.	
2004/0197846 A1	10/2004	Hockersmith et al.	2006/0004270 A1	1/2006	Bedard et al.	
2004/0199056 A1	10/2004	Husemann et al.	2006/0010098 A1	1/2006	Goodnow et al.	
2004/0199059 A1	10/2004	Brauker et al.	2006/0015020 A1	1/2006	Neale et al.	
2004/0204687 A1	10/2004	Mogensen et al.	2006/0015024 A1	1/2006	Brister et al.	
2004/0204868 A1	10/2004	Maynard et al.	2006/0016700 A1	1/2006	Brister et al.	
2004/0219664 A1	11/2004	Heller et al.	2006/0017923 A1	1/2006	Ruchti et al.	
2004/0225338 A1	11/2004	Lebel et al.	2006/0019327 A1	1/2006	Brister et al.	
2004/0236200 A1	11/2004	Say et al.	2006/0020186 A1	1/2006	Brister et al.	
2004/0249253 A1	12/2004	Racchini et al.	2006/0020187 A1	1/2006	Brister et al.	
2004/0254433 A1	12/2004	Bandis et al.	2006/0020188 A1	1/2006	Kamath et al.	
2004/0254434 A1	12/2004	Goodnow et al.	2006/0020189 A1	1/2006	Brister et al.	
2004/0260478 A1	12/2004	Schwamm	2006/0020190 A1	1/2006	Kamath et al.	
2004/0267300 A1	12/2004	Mace	2006/0020191 A1	1/2006	Brister et al.	
2005/0001024 A1	1/2005	Kusaka et al.	2006/0020192 A1	1/2006	Brister et al.	

US 12,390,135 B2

Page 7

(56)	References Cited				
U.S. PATENT DOCUMENTS					
2006/0020300 A1	1/2006	Nghiem et al.	2007/0124002 A1	5/2007	Estes et al.
2006/0025663 A1	2/2006	Talbot et al.	2007/0129621 A1	6/2007	Kellogg et al.
2006/0029177 A1	2/2006	Cranford, Jr. et al.	2007/0149875 A1	6/2007	Ouyang et al.
2006/0031094 A1	2/2006	Cohen et al.	2007/0156033 A1	7/2007	Causey, III et al.
2006/0036139 A1	2/2006	Brister et al.	2007/0163880 A1	7/2007	Woo et al.
2006/0036140 A1	2/2006	Brister et al.	2007/0168224 A1	7/2007	Letzt et al.
2006/0036141 A1	2/2006	Kamath et al.	2007/0173706 A1	7/2007	Neinast et al.
2006/0036142 A1	2/2006	Brister et al.	2007/0173709 A1	7/2007	Petisce et al.
2006/0036143 A1	2/2006	Brister et al.	2007/0173710 A1	7/2007	Petisce et al.
2006/0036144 A1	2/2006	Brister et al.	2007/0173761 A1	7/2007	Kanderian et al.
2006/0036145 A1	2/2006	Brister et al.	2007/0179349 A1	8/2007	Hoyme et al.
2006/0058588 A1	3/2006	Zdeblick	2007/0179352 A1	8/2007	Randlov et al.
2006/0079740 A1	4/2006	Silver et al.	2007/0191701 A1	8/2007	Feldman et al.
2006/0091006 A1	5/2006	Wang et al.	2007/0191702 A1	8/2007	Yodfat et al.
2006/0142651 A1	6/2006	Brister et al.	2007/0202562 A1	8/2007	Curry et al.
2006/0154642 A1	7/2006	Scannell	2007/0203407 A1	8/2007	Hoss et al.
2006/0155180 A1	7/2006	Brister et al.	2007/0203966 A1	8/2007	Brauker et al.
2006/0156796 A1	7/2006	Burke et al.	2007/0208244 A1	9/2007	Brauker et al.
2006/0166629 A1	7/2006	Reggiardo	2007/0208246 A1	9/2007	Brauker et al.
2006/0173260 A1	8/2006	Gaoni et al.	2007/0213657 A1	9/2007	Jennewine et al.
2006/0173406 A1	8/2006	Hayes et al.	2007/0228071 A1	10/2007	Kamen et al.
2006/0173444 A1	8/2006	Choy et al.	2007/0232878 A1	10/2007	Kovatchev et al.
2006/0183984 A1	8/2006	Dobbles et al.	2007/0232880 A1	10/2007	Siddiqui et al.
2006/0183985 A1 *	8/2006	Brister	2007/0235331 A1	10/2007	Simpson et al.
		A61B 5/742			10/2007 Talbot et al.
		600/316			10/2007 Peyser et al.
2006/0189851 A1	8/2006	Tivig et al.	2007/0244383 A1	11/2007	Mehta et al.
2006/0189863 A1	8/2006	Peyser et al.	2007/0249922 A1	11/2007	Mehta et al.
2006/0193375 A1	8/2006	Lee et al.	2007/0253021 A1	11/2007	Gerber et al.
2006/0202805 A1	9/2006	Schulman et al.	2007/0255321 A1	11/2007	Holtzclaw
2006/0211072 A1	9/2006	Ryan et al.	2007/0255348 A1	11/2007	Drew
2006/0222566 A1	10/2006	Brauker et al.	2007/0255531 A1	11/2007	Jollota et al.
2006/0224109 A1	10/2006	Steil et al.	2007/0258395 A1	11/2007	Hayter
2006/0224141 A1	10/2006	Rush et al.	2007/0270672 A1	11/2007	Eichorn et al.
2006/0229512 A1	10/2006	Petisce et al.	2007/0271285 A1	11/2007	Hellwig
2006/0247508 A1	11/2006	Fennell	2007/0282299 A1	12/2007	Batra
2006/0247710 A1	11/2006	Goetz et al.	2007/0285238 A1	12/2007	Willis
2006/0247985 A1	11/2006	Liamos et al.	2007/0299617 A1	12/2007	Jennewine et al.
2006/0253296 A1	11/2006	Liisberg et al.	2008/0004515 A1	1/2008	Jennewine et al.
2006/0258929 A1	11/2006	Goode et al.	2008/0004601 A1	1/2008	Jennewine et al.
2006/0272652 A1	12/2006	Stocker et al.	2008/0009692 A1	1/2008	Stafford
2006/0276771 A1	12/2006	Galley et al.	2008/0012701 A1	1/2008	Kass et al.
2006/0281985 A1	12/2006	Ward et al.	2008/0017522 A1	1/2008	Heller et al.
2006/0287691 A1	12/2006	Drew	2008/0018433 A1	1/2008	Pitt-Pladdy
2006/0290496 A1	12/2006	Peeters et al.	2008/0021436 A1	1/2008	Wolpert et al.
2006/0293607 A1	12/2006	Alt et al.	2008/0021666 A1	1/2008	Goode, Jr. et al.
2007/0010950 A1	1/2007	Abensour et al.	2008/0021972 A1	1/2008	Huelskamp et al.
2007/0016381 A1	1/2007	Kamath et al.	2008/0029391 A1	2/2008	Mao et al.
2007/0017983 A1	1/2007	Frank et al.	2008/0030369 A1	2/2008	Mann et al.
2007/0027381 A1	2/2007	Stafford	2008/0033254 A1	2/2008	Kamath et al.
2007/0027507 A1	2/2007	Burdett et al.	2008/0039702 A1	2/2008	Hayter et al.
2007/0032706 A1	2/2007	Kamath et al.	2008/0045824 A1	2/2008	Tapsak et al.
2007/0032717 A1	2/2007	Brister et al.	2008/0058625 A1	3/2008	McGarraugh et al.
2007/0033074 A1	2/2007	Nitzan et al.	2008/0058773 A1	3/2008	John
2007/0038044 A1	2/2007	Dobbles et al.	2008/0060955 A1	3/2008	Goodnow
2007/0055799 A1	3/2007	Koehler et al.	2008/0061961 A1	3/2008	John
2007/0060803 A1	3/2007	Liljeryd et al.	2008/0064937 A1	3/2008	McGarraugh et al.
2007/0060814 A1	3/2007	Stafford	2008/0064943 A1	3/2008	Talbot et al.
2007/0060869 A1	3/2007	Tolle et al.	2008/0071156 A1	3/2008	Brister et al.
2007/0060979 A1	3/2007	Strother et al.	2008/0071157 A1	3/2008	McGarraugh et al.
2007/0066873 A1 *	3/2007	Kamath	2008/0071158 A1	3/2008	McGarraugh et al.
		A61B 5/1495			3/2008 Haubrich et al.
		600/300			4/2008 Hayter et al.
2007/0066956 A1	3/2007	Finkel	2008/0083617 A1	4/2008	Simpson et al.
2007/0071681 A1	3/2007	Gadkar et al.	2008/0086042 A1	4/2008	Brister et al.
2007/0073129 A1	3/2007	Shah et al.	2008/0086044 A1	4/2008	Brister et al.
2007/0078320 A1	4/2007	Stafford	2008/0086273 A1	4/2008	Shults et al.
2007/0078321 A1	4/2007	Mazza et al.	2008/0092638 A1	4/2008	Brenneman et al.
2007/0078322 A1	4/2007	Stafford	2008/0097246 A1	4/2008	Stafford
2007/0078323 A1	4/2007	Reggiardo et al.	2008/0097289 A1	4/2008	Steil et al.
2007/0078818 A1	4/2007	Zivitz et al.	2008/0103447 A1	5/2008	Reggiardo et al.
2007/0093786 A1	4/2007	Goldsmith et al.	2008/0108942 A1	5/2008	Brister et al.
2007/0094216 A1	4/2007	Mathias et al.	2008/0114228 A1	5/2008	McCluskey et al.
2007/0100222 A1	5/2007	Mastrototaro et al.	2008/0119705 A1	5/2008	Patel et al.
2007/0106135 A1	5/2007	Sloan et al.	2008/0119710 A1	5/2008	Reggiardo et al.
2007/0118030 A1	5/2007	Bruce et al.	2008/0139910 A1	6/2008	Mastrototaro et al.
2007/0118405 A1	5/2007	Campbell et al.	2008/0154099 A1	6/2008	Aspel et al.
			2008/0154513 A1	6/2008	Kovatchev et al.
			2008/0161666 A1	7/2008	Feldman et al.
			2008/0167543 A1	7/2008	Say et al.

(56)	References Cited			
U.S. PATENT DOCUMENTS				
2008/0172205 A1	7/2008	Breton et al.	2009/0006034 A1	1/2009 Hayter et al.
2008/0177149 A1	7/2008	Weinert et al.	2009/0006061 A1	1/2009 Thukral et al.
2008/0177165 A1	7/2008	Blomquist et al.	2009/0006133 A1	1/2009 Weinert et al.
2008/0182537 A1	7/2008	Manku et al.	2009/0012376 A1	1/2009 Agus
2008/0183060 A1	7/2008	Steil et al.	2009/0012379 A1	1/2009 Goode et al.
2008/0183061 A1	7/2008	Goode et al.	2009/0018424 A1	1/2009 Kamath et al.
2008/0183399 A1	7/2008	Goode et al.	2009/0018425 A1	1/2009 Ouyang et al.
2008/0188731 A1	8/2008	Brister et al.	2009/0030293 A1	1/2009 Cooper et al.
2008/0188796 A1	8/2008	Steil et al.	2009/0030294 A1	1/2009 Petisce et al.
2008/0189051 A1	8/2008	Goode et al.	2009/0030641 A1	1/2009 Fjield et al.
2008/0194934 A1	8/2008	Ray et al.	2009/0033482 A1	2/2009 Hayter et al.
2008/0194935 A1	8/2008	Brister et al.	2009/0036747 A1	2/2009 Hayter et al.
2008/0194936 A1	8/2008	Goode et al.	2009/0036758 A1	2/2009 Brauker et al.
2008/0194937 A1	8/2008	Goode et al.	2009/0036760 A1	2/2009 Hayter
2008/0194938 A1	8/2008	Brister et al.	2009/0036763 A1	2/2009 Brauker et al.
2008/0195232 A1	8/2008	Carr-Brendel et al.	2009/0040022 A1	2/2009 Finkenzeller
2008/0195967 A1	8/2008	Goode et al.	2009/0043181 A1	2/2009 Brauker et al.
2008/0197024 A1	8/2008	Simpson et al.	2009/0043182 A1	2/2009 Brauker et al.
2008/0200788 A1	8/2008	Brister et al.	2009/0043525 A1	2/2009 Brauker et al.
2008/0200789 A1	8/2008	Brister et al.	2009/0043541 A1	2/2009 Brauker et al.
2008/0200791 A1	8/2008	Simpson et al.	2009/0043542 A1	2/2009 Brauker et al.
2008/0201325 A1	8/2008	Doniger et al.	2009/0045055 A1	2/2009 Rhodes et al.
2008/0208025 A1	8/2008	Shults et al.	2009/0048503 A1	2/2009 Dalal et al.
2008/0208026 A1	8/2008	Noujaim et al.	2009/0054737 A1	2/2009 Magar et al.
2008/0208113 A1	8/2008	Damiano et al.	2009/0054745 A1	2/2009 Jennewine et al.
2008/0214900 A1	9/2008	Fennell et al.	2009/0054747 A1	2/2009 Fennell
2008/0214910 A1	9/2008	Buck	2009/0062767 A1	3/2009 Van Antwerp et al.
2008/0214915 A1	9/2008	Brister et al.	2009/0063187 A1	3/2009 Johnson et al.
2008/0214918 A1	9/2008	Brister et al.	2009/0063402 A1	3/2009 Hayter
2008/0228051 A1	9/2008	Shults et al.	2009/0076356 A1	3/2009 Simpson et al.
2008/0228054 A1	9/2008	Shults et al.	2009/0076360 A1	3/2009 Brister et al.
2008/0228055 A1	9/2008	Sher	2009/0076361 A1	3/2009 Kamath et al.
2008/0234663 A1	9/2008	Yodfat et al.	2009/0082693 A1	3/2009 Stafford
2008/0234943 A1	9/2008	Ray et al.	2009/0085768 A1	4/2009 Patel et al.
2008/0234992 A1	9/2008	Ray et al.	2009/0085873 A1	4/2009 Betts et al.
2008/0235469 A1	9/2008	Drew	2009/0088614 A1	4/2009 Taub et al.
2008/0242961 A1	10/2008	Brister et al.	2009/0093687 A1	4/2009 Telfort et al.
2008/0242963 A1	10/2008	Essenpreis et al.	2009/0099436 A1	4/2009 Brister et al.
2008/0254544 A1	10/2008	Modzelewski et al.	2009/0105554 A1	4/2009 Stahmann et al.
2008/0255434 A1	10/2008	Hayter et al.	2009/0105560 A1	4/2009 Solomon
2008/0255437 A1	10/2008	Hayter	2009/0105568 A1	4/2009 Bugler
2008/0255438 A1	10/2008	Saidara et al.	2009/0105570 A1	4/2009 Sloan et al.
2008/0255808 A1	10/2008	Hayter	2009/0105571 A1	4/2009 Fennell et al.
2008/0256048 A1	10/2008	Hayter	2009/0105636 A1	4/2009 Hayter et al.
2008/0262469 A1	10/2008	Brister et al.	2009/0112478 A1	4/2009 Mueller, Jr. et al.
2008/0269714 A1	10/2008	Mastrototaro et al.	2009/0112626 A1	4/2009 Talbot et al.
2008/0269723 A1	10/2008	Mastrototaro et al.	2009/0124877 A1	5/2009 Goode et al.
2008/0275313 A1	11/2008	Brister et al.	2009/0124878 A1	5/2009 Goode et al.
2008/0278333 A1	11/2008	Fennell et al.	2009/0124879 A1	5/2009 Brister et al.
2008/0287761 A1	11/2008	Hayter	2009/0124964 A1	5/2009 Leach et al.
2008/0287762 A1	11/2008	Hayter	2009/0131768 A1	5/2009 Simpson et al.
2008/0287763 A1	11/2008	Hayter	2009/0131769 A1	5/2009 Leach et al.
2008/0287764 A1	11/2008	Rasdal et al.	2009/0131776 A1	5/2009 Simpson et al.
2008/0287765 A1	11/2008	Rasdal et al.	2009/0131777 A1	5/2009 Simpson et al.
2008/0287766 A1	11/2008	Rasdal et al.	2009/0137886 A1	5/2009 Shariati et al.
2008/0288180 A1	11/2008	Hayter	2009/0137887 A1	5/2009 Shariati et al.
2008/0288204 A1	11/2008	Hayter et al.	2009/0143659 A1	6/2009 Li et al.
2008/0294024 A1	11/2008	Cosentino et al.	2009/0143660 A1	6/2009 Brister et al.
2008/0296155 A1	12/2008	Shults et al.	2009/0149717 A1	6/2009 Brauer et al.
2008/0300572 A1	12/2008	Rankers et al.	2009/0149728 A1	6/2009 Van Antwerp et al.
2008/0306368 A1	12/2008	Goode et al.	2009/0150186 A1	6/2009 Cohen et al.
2008/0306434 A1	12/2008	Dubbles et al.	2009/0156919 A1	6/2009 Brister et al.
2008/0306435 A1	12/2008	Kamath et al.	2009/0156924 A1	6/2009 Shariati et al.
2008/0306444 A1	12/2008	Brister et al.	2009/0163790 A1	6/2009 Brister et al.
2008/0312518 A1	12/2008	Jina et al.	2009/0163791 A1	6/2009 Brister et al.
2008/0312841 A1	12/2008	Hayter	2009/0163855 A1	6/2009 Shin et al.
2008/0312842 A1	12/2008	Hayter	2009/0164190 A1	6/2009 Hayter
2008/0312844 A1	12/2008	Hayter et al.	2009/0164239 A1	6/2009 Hayter et al.
2008/0312845 A1	12/2008	Hayter et al.	2009/0164251 A1	6/2009 Hayter
2008/0314395 A1	12/2008	Kovatchev et al.	2009/0177068 A1	7/2009 Stivoric et al.
2008/0319085 A1	12/2008	Wright et al.	2009/0178459 A1	7/2009 Li et al.
2008/0319279 A1	12/2008	Ramsay et al.	2009/0182217 A1	7/2009 Li et al.
2009/0005665 A1	1/2009	Hayter et al.	2009/0189738 A1	7/2009 Hermle
2009/0005666 A1	1/2009	Shin et al.	2009/0192366 A1	7/2009 Mensinger et al.
2009/0005729 A1	1/2009	Hendrixson et al.		

(56)	References Cited					
U.S. PATENT DOCUMENTS						
2009/0192380 A1	7/2009	Shariati et al.	2010/009970 A1	4/2010	Shults et al.	
2009/0192722 A1	7/2009	Shariati et al.	2010/009971 A1	4/2010	Shults et al.	
2009/0192724 A1	7/2009	Brauker et al.	2010/0141656 A1	4/2010	Dixon et al.	
2009/0192745 A1	7/2009	Kamath et al.	2010/0152554 A1	6/2010	Steine et al.	
2009/0192751 A1	7/2009	Kamath et al.	2010/0160759 A1	6/2010	Celentano et al.	
2009/0198118 A1	8/2009	Hayter et al.	2010/0168538 A1	7/2010	Keenan et al.	
2009/0203981 A1	8/2009	Brauker et al.	2010/0168546 A1	7/2010	Kamath et al.	
2009/0204341 A1	8/2009	Brauker et al.	2010/0174266 A1	7/2010	Estes	
2009/0216100 A1	8/2009	Ebner et al.	2010/0185175 A1	7/2010	Kamen et al.	
2009/0216103 A1	8/2009	Brister et al.	2010/0190435 A1	7/2010	Cook et al.	
2009/0221890 A1	9/2009	Saffer et al.	2010/0191082 A1	7/2010	Brister et al.	
2009/0227855 A1	9/2009	Hill et al.	2010/0191085 A1	7/2010	Budiman	
2009/0234200 A1	9/2009	Husheer	2010/0191472 A1	7/2010	Doniger et al.	
2009/0240120 A1	9/2009	Mensinger et al.	2010/0198142 A1	8/2010	Sloan et al.	
2009/0240128 A1	9/2009	Mensinger et al.	2010/0198314 A1	8/2010	Wei	
2009/0240193 A1	9/2009	Mensinger et al.	2010/0204557 A1	8/2010	Kiae et al.	
2009/0240440 A1	9/2009	Shurabura et al.	2010/0213080 A1	8/2010	Celentano et al.	
2009/0242399 A1	10/2009	Kamath et al.	2010/0230285 A1	9/2010	Hoss et al.	
2009/0242425 A1	10/2009	Kamath et al.	2010/0234710 A1	9/2010	Budiman et al.	
2009/0247855 A1	10/2009	Boock et al.	2010/0240975 A1	9/2010	Goode et al.	
2009/0247856 A1	10/2009	Boock et al.	2010/0261987 A1	10/2010	Kamath et al.	
2009/0247857 A1	10/2009	Harper et al.	2010/0268157 A1	10/2010	Wehba et al.	
2009/0247931 A1	10/2009	Damgaard-Sorensen	2010/0274111 A1	10/2010	Say et al.	
2009/0253973 A1	10/2009	Bashan et al.	2010/0274515 A1	10/2010	Hoss et al.	
2009/0267765 A1	10/2009	Greene et al.	2010/0312176 A1	12/2010	Lauer et al.	
2009/0275815 A1	11/2009	Bickoff et al.	2010/0313105 A1	12/2010	Nekoomaram et al.	
2009/0287073 A1	11/2009	Boock et al.	2011/0004085 A1	1/2011	Mensinger et al.	
2009/0287074 A1	11/2009	Shults et al.	2011/0004276 A1	1/2011	Blair et al.	
2009/0289796 A1	11/2009	Blumberg	2011/0024043 A1	2/2011	Boock et al.	
2009/0291634 A1	11/2009	Saarisalo	2011/0024307 A1	2/2011	Simpson et al.	
2009/0292188 A1	11/2009	Hoss et al.	2011/0027127 A1	2/2011	Simpson et al.	
2009/0296742 A1	12/2009	Sicurello et al.	2011/0027453 A1	2/2011	Boock et al.	
2009/0298182 A1	12/2009	Schulat et al.	2011/0027458 A1	2/2011	Boock et al.	
2009/0299155 A1	12/2009	Yang et al.	2011/0028815 A1	2/2011	Simpson et al.	
2009/0299156 A1	12/2009	Simpson et al.	2011/0028816 A1	2/2011	Simpson et al.	
2009/0299162 A1	12/2009	Brauker et al.	2011/0031986 A1	2/2011	Bhat et al.	
2009/0299276 A1	12/2009	Brauker et al.	2011/0040163 A1	2/2011	Telson et al.	
2010/0010324 A1	1/2010	Brauker et al.	2011/0058485 A1	3/2011	Sloan	
2010/0010329 A1	1/2010	Taub et al.	2011/0077490 A1	3/2011	Simpson et al.	
2010/0010331 A1	1/2010	Brauker et al.	2011/0077494 A1	3/2011	Doniger et al.	
2010/0010332 A1	1/2010	Brauker et al.	2011/0106011 A1	5/2011	Cinar et al.	
2010/0016687 A1	1/2010	Brauker et al.	2011/0112696 A1	5/2011	Yodfat et al.	
2010/0016698 A1	1/2010	Rasdal et al.	2011/0148905 A1	6/2011	Simmons et al.	
2010/0022855 A1	1/2010	Brauker et al.	2011/0152637 A1	6/2011	Kateraas et al.	
2010/0022988 A1	1/2010	Wochner et al.	2011/0173308 A1	7/2011	Gutekunst	
2010/0030038 A1	2/2010	Brauker et al.	2011/0178717 A1	7/2011	Goodnow et al.	
2010/0030053 A1	2/2010	Goode, Jr. et al.	2011/0184267 A1	7/2011	Duke et al.	
2010/0030484 A1	2/2010	Brauker et al.	2011/0193704 A1	8/2011	Harper et al.	
2010/0030485 A1	2/2010	Brauker et al.	2011/0202495 A1	8/2011	Gawlick	
2010/0036215 A1	2/2010	Goode, Jr. et al.	2011/0208027 A1	8/2011	Wagner et al.	
2010/0036216 A1	2/2010	Goode, Jr. et al.	2011/0210830 A1	9/2011	Talty et al.	
2010/0036222 A1	2/2010	Goode, Jr. et al.	2011/0257895 A1	10/2011	Brauker et al.	
2010/0036223 A1	2/2010	Goode, Jr. et al.	2011/0282327 A1	11/2011	Kellogg et al.	
2010/0036225 A1	2/2010	Goode, Jr. et al.	2011/0287528 A1	11/2011	Fern et al.	
2010/0041971 A1	2/2010	Goode, Jr. et al.	2011/0289497 A1	11/2011	Kiae et al.	
2010/0045425 A1	2/2010	Chivallier	2011/0320130 A1	12/2011	Valdes et al.	
2010/0045465 A1	2/2010	Brauker et al.	2012/0078071 A1	3/2012	Bohm et al.	
2010/0049024 A1	2/2010	Saint et al.	2012/0084053 A1	4/2012	Yuen et al.	
2010/0057040 A1	3/2010	Hayter	2012/0108934 A1	5/2012	Valdes et al.	
2010/0057041 A1	3/2010	Hayter	2012/0165626 A1	6/2012	Irina et al.	
2010/0057042 A1	3/2010	Hayter	2012/0165640 A1	6/2012	Galley et al.	
2010/0057044 A1	3/2010	Hayter	2012/0173200 A1	7/2012	Breton et al.	
2010/0057057 A1	3/2010	Hayter et al.	2012/0233679 A1	9/2012	Shedrinsky	
2010/0063373 A1	3/2010	Kamath et al.	2012/0238851 A1	9/2012	Kamen et al.	
2010/0064764 A1	3/2010	Hayter et al.	2012/0255875 A1	10/2012	Vicente et al.	
2010/0076283 A1	3/2010	Simpson et al.	2012/0309302 A1	12/2012	Buhot	
2010/0081906 A1	4/2010	Hayter et al.	2012/0313785 A1	12/2012	Hanson et al.	
2010/0081908 A1	4/2010	Dobbles et al.	2013/0035575 A1	2/2013	Mayou et al.	
2010/0081909 A1	4/2010	Budiman et al.	2013/0225959 A1	8/2013	Bugler	
2010/0081910 A1	4/2010	Brister et al.	2013/0231541 A1	9/2013	Hayter et al.	
2010/0081953 A1	4/2010	Syeda-Mahmood et al.	2013/0235166 A1	9/2013	Jones et al.	
2010/0087724 A1	4/2010	Brauker et al.	2013/0324823 A1	12/2013	Koski et al.	
2010/0094111 A1	4/2010	Heller et al.	2014/0054991 A1	1/2014	Catt et al.	
2010/0094251 A1	4/2010	Estes et al.	2014/0046160 A1	2/2014	Terashima et al.	
2010/0096259 A1	4/2010	Zhang et al.	2014/0266785 A1	9/2014	Miller et al.	

(56)	References Cited				
U.S. PATENT DOCUMENTS					
2014/0313052 A1	10/2014	Yarger et al.	WO	WO-2006/064397	6/2006
2014/0379273 A1	12/2014	Pestice et al.	WO	WO-2006/079114	7/2006
2015/0123810 A1	5/2015	Hernandez-Rosas et al.	WO	WO-2006/085087	8/2006
2015/0205947 A1	7/2015	Berman et al.	WO	WO-2006/118947	11/2006
2015/0207796 A1	7/2015	Love et al.	WO	WO-2006/124099	11/2006
2015/0241407 A1	8/2015	Ou et al.	WO	WO-2007/007459	1/2007
FOREIGN PATENT DOCUMENTS					
CA 2413148	8/2010		WO	WO-2007/016399	2/2007
DE 4401400	7/1995		WO	WO-2007/027788	3/2007
EP 0098592	1/1984		WO	WO-2007/041069	4/2007
EP 0127958	12/1984		WO	WO-2007/041070	4/2007
EP 0320109	6/1989		WO	WO-2007/041248	4/2007
EP 0353328	2/1990		WO	WO-2007/056638	5/2007
EP 0390390	10/1990		WO	WO-2007/097754	8/2007
EP 0396788	11/1990		WO	WO-2007/101223	9/2007
EP 0286118	1/1995		WO	WO-2007/120363	10/2007
EP 0724859	8/1996		WO	WO-2007/126444	11/2007
EP 0678308	5/2000		WO	WO-2007/143225	12/2007
EP 1048264	11/2000		WO	WO-2008/021913	2/2008
EP 1292218	3/2003		WO	WO-2008/042760	4/2008
EP 1077634	7/2003		WO	WO-2008/086541	7/2008
EP 1568309	8/2005		WO	WO-2008/128210	10/2008
EP 1666091	6/2006		WO	WO-2008/130896	10/2008
EP 1703697	9/2006		WO	WO-2008/130897	10/2008
EP 1704893	9/2006		WO	WO-2008/143943	11/2008
EP 1897487	11/2009		WO	WO-2008/151452	12/2008
EP 1897492	11/2009		WO	WO-2009/018058	2/2009
EP 2113864	11/2009		WO	WO-2009/049252	4/2009
EP 1897488	12/2009		WO	WO-2009/086216	7/2009
EP 1681992	4/2010		WO	WO-2009/096992	8/2009
EP 1448489	8/2010		WO	WO-2009/097594	8/2009
EP 1971396	8/2010		WO	WO-2009/136372	11/2009
EP 2201969	3/2011		WO	WO-2010/077329	7/2010
EP 2153382	2/2012		WO	WO-2011/022418	2/2011
EP 2284773	2/2012		WO	WO 2012/154286 A1	11/2012
EP 2 498 196	9/2012		WO	WO 2013/019225	2/2013
EP 3 210 137 B1	3/2021		WO	WO 2014/070456	5/2014
EP 2939158	3/2022		WO	WO 2014/105631 A2	7/2014
EP 3831282 B1	3/2022		WO	WO 2015/069797 A1	5/2015
EP 3988471 B1	7/2023		WO	WO 2016/092448 A1	6/2016
GB 2409951	7/2005				
WO WO-1993/006237	4/1993				
WO WO-1996/025089	8/1996				
WO WO-1996/035370	11/1996				
WO WO 97/18639	5/1997				
WO WO-1997/033513	9/1997				
WO WO-1998/035053	8/1998				
WO WO-1999/056613	11/1999				
WO WO-2000/049940	8/2000				
WO WO-2000/059370	10/2000				
WO WO-2000/074753	12/2000				
WO WO-2000/078992	12/2000				
WO WO-2001/052935	7/2001				
WO WO-2001/054753	8/2001				
WO WO-2002/016905	2/2002				
WO WO-2002/058537	8/2002				
WO WO-2003/076893	9/2003				
WO WO-2003/082091	10/2003				
WO WO-2003/085372	10/2003				
WO WO 2004/006982 A2	1/2004				
WO WO-2004/047445	6/2004				
WO WO-2004/061420	7/2004				
WO WO-2005/010756	2/2005				
WO WO-2005/040404	5/2005				
WO WO-2005/041766	5/2005				
WO WO-2005/045744	5/2005				
WO WO 2005/065538	7/2005				
WO WO-2005/089103	9/2005				
WO WO-2005/119238	12/2005				
WO WO 2005/121785	12/2005				
WO WO-2006/024671	3/2006				
WO WO-2006/032653	3/2006				
WO WO-2006/051466	5/2006				

OTHER PUBLICATIONS

- About the Congressional Record, Congress.gov, Library of Congress, 3 (2022) pages.
- Bindra, D.S., et al., Design and in Vitro Studies of a Needle-Type Glucose Sensor for Subcutaneous Monitoring, *Analytical Chemistry*, vol. 63, No. 17, pp. 1692-1696 (1991).
- Burton, H.D., Urging FDA to Act Promptly to Approve Artificial Pancreas Technologies, *Congressional Record (Bound Edition)*, vol. 157, Part 13, 3 pages (2011).
- Cass, A.E.G., et al., Ferrocene-Mediated Enzyme Electrode for Amperometric Determination of Glucose, *Analytical Chemistry*, vol. 56, No. 4, 5 pages (1984).
- Choudhary, P., et al., Insulin Pump Therapy with Automated Insulin Suspension in Response to Hypoglycemia, Reduction in nocturnal hypoglycemia in those at greatest risk, *Diabetes Care*, vol. 34, pp. 2023-2025 (2011).
- Claims, Specification and Drawings for System and Methods for Providing Sensitive and Specific Alarms, 103 pages.
- Clarke, W., et al., Statistical Tools to Analyze Continuous Glucose Monitor Data, *Diabetes Technology & Therapeutics*, vol. 11, Supplement 1, pp. S-45-S-54 (2009).
- Cunningham, D.D., et al., In Vivo Glucose Sensing, *Chemical Analysis: A Series of Monographs on Analytical Chemistry and Its Applications*, vol. 174, Wiley, 466 pages (2010).
- Declaration of Duncan Hall (2021) including DexCom™ STS™ Continuous Glucose Monitoring System User's Guide (2006), 64 pages.
- Decuir, "Bluetooth 4.0:Low Energy", Standards Architect, CSR Technology, Councilor, Bluetooth Architecture Review Board, IEEE Region 6 Northwest Area Chair, 104 pages (2012).
- Dementyev, et al., "Power Consumption Analysis of Bluetooth Low Energy, ZigBee and ANT Sensor Nodes in a Cyclic Sleep Scenario", *IEEE International Wireless Symposium (IWS)*, 5 pages (2013).

(56)

References Cited**OTHER PUBLICATIONS**

- Facchinetti, A, et al., A New Index to Optimally Design and Compare Continuous Glucose Monitoring Glucose Prediction Algorithms, *Diabetes Technology & Therapeutics*, vol. 13, No. 2, pp. 111-119 (2011).
- FDA PMA Approvals, 3 pages.
- FDA Premarket Approval (PMA) for Freestyle Navigator Continuous Glucose Monitor, 6 pages, Notice Date: Apr. 1, 2008.
- Feature Analysis, 1 page.
- Federal Register, vol. 76, No. 120, pp. 36542-36543 (2011).
- FreeStyle Navigator® Continuous Glucose Monitoring System, User's Guide, Abbott, 196 pages (2008).
- Garg, S.K., et al., Improved Glucose Excursions Using an Implantable Real-Time Continuous Glucose Sensor in Adults with Type 1 Diabetes, *Diabetes Care*, vol. 27, No. 3, pp. 734-738 (2004).
- Guerra, S., et al., A Dynamic Risk Measure from Continuous Glucose Monitoring Data, *Diabetes Technology & Therapeutics*, vol. 13, No. 8, pp. 843-852 (2011).
- Hayter, P.G. et al., Performance Standards for Continuous Glucose Monitors, *Diabetes Technology & Therapeutics*, vol. 7, No. 5, pp. 721-726 (2005).
- Heller, A., et al., Electrochemical Glucose Sensors and Their Applications in Diabetes Management, *Chemical Reviews*, vol. 108, No. 7, pp. 2482-2505 (2008).
- Instructions for Use DexCom™ STS™ Sensor, 1 page.
- International Standard, IEC 60601-1-8, Medical Electrical Equipment, 166 pages (2006).
- Klonoff, "A Review of Continuous Glucose Monitoring Technology", *Diabetes Technology & Therapeutics*, 7(5):770-775 (2005).
- Klonoff, "Continuous Glucose Monitoring: Roadmap for 21st century diabetes therapy", *Diabetes Care*, 28(5):1231-1239 (2005).
- Letter from Department of Health & Human Services re. FreeStyle Navigator Continuous Glucose Monitoring System, 7 pages (2008).
- Letter to EPO re. Divisional Application of EP Application No. 13784079.9 in the name of Dexcom, Inc., 2 pages (2020).
- McMurry Jr., The Artificial Pancreas Today, *Henry Ford Hospital Medical Journal*, vol. 31, No. 2, Article 4, 8 pages (1983).
- Morak, et al., "Design and Evaluation of a Telemonitoring Concept Based on NFC-Enabled Mobile Phones and Sensor Devices", *IEEE Transactions on Information Technology in Biomedicine*, 16(1):17-23 (2012).
- Movassaghi, et al., "Wireless Technologies for Body Area Networks: Characteristics and Challenges", *IEEE, International Symposium on Communications, and Information Technologies (ISCIT)*, pp. 42-47 (2012).
- Palerm, C.C., et al., Hypoglycemia Detection and Prediction Using Continuous Glucose Monitoring—A Study on Hypoglycemic Clamp Data, *Journal of Diabetes Science and Technology*, vol. 1, Issue 5, pp. 624-629 (2007).
- Sandham, W., et al., Blood Glucose Prediction for Diabetes Therapy Using a Recurrent Artificial Neural Network, 4 pages.
- Sparacino, G., et al., Glucose Concentration can be Predicted Ahead in Time From Continuous Glucose Monitoring Sensor Time-Series, *IEEE Transaction on Biomedical Engineering*, vol. 54, No. 5, pp. 931-937 (2007).
- Specification of the Bluetooth System, Experience More, Specification vol. 0, Covered Core Package Version: 4.0, 2 302 pages (2010).
- STS® Seven Continuous Glucose Monitoring System, User's Guide, 74 pages (2007).
- Summary of Safety and Effectiveness Data for Continuous Glucose Monitor, 27 pages (2008).
- Summary of Safety and Effectiveness Data for DexCom™ STS™ Continuous Glucose Monitoring System, 20 pages (2006).
- Summary of Safety and Effectiveness Data for STS®-7 Continuous Glucose Monitoring System, 14 pages (2007).
- Townsend, et al., "Getting Started with Bluetooth Low Energy [Book]", O'Reilly, retrieved from <https://www.oreilly.com/library/view/getting-started-with/9781491900550/ch01.html> on (May 5, 2020), 26 pages.
- Wikipedia, "Blood glucose monitoring" retrieved from "https://web.archive.org/web/20111215063153/http://en.wikipedia.org/wiki/Blood_glucose_monitoring" on Aug. 1, 2021, 6 pages.
- Wikipedia, "Near field communication" retrieved from "http://en.wikipedia.org/w/index.php?title=Near_field_communication&oldid=543740757" on Jun. 27, 2014, 14 pages.
- Certified Copy of U.S. Appl. No. 61/238,657, filed Aug. 31, 2009, 60 pages.
- Declaration of Thomas Edward Foster of Taylor Wessing LLP, Hill House, 1 Little New St. London EC4A 3TR ("Taylor Wessing"), in Relation to STS-7 Use's Guide, Jan. 30, 2024, 160 pages.
- DeXCom STS-7 Approval Order, Department of Health and Human Services, FDA, May 31, 2007, 7 pages.
- FDA Premarket Approval PMA Order for the STS-7, 3 pages, May 31, 2007.
- File History of U.S. Pat. No. 10,375,222, issued Aug. 6, 2019, 442 pages.
- NFC Forum, Bluetooth® Secure Simple Pairing Using NFC Application Document NFC ForumTM, NFCForum-AD-BTSSP_1_1, Jan. 9, 2014, 39 pages.
- Omre, "Bluetooth Low Energy: Wireless Connectivity for Medical Monitoring," *Journal of Diabetes Science and Technology*, vol. 4, Issue 2, 457-463, Mar. 2010.
- Padgett et al., "Guide to Bluetooth Security, Recommendations of the National Institute of Standards and Technology," National Institute of Standards and Technology, U.S. Department of Commerce, Special Publication 800-121 Revision 1, 48 pages, May 2007.
- Specification Bluetooth System Experience More, 134 pages, Jun. 2010.
- Specification Bluetooth System Wireless connections, 92 pages, Nov. 2003.
- Strömmér et al., "Application of Near Field Communication for Health Monitoring in Daily Life," Proceedings of the 28th IEEE FrC09.1 EMBS Annual International Conference New York City, USA, 3246-3249, Aug. 30-Sep. 3, 2006.
- Wayback Machine internet archive of US FDA CDRH PMA Final Decisions Rendered, 21 pages, May 2007.
- Wayback Machine internet archive of US FDA CDRH PMA for STS-7, May 31, 2007, 1 page.
- Zhang et al., "Bluetooth Low Energy for Wearable Sensor-based Healthcare Systems," 2014 Health Innovations and Point-of-Care Technologies Conference Seattle, Washington USA, 251-254, Oct. 8-10, 2014.
- Exhibit CP-2, Expert Report of Dr. Cesar C. Palerm, Sep. 20, 2022: Sparacino, et al., Glucose Concentration can be Predicted Ahead in Time From Continuous Glucose Monitoring Sensor Time-Series, *IEEE Transactions on Biomedical Engineering*, vol. 54, No. 5, pp. 931-937 (2007).
- Exhibit CP-3, Expert Report of Dr. Cesar C. Palerm, Sep. 20, 2022: In Vivo Glucose Sensing, Chemical Analysis, A Series of Monographs on Analytical Chemistry and Its Applications, vol. 174, Wiley (2010).
- Exhibit CP-4, Expert Report of Dr. Cesar C. Palerm, Sep. 20, 2022: Animas® Vibe™, the First Integrated Offering from Animas Corporation and Dexcom, Inc., Receives European CE Mark Approval (2011).
- Exhibit CP-6, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Bailey, et al., Reduction in Hemoglobin Alc with Real-Time Continuous Glucose Monitoring: Results from a 12-Week Observational Study, *Diabetes Technology & Therapeutics*, vol. 9, No. 3, pp. 203-210 (2007).
- Exhibit CP-7, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Garg, et al., Improvement in Glycemic Excursions With a Transcutaneous, Real-Time Continuous Glucose Sensor, *Diabetes Care*, vol. 29, No. 1, pp. 44-50 (2006).
- Exhibit CP-8, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Garg, et al., Relationship of Fasting and Hourly Blood Glucose Levels to HbA_{1c} Values, *Diabetes Care*, vol. 29, No. 12, pp. 2644-2649 (2006).
- Exhibit CP-9, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Welcome to Your FreeStyle Libre System, In-Service Guide, Abbott (2017).

(56)

References Cited**OTHER PUBLICATIONS**

- Exhibit CP-10, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022: Standards of Medical Care in Diabetes—2009, American Diabetes Association, *Diabetes Care*, vol. 32, Supplement 1, pp. S13-S61 (2009).
- Exhibit No. 2, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Committee for Proprietary Medicinal Products (CPMP), Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Diabetes Mellitus, EMEA, The European Agency for the Evaluation of Medicinal Products (2002).
- Exhibit No. 3, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Defining and Reporting Hypoglycemia in Diabetes, *Diabetes Care*, vol. 28, No. 5, pp. 1245-1249 (2005).
- Exhibit No. 4, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Amiel, et al., Review Article, Hypoglycaemia in Type 2 diabetes, *Diabetic Medicine*, vol. 25, pp. 245-254 (2008).
- Exhibit No. 5, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Swinnen, et al., Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia, *Diabetologia*, vol. 52, pp. 38-41 (2009).
- Exhibit No. 6, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Frier, Defining hypoglycaemia: what level has clinical relevance?, *Diabetologia*, vol. 52, pp. 31-34 (2009).
- Exhibit No. 7, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Cryer, Preventing hypoglycaemia: what is the appropriate glucose alert value?, *Diabetologia*, vol. 52, pp. 35-37 (2009).
- Exhibit No. 8, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Oxford Textbook of Endocrinology and Diabetes (2011).
- Exhibit No. 9, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus, European Medicines Agency, Science Medicines Health (2012).
- Exhibit No. 10, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Type 1 Diabetes Research Roadmap, Identifying the strengths and weaknesses, gaps and opportunities of UK type 1 diabetes research; clearing a path to the cure, JDRF Improving Lives. Curing Type 1 Diabetes. Join us in finding the cure for type 1 diabetes (2013).
- Exhibit No. 11, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus, *The New England Journal of Medicine*, vol. 329, No. 14 (1993).
- Exhibit No. 12, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Modern Standards and Service Models, Diabetes, National Service Framework for Diabetes: Standards, Department of Health (2000).
- Exhibit No. 13, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Training in flexible, intensive, insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial, *BMJ*, vol. 325 (2002).
- Exhibit No. 14, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Type 1 diabetes: diagnosis and management of type 1 diabetes in children, young people and adults, Clinical Guideline 15, NHS, National Institute for Clinical Excellence (2004).
- Exhibit No. 15, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Oxford Textbook of Endocrinology and Diabetes (2011).
- Exhibit No. 16, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Pickup, et al., Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data, *BMJ* (2011).
- Exhibit No. 17, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Diabetes (type 1), NIHR (2011).
- Exhibit No. 18, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Aleppo, et al., Replace-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes, *Diabetes Care*, vol. 40, pp. 538-545 (2017).
- Exhibit No. 19, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes, *Diabetes Care*, vol. 40, pp. 155-157 (2017).
- Exhibit No. 20, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Continuous Glucose Sensors: Continuing Questions about Clinical Accuracy, *J Diabetes Sci Technol* vol. 1, Issue 5, pp. 669-675 (2007).
- Exhibit No. 21, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: DeVries, Glucose Sensing Issues for the Artificial Pancreas, *Journal of Diabetes Science and Technology*, vol. 2, Issue 4, pp. 732-734 (2008).
- Exhibit No. 22, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Innovation Milestones, et al.
- Exhibit No. 23, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: CGMS® System Gold™ Continuous Glucose Monitoring Overview, Medtronic MiniMed (2004).
- Exhibit No. 24, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: GlucoWatch G2, Automatic Glucose Biographer and Auto Sensors (2002).
- Exhibit No. 25, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Guardian® Real-Time, Continuous Glucose Monitoring System, User Guide, Medtronic MiniMed (2006).
- Exhibit No. 26, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: CGMS® iPro™ Continuous Glucose Recorder, User Guide, Medtronic MiniMed (2007).
- Exhibit No. 27, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: FreeStyle Navigator, Continuous Glucose Monitoring System, User Guide, Abbott (2008, 2010).
- Exhibit No. 28, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: FreeStyle Navigator II, Continuous Glucose Monitoring System, User's Manual, Abbott (2011-2013).
- Exhibit No. 29, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Dexcom G4, Continuous Glucose Monitoring System, User's Guide (2013).
- Exhibit No. 30, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Revised Specification for US 2007/208244A1.
- Exhibit No. 31, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Revised Specification for EP625.
- Exhibit No. 32, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Puhr, et al., Real-World Hypoglycemia Avoidance with a Predictive Low Glucose Alert Does Not Depend on Frequent Screen Views, *Journal of Diabetes Science and Technology*, vol. 14(1), pp. 83-86 (2020).
- Exhibit No. 33, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: Rilstone, et al., The impact of CGM with a predictive hypoglycaemia alert function on hypoglycaemia in physical activity for people with type 1 diabetes: Pace study (2022).
- Exhibit No. 34, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: FreeStyle Libre 2, Flash Glucose Monitoring System, User's Manual, Abbott (2019-2021).
- Exhibit No. 35, to the Expert Report of Professor Nick Oliver, Sep. 20, 2022: FreeStyle Libre 3, Continuous Glucose Monitoring System, User's Manual, Abbott (2022).
- Exhibit No. 37, to the Second Expert Report of Professor Nick Oliver, Oct. 21, 2022: Oliver, et al., Review Article, Glucose sensors, a review of current and emerging technology, *Diabetic Medicine*, vol. 26, pp. 197-210 (2009).
- File History of U.S. Appl. No. 61/551,773, filed Oct. 26, 2011, 27 pages.
- Harvey, et al., Clinically Relevant Hypoglycemia Prediction Metrics for Event Mitigation, *Diabetes Technology & Therapeutics*, vol. 14, No. 8, pp. 719-727 (2012).
- Hughes, et al., Hypoglycemia Prevention via Pump Attenuation and Red-Yellow-Green "Traffic" Lights Using Continuous Glucose Monitoring and Insulin Pump Data, *Journal of Diabetes Science and Technology*, vol. 4, Issue 5, pp. 1146-1155 (2010).
- Premarket Approval Letter with Summary of Safety and Effectiveness Data for the Freestyle Navigator Continuous Glucose Monitor, Mar. 12, 2008 [34 pgs.].

(56)

References Cited**OTHER PUBLICATIONS**

- Schiavon, An online method for prevention of the risk of glycemic shock in diabetic patients from continuous glucose monitoring data, 117 pages (2010) with English translation of summary attached. User Guide for the Navigator Freestyle (Mar. 2008) [38 pgs.]. "DexCom's 7-Day STS Continuous Glucose Monitoring System", Jun. 1, 2007 <https://newatlas.com/dexcoms-7-day-sts-continuous-glucose-monitoring-system/7376/> 1 page.
- Chuang et al., "Pilot Studies of Transdermal Continuous Glucose Measurement in Outpatient Diabetic Patients and in Patients during and after Cardiac Surgery," *Journal of Diabetes Science and Technology*, 595-602 (2008).
- Exhibit B-22.pdf—Opponent's Written Response in Opposition of EP 3 730 045, Sep. 27, 2023, 43 pages.
- McCartney et al., "In vivo glucose sensing for diabetes management: progress towards non-invasive monitoring," *BMJ*, vol. 319, 4 pages (1999).
- Townsend et al., "Getting Started with Bluetooth Low Energy—Tools and Techniques for Low-Power Networking," O'Reilly Media, Inc., 180 pages (2014).
- Wang et al. "A Feasible IMD Communication Protocol: Security without Obscurity," School of Engineering and Computing Sciences, NYIT Research Experience for Undergraduates (REU), May 26-Jul. 30, 2015, 1 page.
- Alva et al., "Accuracy of a 14-Day Factory-Calibrated Continuous Glucose Monitoring System with Advanced Algorithm in Pediatric and Adult Population with Diabetes," *Journal of Diabetes Science and Technology*, vol. 16(1) 70-77 (2022).
- Campbell et al., "Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study," *Pediatric Diabetes*, 1294-1301 (2018).
- Deshmuk et al., "Effect of Flash Glucose Monitoring on Glycemic Control, Hypoglycemia, Diabetes-Related Distress, and Resource Utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide Audit," <https://doi.org/10.2337/dc20-0738>, *Diabetes Care*, 8 pages (2020).
- Deutscher Gesundheitsbericht, Diabetes 2021, Die Bestandsaufnahme, German Diabetes Society, with English Abstract, 15 pages (2021).
- DexCom™ STS™ Continuous Glucose Monitoring System, User's Guide, 2006, 57 pages.
- FDA, STS-7 Continuous Glucose Monitoring System, P050012/S001, May 31, 2007, 95 pages.
- Haak et al., "Use of Flash Glucose-Sensing Technology for 12 months as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 Diabetes," *Diabetes Ther.*, 14 pages (2017).
- Roussel et al., "Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The Relief Study," *American Diabetes Association, Diabetes Care*, 1368-1376 (2021).
- U.S. Appl. No. 15/681,345 (U.S. Pat. No. 11,076,785), filed Aug. 19, 2017 (Aug. 3, 2021).
- U.S. Appl. No. 14/741,457 (U.S. Pat. No. 9,737,249), filed Jun. 17, 2015 (Aug. 22, 2015).
- U.S. Appl. No. 14/106,000 (U.S. Pat. No. 9,060,719), filed Dec. 13, 2013 (Jun. 23, 2015).
- U.S. Appl. No. 13/599,847 (U.S. Pat. No. 8,612,163), filed Aug. 30, 2012 (Dec. 17, 2013).
- U.S. Appl. No. 12/152,636 (U.S. Pat. No. 8,260,558), filed May 14, 2008 (Sep. 4, 2012).
- U.S. Appl. No. 15/681,345, Jun. 30, 2021 Issue Fee Payment.
- U.S. Appl. No. 15/681,345, Mar. 31, 2021 Notice of Allowance.
- U.S. Appl. No. 15/681,345, Jan. 22, 2021 Request for Continued Examination.
- U.S. Appl. No. 15/681,345, Jan. 19, 2021 Response to Final Office Action.
- U.S. Appl. No. 15/681,345, Oct. 20, 2020 Final Office Action.
- U.S. Appl. No. 15/681,345, Jul. 2, 2020 Response to Non-Final Office Action.
- U.S. Appl. No. 15/681,345, Apr. 6, 2020 Non-Final Office Action.
- Armour, J. C., et al., "Application of Chronic Intravascular Blood Glucose Sensor in Dogs", *Diabetes*, vol. 39, 1990, pp. 1519-1526.
- Arnold, M. A., et al., "Selectivity Assessment of Noninvasive Glucose Measurements Based on Analysis of Multivariate Calibration Vectors", *Journal of Diabetes Science and Technology*, vol. 1, No. 4, 2007, pp. 454-462.
- Aussedad, B., et al., "A User-Friendly Method for Calibrating a Subcutaneous Glucose Sensor-Based Hypoglycemic Alarm", *Biosensors & Bioelectronics*, vol. 12, No. 11, 1997, pp. 1061-1070.
- Bennion, N., et al., "Alternate Site Glucose Testing: A Crossover Design", *Diabetes Technology & Therapeutics*, vol. 4, No. 1, 2002, pp. 25-33.
- Blank, T. B., et al., "Clinical Results From a Non-Invasive Blood Glucose Monitor", *Optical Diagnostics and Sensing of Biological Fluids and Glucose and Cholesterol Monitoring II*, Proceedings of SPIE, vol. 4624, 2002, pp. 1-10.
- Boyne, M. S., et al., "Timing of Changes in Interstitial and Venous Blood Glucose Measured With a Continuous Subcutaneous Glucose Sensor", *Diabetes*, vol. 52, Nov. 2003, pp. 2790-2794.
- Bremer, T. M., et al., "Benchmark Data from the Literature for Evaluation of New Glucose Sensing Technologies", *Diabetes Technology & Therapeutics*, vol. 3, No. 3, 2001, pp. 409-418.
- Brooks, S. L., et al., "Development of an On-Line Glucose Sensor for Fermentation Monitoring", *Biosensors*, vol. 3, 1987/88, pp. 45-56.
- Cass, A. E., et al., "Ferrocene-Medicated Enzyme Electrode for Amperometric Determination of Glucose", *Analytical Chemistry*, vol. 56, No. 4, 1984, 667-671.
- Cheyne, E. H., et al., "Performance of a Continuous Glucose Monitoring System During Controlled Hypoglycaemia in Healthy Volunteers", *Diabetes Technology & Therapeutics*, vol. 4, No. 5, 2002, pp. 607-613.
- Csoregi, E., et al., "Design and Optimization of a Selective Subcutaneously Implantable Glucose Electrode Based on 'Wired' Glucose Oxidase", *Analytical Chemistry*, vol. 67, No. 7, 1995, pp. 1240-1244.
- El-Khatib, F. H., et al., "Adaptive Closed-Loop Control Provides Blood-Glucose Regulation Using Subcutaneous Insulin and Glucagon Infusion in Diabetic Swine", *Journal of Diabetes Science and Technology*, vol. 1, No. 2, 2007, pp. 181-192.
- Eren-Oruklu, M., et al., "Estimation of Future Glucose Concentrations with Subject-Specific Recursive Linear Models", *Diabetes Technology & Therapeutics* vol. 11(4), 2009, pp. 243-253.
- Feldman, B., et al., "A Continuous Glucose Sensor Based on Wired Enzyme™ Technology—Results from a 3-Day Trial in Patients with Type 1 Diabetes", *Diabetes Technology & Therapeutics*, vol. 5, No. 5, 2003, pp. 769-779.
- Feldman, B., et al., "Correlation of Glucose Concentrations in Interstitial Fluid and Venous Blood During Periods of Rapid Glucose Change", Abbott Diabetes Care, Inc. Freestyle Navigator Continuous Glucose Monitor Pamphlet, 2004.
- Garg, S., et al., "Improvement in Glycemic Excursions with a Transcutaneous, Real-Time Continuous Glucose Sensor", *Diabetes Care*, vol. 29, No. 1, 2006, pp. 44-50.
- Hovorka, R., et al., "Nonlinear Model Predictive Control of Glucose Concentration in Subjects with Type 1 Diabetes", *Physiological Measurement*, vol. 55, Jul. 2004, pp. 905-920.
- Isermann, R., "Supervision, Fault-Detection and Fault-Diagnosis Methods—An Introduction", *Control Engineering Practice*, vol. 5, No. 5, 1997, pp. 639-652.
- Isermann, R., et al., "Trends in the Application of Model-Based Fault Detection and Diagnosis of Technical Processes", *Control Engineering Practice*, vol. 5, No. 5, 1997, pp. 709-719.
- Johnson, P. C., "Peripheral Circulation", John Wiley & Sons, 1978, pp. 198.
- Jungheim, K., et al., "How Rapid Does Glucose Concentration Change in Daily Life of Patients with Type 1 Diabetes?", 2002, pp. 250.
- Jungheim, K., et al., "Risky Delay of Hypoglycemia Detection by Glucose Monitoring at the Arm", *Diabetes Care*, vol. 24, No. 7, 2001, pp. 1303-1304.
- Kaplan, S. M., "Wiley Electrical and Electronics Engineering Dictionary", IEEE Press, 2004, pp. 141, 142, 548, 549.

(56)

References Cited**OTHER PUBLICATIONS**

- Kovatchev, B. P., et al., "Graphical and Numerical Evaluation of Continuous Glucose Sensing Time Lag", *Diabetes Technology & Therapeutics*, vol. 11, No. 3, 2009, pp. 139-143.
- Kuure-Kinsey, M., et al., "A Dual-Rate Kalman Filter for Continuous Glucose Monitoring", *Proceedings of the 28th IEEE, EMBS Annual International Conference*, New York City, 2006, pp. 63-66.
- Li, Y., et al., "In Vivo Release From a Drug Delivery MEMS Device", *Journal of Controlled Release*, vol. 100, 2004, pp. 211-219.
- Lo, B., et al., "Key Technical Challenges and Current Implementations of Body Sensor Networks", *Body Sensor Networks*, 2005, pp. 1-5.
- Lodwig, V., et al., "Continuous Glucose Monitoring with Glucose Sensors: Calibration and Assessment Criteria", *Diabetes Technology & Therapeutics*, vol. 5, No. 4, 2003, pp. 573-587.
- Lortz, J., et al., "What is Bluetooth? We Explain The Newest Short-Range Connectivity Technology", *Smart Computing Learning Series, Wireless Computing*, vol. 8, Issue 5, 2002, pp. 72-74.
- Malin, S. F., et al., "Noninvasive Prediction of Glucose by Near-Infrared Diffuse Reflectance Spectroscopy", *Clinical Chemistry*, vol. 45, No. 9, 1999, pp. 1651-1658.
- McGarraugh, G., et al., "Glucose Measurements Using Blood Extracted from the Forearm and the Finger", TheraSense, Inc., 2001, 16 Pages.
- McGarraugh, G., et al., "Physiological Influences on Off-Finger Glucose Testing", *Diabetes Technology & Therapeutics*, vol. 3, No. 3, 2001, pp. 367-376.
- McKean, B. D., et al., "A Telemetry-Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors", *IEEE Transactions on Biomedical Engineering*, vol. 35, No. 7, 1988, pp. 526-532.
- Morbiducci, U., et al., "Improved Usability of the Minimal Model of Insulin Sensitivity Based on an Automated Approach and Genetic Algorithms for Parameter Estimation", *Clinical Science*, vol. 112, 2007, pp. 257-263.
- Mougiakakou, et al., "A Real Time Simulation Model of Glucose-Insulin Metabolism for Type 1 Diabetes Patients", *Proceedings of the 2005 IEEE*, 2005, pp. 298-301.
- Panteleon, A. E., et al., "The Role of the Independent Variable to Glucose Sensor Calibration", *Diabetes Technology & Therapeutics*, vol. 5, No. 3, 2003, pp. 401-410.
- Parker, R., et al., "Robust H_∞ Glucose Control in Diabetes Using a Physiological Model", *AICHE Journal*, vol. 46, No. 12, 2000, pp. 2537-2549.
- Pickup, J., et al., "Implantable Glucose Sensors: Choosing the Appropriate Sensing Strategy", *Biosensors*, vol. 3, 1987/88, pp. 335-346.
- Pickup, J., et al., "In Vivo Molecular Sensing in Diabetes Mellitus: An Implantable Glucose Sensor with Direct Electron Transfer", *Diabetologia*, vol. 32, 1989, pp. 213-217.
- Pishko, M. V., et al., "Amperometric Glucose Microelectrodes Prepared Through Immobilization of Glucose Oxidase in Redox Hydrogels", *Analytical Chemistry*, vol. 63, No. 20, 1991, pp. 2268-2272.
- Quinn, C. P., et al., "Kinetics of Glucose Delivery to Subcutaneous Tissue in Rats Measured with 0.3-mm Amperometric Microsensors", *The American Physiological Society*, 1995, E155-E161.
- Rodriguez, N., et al., "Flexible Communication and Control Protocol for Injectable Neuromuscular Interfaces", *IEEE Transactions on Biomedical Circuits and Systems*, vol. 1, No. 1, 2007, pp. 19-27.
- Roe, J. N., et al., "Bloodless Glucose Measurements", *Critical Review in Therapeutic Drug Carrier Systems*, vol. 15, Issue 3, 1998, pp. 199-241.
- Sakakida, M., et al., "Development of Ferrocene-Mediated Needle-Type Glucose Sensor as a Measure of True Subcutaneous Tissue Glucose Concentrations", *Artificial Organs Today*, vol. 2, No. 2, 1992, pp. 145-158.
- Sakakida, M., et al., "Ferrocene-Mediated Needle-Type Glucose Sensor Covered with Newly Designed Biocompatible Membrane", *Sensors and Actuators B*, vol. 13-14, 1993, pp. 319-322.
- Salehi, C., et al., "A Telemetry-Instrumentation System for Long-Term Implantable Glucose and Oxygen Sensors", *Analytical Letters*, vol. 29, No. 13, 1996, pp. 2289-2308.
- Schmidtke, D. W., et al., "Measurement and Modeling of the Transient Difference Between Blood and Subcutaneous Glucose Concentrations in the Rat After Injection of Insulin", *Proceedings of the National Academy of Sciences*, vol. 95, 1998, pp. 294-299.
- Shaw, G. W., et al., "In Vitro Testing of a Simply Constructed, Highly Stable Glucose Sensor Suitable for Implantation in Diabetic Patients", *Biosensors & Bioelectronics*, vol. 6, 1991, pp. 401-406.
- Shichiri, M., et al., "Glycaemic Control in Pancreatectomized Dogs with a Wearable Artificial Endocrine Pancreas", *Diabetologia*, vol. 24, 1983, pp. 179-184.
- Shichiri, M., et al., "In Vivo Characteristics of Needle-Type Glucose Sensor—Measurements of Subcutaneous Glucose Concentrations in Human Volunteers", *Hormone and Metabolic Research Supplement Series*, vol. 20, 1988, pp. 17-20.
- Shichiri, M., et al., "Membrane Design for Extending the Long-Life of an Implantable Glucose Sensor", *Diabetes Nutrition and Metabolism*, vol. 2, 1989, pp. 309-313.
- Shichiri, M., et al., "Needle-type Glucose Sensor for Wearable Artificial Endocrine Pancreas", *Implantable Sensors for Closed-Loop Prosthetic Systems*, Chapter 15, 1985, pp. 197-210.
- Shichiri, M., et al., "Telemetry Glucose Monitoring Device With Needle-Type Glucose Sensor: A Useful Tool for Blood Glucose Monitoring in Diabetic Individuals", *Diabetes Care*, vol. 9, No. 3, 1986, pp. 298-301.
- Shichiri, M., et al., "Wearable Artificial Endocrine Pancreas With Needle-Type Glucose Sensor", *The Lancet*, 1982, pp. 1129-1131.
- Shults, M. C., et al., "A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors", *IEEE Transactions on Biomedical Engineering*, vol. 41, No. 10, 1994, pp. 937-942.
- Steil, G. M., et al., "Closed-Loop Insulin Delivery—the Path of Physiological Glucose Control", *Advanced Drug Delivery Reviews*, vol. 56, 2004, pp. 125-144.
- Steil, G. M., et al., "Determination of Plasma Glucose During Rapid Glucose Excursions with a Subcutaneous Glucose Sensor", *Diabetes Technology & Therapeutics*, vol. 5, No. 1, 2003, pp. 27-31.
- Sternberg, R., et al., "Study and Development of Multilayer Needle-Type Enzyme-Based Glucose Microsensors", *Biosensors*, vol. 4, 1988, pp. 27-40.
- Thompson, M., et al., "In Vivo Probes: Problems and Perspectives", *Clinical Biochemistry*, vol. 19, 1986, pp. 255-261.
- Turner, A., et al., "Diabetes Mellitus: Biosensors for Research and Management", *Biosensors*, vol. 1, 1985, pp. 85-115.
- Updike, S. J., et al., "Principles of Long-Term Fully Implanted Sensors with Emphasis on Radiotelemetric Monitoring of Blood Glucose from Inside a Subcutaneous Foreign Body Capsule (FBC)", *Biosensors in the Body: Continuous in vivo Monitoring*, Chapter 4, 1997, pp. 117-137.
- Velho, G., et al., "Strategies for Calibrating a Subcutaneous Glucose Sensor", *Biomedica Biochimica Acta*, vol. 48, 1989, pp. 957-964.
- Wilson, G. S., et al., "Progress Toward the Development of an Implantable Sensor for Glucose", *Clinical Chemistry*, vol. 38, No. 9, 1992, pp. 1613-1617.
- Canadian Patent Application No. 2,683,930, Examiner's Report mailed Aug. 17, 2015.
- Canadian Patent Application No. 2,683,930, Examiner's Report mailed Jul. 22, 2014.
- European Patent Application No. 08745803.0, Extended European Search Report mailed Sep. 27, 2012.
- European Patent Application No. 08745805.5, Examination Report mailed Jan. 30, 2015.
- European Patent Application No. 08745805.5, Extended European Search Report mailed May 23, 2012.
- European Patent Application No. 08745807.1, Extended European Search Report mailed Oct. 8, 2012.
- European Patent Application No. 08745809.7, Examination Report mailed Aug. 16, 2016.

(56)

References Cited

OTHER PUBLICATIONS

- European Patent Application No. 08745809.7, Extended European Search Report mailed Jul. 2, 2012.
- European Patent Application No. 08754499.5, Extended European Search Report mailed Sep. 20, 2012.
- European Patent Application No. 08796500.0, Examination Report mailed Dec. 4, 2014.
- European Patent Application No. 08796500.0, Extended European Search Report mailed Jan. 14, 2014.
- European Patent Application No. 08871628.7, Extended European Search Report mailed Oct. 15, 2012.
- PCT Application No. PCT/US2008/006247, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority mailed Nov. 26, 2009.
- PCT Application No. PCT/US2008/006247, International Search Report and Written Opinion of the International Searching Authority mailed Sep. 5, 2008.
- PCT Application No. PCT/US2008/060277, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority mailed Oct. 29, 2009.
- PCT Application No. PCT/US2008/060277, International Search Report and Written Opinion of the International Searching Authority mailed Sep. 22, 2008.
- PCT Application No. PCT/US2008/060279, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority mailed Oct. 29, 2009.
- PCT Application No. PCT/US2008/060279, International Search Report and Written Opinion of the International Searching Authority mailed Jul. 14, 2008.
- PCT Application No. PCT/US2008/060281, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority mailed Oct. 29, 2009.
- PCT Application No. PCT/US2008/060281, International Search Report and Written Opinion of the International Searching Authority mailed Sep. 23, 2008.
- PCT Application No. PCT/US2008/060282, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority mailed Oct. 29, 2009.
- PCT Application No. PCT/US2008/060282, International Search Report and Written Opinion of the International Searching Authority mailed Jun. 18, 2009.
- PCT Application No. PCT/US2008/060284, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority mailed Oct. 29, 2009.
- PCT Application No. PCT/US2008/060284, International Search Report and Written Opinion of the International Searching Authority mailed Sep. 23, 2008.
- PCT Application No. PCT/US2008/070923, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority, mailed Feb. 11, 2010.
- PCT Application No. PCT/US2008/070923, International Search Report and Written Opinion of the International Searching Authority mailed Oct. 1, 2008.
- PCT Application No. PCT/US2009/032756, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority, mailed Aug. 12, 2010.
- PCT Application No. PCT/US2009/032756, International Search Report and Written Opinion of the International Searching Authority mailed Apr. 7, 2009.
- U.S. Appl. No. 11/831,866, Notice of Allowance mailed May 26, 2010.
- U.S. Appl. No. 11/831,866, Office Action mailed Jun. 25, 2009.
- U.S. Appl. No. 11/831,866, Supplemental Office Action mailed Dec. 9, 2009.
- U.S. Appl. No. 11/831,881, Advisory Action mailed Aug. 23, 2013.
- U.S. Appl. No. 11/831,881, Notice of Allowance mailed Jun. 20, 2014.
- U.S. Appl. No. 11/831,881, Office Action mailed Jun. 21, 2011.
- U.S. Appl. No. 11/831,881, Office Action mailed Mar. 13, 2014.
- U.S. Appl. No. 11/831,881, Office Action mailed May 23, 2013.
- U.S. Appl. No. 11/831,881, Office Action mailed Nov. 17, 2011.
- U.S. Appl. No. 11/831,881, Office Action mailed Oct. 1, 2012.
- U.S. Appl. No. 11/831,895, Advisory Action mailed Apr. 22, 2015.
- U.S. Appl. No. 11/831,895, Advisory Action mailed Aug. 5, 2013.
- U.S. Appl. No. 11/831,895, Advisory Action mailed Jan. 18, 2012.
- U.S. Appl. No. 11/831,895, Advisory Action mailed Jan. 25, 2012.
- U.S. Appl. No. 11/831,895, Office Action mailed Feb. 13, 2015.
- U.S. Appl. No. 11/831,895, Office Action mailed Jul. 17, 2014.
- U.S. Appl. No. 11/831,895, Office Action mailed Jul. 20, 2012.
- U.S. Appl. No. 11/831,895, Office Action mailed Mar. 21, 2016.
- U.S. Appl. No. 11/831,895, Office Action mailed May 16, 2013.
- U.S. Appl. No. 11/831,895, Office Action mailed May 25, 2011.
- U.S. Appl. No. 11/831,895, Office Action mailed Oct. 1, 2013.
- U.S. Appl. No. 11/831,895, Office Action mailed Oct. 14, 2011.
- U.S. Appl. No. 12/024,101, Notice of Allowance Jan. 9, 2012.
- U.S. Appl. No. 12/024,101, Office Action mailed Feb. 17, 2011.
- U.S. Appl. No. 12/024,101, Office Action mailed Oct. 17, 2011.
- U.S. Appl. No. 12/102,839, Advisory Action mailed May 1, 2013.
- U.S. Appl. No. 12/102,839, Notice of Allowance mailed Oct. 30, 2015.
- U.S. Appl. No. 12/102,839, Office Action mailed Aug. 1, 2013.
- U.S. Appl. No. 12/102,839, Office Action mailed Aug. 5, 2010.
- U.S. Appl. No. 12/102,839, Office Action mailed Dec. 14, 2009.
- U.S. Appl. No. 12/102,839, Office Action mailed Dec. 14, 2012.
- U.S. Appl. No. 12/102,839, Office Action mailed Dec. 5, 2013.
- U.S. Appl. No. 12/102,839, Office Action mailed Jan. 25, 2011.
- U.S. Appl. No. 12/102,839, Office Action mailed Jul. 17, 2015.
- U.S. Appl. No. 12/102,839, Office Action mailed May 25, 2012.
- U.S. Appl. No. 12/102,839, Office Action mailed Oct. 27, 2011.
- U.S. Appl. No. 12/102,844, Notice of Allowance mailed Jan. 10, 2012.
- U.S. Appl. No. 12/102,844, Office Action mailed Aug. 17, 2011.
- U.S. Appl. No. 12/102,847, Advisory Action mailed Aug. 27, 2014.
- U.S. Appl. No. 12/102,847, Office Action mailed Apr. 24, 2014.
- U.S. Appl. No. 12/102,847, Office Action mailed Aug. 18, 2011.
- U.S. Appl. No. 12/102,847, Office Action mailed Aug. 3, 2015.
- U.S. Appl. No. 12/102,847, Office Action mailed Dec. 31, 2015.
- U.S. Appl. No. 12/102,847, Office Action mailed Feb. 12, 2015.
- U.S. Appl. No. 12/102,847, Office Action mailed Jan. 10, 2012.
- U.S. Appl. No. 12/102,847, Office Action mailed Jun. 16, 2014.
- U.S. Appl. No. 12/102,855, Office Action mailed Aug. 24, 2011.
- U.S. Appl. No. 12/102,855, Office Action mailed Jan. 10, 2012.
- U.S. Appl. No. 12/102,855, Office Action mailed Jun. 11, 2014.
- U.S. Appl. No. 12/102,855, Office Action mailed Mar. 23, 2016.
- U.S. Appl. No. 12/102,855, Office Action mailed May 13, 2015.
- U.S. Appl. No. 12/102,855, Office Action mailed Oct. 24, 2014.
- U.S. Appl. No. 12/102,855, Office Action mailed Sep. 2, 2015.
- U.S. Appl. No. 12/102,856, Notice of Allowance mailed Feb. 25, 2015.
- U.S. Appl. No. 12/102,856, Office Action mailed Aug. 17, 2011.
- U.S. Appl. No. 12/102,856, Office Action mailed Jan. 10, 2012.
- U.S. Appl. No. 12/102,856, Office Action mailed May 7, 2014.
- U.S. Appl. No. 12/102,856, Office Action mailed Nov. 25, 2014.
- U.S. Appl. No. 12/152,623, Notice of Allowance Mailed Nov. 3, 2011.
- U.S. Appl. No. 12/152,623, Office Action mailed May 26, 2011.
- U.S. Appl. No. 12/152,636, Advisory Action mailed Jan. 19, 2012.
- U.S. Appl. No. 12/152,636, Advisory Action mailed Jan. 6, 2012.
- U.S. Appl. No. 12/152,636, Notice of Allowance mailed Jun. 19, 2012.
- U.S. Appl. No. 12/152,636, Office Action mailed Dec. 27, 2010.
- U.S. Appl. No. 12/152,636, Office Action mailed Sep. 20, 2011.
- U.S. Appl. No. 12/152,648, Notice of Allowance mailed Aug. 2, 2013.
- U.S. Appl. No. 12/152,648, Office Action mailed Aug. 12, 2011.
- U.S. Appl. No. 12/152,648, Office Action mailed Aug. 29, 2012.
- U.S. Appl. No. 12/152,648, Office Action mailed Jan. 27, 2012.
- U.S. Appl. No. 12/152,648, Office Action mailed Mar. 13, 2013.
- U.S. Appl. No. 12/152,649, Notice of Allowance mailed Jul. 1, 2013.
- U.S. Appl. No. 12/152,649, Office Action mailed Aug. 5, 2011.
- U.S. Appl. No. 12/152,649, Office Action mailed Jan. 27, 2012.
- U.S. Appl. No. 12/152,649, Office Action mailed Nov. 5, 2012.

(56)

References Cited

OTHER PUBLICATIONS

- U.S. Appl. No. 12/152,650, Notice of Allowance mailed Jan. 22, 2013.
- U.S. Appl. No. 12/152,650, Office Action mailed Aug. 11, 2011.
- U.S. Appl. No. 12/152,650, Office Action mailed Jan. 26, 2012.
- U.S. Appl. No. 12/152,650, Office Action mailed Jul. 25, 2012.
- U.S. Appl. No. 12/152,652, Advisory Action mailed Jan. 13, 2012.
- U.S. Appl. No. 12/152,652, Notice of Allowance mailed May 3, 2012.
- U.S. Appl. No. 12/152,652, Office Action mailed Jun. 23, 2011.
- U.S. Appl. No. 12/152,652, Office Action mailed Nov. 1, 2011.
- U.S. Appl. No. 12/152,657, Notice of Allowance mailed Jul. 10, 2015.
- U.S. Appl. No. 12/152,657, Office Action mailed Apr. 24, 2015.
- U.S. Appl. No. 12/152,657, Office Action mailed Aug. 11, 2011.
- U.S. Appl. No. 12/152,657, Office Action mailed Jan. 26, 2012.
- U.S. Appl. No. 12/152,657, Office Action mailed Sep. 18, 2014.
- U.S. Appl. No. 12/152,662, Advisory Action mailed Sep. 3, 2014.
- U.S. Appl. No. 12/152,662, Office Action mailed Aug. 19, 2011.
- U.S. Appl. No. 12/152,662, Office Action mailed Aug. 19, 2015.
- U.S. Appl. No. 12/152,662, Office Action mailed Jan. 11, 2012.
- U.S. Appl. No. 12/152,662, Office Action mailed Jan. 23, 2015.
- U.S. Appl. No. 12/152,662, Office Action mailed Jun. 12, 2014.
- U.S. Appl. No. 12/152,662, Office Action mailed Mar. 9, 2016.
- U.S. Appl. No. 12/152,670, Notice of Allowance mailed Jun. 20, 2011.
- U.S. Appl. No. 12/152,670, Office Action mailed Jan. 7, 2011.
- U.S. Appl. No. 12/152,673, Advisory Action mailed Apr. 9, 2013.
- U.S. Appl. No. 12/152,673, Office Action mailed Aug. 26, 2011.
- U.S. Appl. No. 12/152,673, Office Action mailed Jan. 30, 2013.
- U.S. Appl. No. 12/152,673, Office Action mailed Jan. 5, 2012.
- U.S. Appl. No. 12/152,673, Office Action mailed Jul. 11, 2012.
- U.S. Appl. No. 13/356,598, Notice of Allowance mailed Jul. 11, 2013.
- U.S. Appl. No. 13/356,598, Office Action mailed Aug. 30, 2012.
- U.S. Appl. No. 13/356,598, Office Action mailed May 2, 2013.
- U.S. Appl. No. 13/424,291, Notice of Allowance mailed Apr. 24, 2013.
- U.S. Appl. No. 13/424,291, Office Action mailed Feb. 6, 2013.
- U.S. Appl. No. 13/424,291, Office Action mailed Jul. 31, 2012.
- U.S. Appl. No. 13/567,038, Notice of Allowance Nov. 22, 2013.
- U.S. Appl. No. 13/567,038, Office Action mailed Jun. 6, 2013.
- U.S. Appl. No. 13/567,038, Office Action mailed Oct. 10, 2013.
- U.S. Appl. No. 13/599,847, Notice of Allowance mailed Aug. 21, 2013.
- U.S. Appl. No. 13/599,847, Office Action mailed Jan. 29, 2013.
- U.S. Appl. No. 13/898,139, Notice of Allowance mailed Sep. 15, 2016.
- U.S. Appl. No. 13/898,139, Office Action mailed Jan. 21, 2016.
- U.S. Appl. No. 13/925,685, Notice of Allowance mailed Sep. 20, 2016.
- U.S. Appl. No. 13/925,685, Office Action mailed May 16, 2016.
- U.S. Appl. No. 14/028,358, Notice of Allowance mailed Jul. 19, 2017.
- U.S. Appl. No. 14/028,358, Office Action mailed Mar. 22, 2017.
- U.S. Appl. No. 14/028,358, Office Action mailed Nov. 2, 2016.
- U.S. Appl. No. 14/052,381, Advisory Action mailed May 10, 2017.
- U.S. Appl. No. 14/052,381, Notice of Allowance mailed Jun. 16, 2017.
- U.S. Appl. No. 14/052,381, Office Action mailed Feb. 21, 2017.
- U.S. Appl. No. 14/052,381, Office Action mailed Oct. 3, 2016.
- U.S. Appl. No. 14/077,004, Office Action mailed Jul. 26, 2016.
- U.S. Appl. No. 14/094,721, Advisory Action mailed Sep. 28, 2016.
- U.S. Appl. No. 14/094,721, Office Action mailed Feb. 25, 2016.
- U.S. Appl. No. 14/094,721, Office Action mailed Jun. 30, 2016.
- U.S. Appl. No. 14/094,721, Office Action mailed Mar. 17, 2107.
- U.S. Appl. No. 14/094,721, Office Action mailed Nov. 17, 2016.
- U.S. Appl. No. 14/094,721, Office Action mailed Nov. 16, 2017.
- U.S. Appl. No. 14/106,000, Notice of Allowance mailed Apr. 24, 2015.
- U.S. Appl. No. 14/106,000, Office Action mailed Aug. 26, 2014.
- U.S. Appl. No. 14/106,000, Office Action mailed Jun. 17, 2014.
- U.S. Appl. No. 14/106,000, Office Action mailed Nov. 26, 2014.
- U.S. Appl. No. 14/223,893, Notice of Allowance mailed Aug. 11, 2017.
- U.S. Appl. No. 14/223,893, Office Action mailed Mar. 28, 2017.
- U.S. Appl. No. 14/223,893, Office Action mailed Nov. 14, 2016.
- U.S. Appl. No. 14/223,893, Office Action mailed Nov. 7, 2016.
- U.S. Appl. No. 14/472,341, Notice of Allowance mailed Mar. 28, 2016.
- U.S. Appl. No. 14/472,341, Office Action mailed Apr. 10, 2015.
- U.S. Appl. No. 14/472,341, Office Action mailed Dec. 23, 2014.
- U.S. Appl. No. 14/472,341, Office Action mailed Oct. 9, 2015.
- U.S. Appl. No. 14/741,457, Notice of Allowance mailed Apr. 12, 2017.
- U.S. Appl. No. 14/741,457, Office Action mailed Apr. 8, 2016.
- U.S. Appl. No. 14/741,457, Office Action mailed Oct. 28, 2016.
- U.S. Appl. No. 14/846,986, Office Action mailed Aug. 3, 2017.
- U.S. Appl. No. 15/294,683, Office Action mailed Feb. 10, 2017.
- U.S. Appl. No. 15/461,459, Office Action mailed Dec. 11, 2017.
- U.S. Appl. No. 15/796,262, Office Action mailed Jan. 11, 2018.
- U.S. Appl. No. 15/796,274, Office Action mailed Dec. 29, 2017.
- Select pages from OneTouch UltraVue User Manual published on Oct. 1, 2009 (with English Translation), 4 pages.
- Annex A2 Documents relating to the Patent Extract from the EP Register for the Patent, EP 3988471, 6 pages (2023).
- Annex B1 Evidence relating to infringing products Dexcom G6 Start Here Guide, 21 pages (2023).
- Annex B3 User Guide LibreLinkUp, 28 pages (2023).
- Annex B4 Extract from the pricacy notice for Libre View, 7 pages (2024).
- Annex D1 UPC Court of Appeal Feb. 26, 2024, 335/2023, 38 pages (2024).
- Annex E3 Excerpts from the “German Health Report Diabetes 2023” of the German Diabetes Society, 24 pages (2023) with English translation.
- Annex F5 Application to amend the Patent under R30 RoP, 5 pages (2024).
- Annex G2 Case law of the Boards of Appeal, I.C-4.3, 3 pages (2024).
- Annex G3 European Patent Guide, 23rd ed., chapter 3 (“Patentability”), 3.4, 6 pages (2023).
- Annex G5 Case Law of the Boards of Appeal, I-D, 4.2.0, 2 pages (2023).
- Annex G6 UPC Court of Appeal Feb. 26, 2024 *NanoString Technologies v. 10x Genomics*, 38 pages (2024).
- Annex G7 Decision of the Enlarged Board of the EPO, G 3/14, 97 pages (2015).
- Annex G8 Willem Hoyng, “The Unified Patent Court (UPC) opens its doors! Some observations”, 42 pages (2023).
- Annex G10 Düsseldorf Local Division Oct. 18, 2023, UPC_CFI_177 2023 (*MyStromer v Revolt Cycling*), 19 pages (2023).
- Annex G11 Munich Local Division Apr. 23, 2024, UPC CFI 514/2023 (*Volkswagen AG, Audi AG, Texas Instruments Inc. and Texas Instruments Deutschland GmbH v. Network system Technologies LLC*), 10 pages (2024).
- Annex G12 Munich Local Division, Sep. 19, 2023, UPC_CFI_2/2023 (*NanoString Technologies v. 10x Genomics*), 107 pages (2023).
- Annex G13 Regulation 2017/745 (EU), 176 pages (2017).
- Annex G14 P. England, ‘A Practitioner’s Guide to the Unified Patent Court and Unitary Patent’, Hart Publishing 2022, p. 159, 7 pages (2022).
- Ballard, User Interface Design Guidelines for J2ME MIDP 2.0, 9 pages (2005).
- Cunningham et al., “In Vivo Glucose Sensing,” Wiley & Sons, 111 pages (2010).
- Cunningham et al., “In Vivo Glucose Sensing Chemical Analysis: A Series of Monographs on Analytical chemistry and Its Applications,” Wiley & Sons, 1 page (2010).
- Custodio et al., “A Review on Architectures and Communications Technologies for Wearable Health-Monitoring Systems,” *Sensors* 12, 13907-13946 (2012).

(56)

References Cited**OTHER PUBLICATIONS**

D26 Microsoft Applications for Windows Mobile 6, User Guide, Part 1 92 pages, Part 2 92 pages (2008).
D29 Medtronic, Paradigm Real-Time Revel™ Minimed, Part 1 132 pages, Part 2 133 pages (2009).
Dexcom, Seven Plus CGMS Users Guide, Part 1, 72 pages, Part 2, 72 pages (2008).
FreeStyle Navigator® CGMS Indications for Use, 96 pages (2008).
FreeStyle Navigator® CGMS Indications for Use, Part 1, 65 pages, Part 2, 65 pages, Part 3, 66 pages (2008).
Huizinga et al., "Automated Defect Prevention, Best Practices in Software Management," 6 pages (2007).
Medtronic, The MiniMed Paradigm® Real-time System, Insulin Pump and CGMS, 8 pages (2008).
Medtronic, The MiniMed Paradigm® Real-Time Insulin Pump User Guide, Paradigm® 522 and 722 Insulin Pumps, 176 pages (2006).
Medtronic, Guardian® Real-Time Continuous Glucose Monitoring System, User Guide, 184 pages (2006).

Medronic, The MiniMed Paradigm® Real-Time Sensor Features User Guide, Paradigm® 522 and 722 Insulin Pumps, 76 pages (2006).
Medtronic, Paradigm® Real-Time, Revel™ Insulin PumpUser Guide, 132 pages (2009).
Mosa et al., "A Systematic Review of Healthcare Applications for Smartphones," BMC Med Informatic and Secision Making, 32 pages (2012).
Section 10 Response to Alarms, Errors, and Problems, 96 pages (2008).
Seven Plus continuous glucose monitoring system User's Guide, Dexcom, 72 pages (2008).
Sommerville, "Software Engineering," 7 pages (2007).
Stone et al., "User Interface Design and Evaluation," The Open University, 153 pages (2005).
Stoodley et al., "The Automatic Detection of Transients, Step Changes and Slope Changes in the Monitoring of Medical Time Series," The Statistician, vol. 28, No. 3, 163-170 (1979).

* cited by examiner




FIGURE 1




FIGURE 2






FIGURE 3






FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9




FIGURE 10




FIGURE 11




FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15




FIGURE 16




FIGURE 17




FIGURE 18




FIGURE 19




FIGURE 20

1

**METHOD AND APPARATUS FOR
PROVIDING DATA PROCESSING AND
CONTROL IN A MEDICAL
COMMUNICATION SYSTEM**

RELATED APPLICATION

The present application is a continuation of U.S. patent application Ser. No. 15/681,345, filed Aug. 19, 2017, which is U.S. patent application Ser. No. 14/741,457, filed Jun. 17, 2015, now U.S. Pat. No. 9,737,249, which is a continuation of U.S. patent application Ser. No. 14/106,000 filed Dec. 13, 2013, now U.S. Pat. No. 9,060,719, which is a continuation of U.S. patent application Ser. No. 13/599,847 filed Aug. 30, 2012, now U.S. Pat. No. 8,612,163, which is a continuation of U.S. patent application Ser. No. 12/152,636 filed May 14, 2008, now U.S. Pat. No. 8,260,558, which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 60/917,889 filed May 14, 2007, entitled "Method and Apparatus for Providing Data Processing and Control in a Medical Communication System," the disclosures of each of which are incorporated herein by reference for all purposes.

BACKGROUND

Analyte, e.g., glucose monitoring systems including continuous and discrete monitoring systems generally include a small, lightweight battery powered and microprocessor controlled system which is configured to detect signals proportional to the corresponding measured glucose levels using an electrometer, and RF signals to transmit the collected data. One aspect of certain analyte monitoring systems include a transcutaneous or subcutaneous analyte sensor configuration which is, for example, partially mounted on the skin of a subject whose analyte level is to be monitored. The sensor cell may use a two or three-electrode (work, reference and counter electrodes) configuration driven by a controlled potential (potentiostat) analog circuit connected through a contact system.

The analyte sensor may be configured so that a portion thereof is placed under the skin of the patient so as to detect the analyte levels of the patient, and another portion or segment of the analyte sensor that is in communication with the transmitter unit. The transmitter unit is configured to transmit the analyte levels detected by the sensor over a wireless communication link such as an RF (radio frequency) communication link to a receiver/monitor unit. The receiver/monitor unit performs data analysis, among others on the received analyte levels to generate information pertaining to the monitored analyte levels. To provide flexibility in analyte sensor manufacturing and/or design, among others, tolerance of a larger range of the analyte sensor sensitivities for processing by the transmitter unit is desirable.

In view of the foregoing, it would be desirable to have a method and system for providing data processing and control for use in medical telemetry systems such as, for example, analyte monitoring systems.

SUMMARY

In one embodiment, method and apparatus for receiving a plurality of signals associated with a monitored analyte level detected by an in vivo sensor for a predetermined time period, comparing each of the plurality of the received signals to a predefined signal range, and modifying a parameter associated with a trend information determined based on

2

comparing the plurality of the received signals to the pre-defined signal range, is disclosed.

These and other objects, features and advantages of the present disclosure will become more fully apparent from the following detailed description of the embodiments, the appended claims and the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

- 10 FIG. 1 illustrates a block diagram of a data monitoring and management system for practicing one or more embodiments of the present disclosure;
- 15 FIG. 2 is a block diagram of the transmitter unit of the data monitoring and management system shown in FIG. 1 in accordance with one embodiment of the present disclosure;
- 20 FIG. 3 is a block diagram of the receiver/monitor unit of the data monitoring and management system shown in FIG. 1 in accordance with one embodiment of the present disclosure;
- 25 FIGS. 4A-4B illustrate a perspective view and a cross sectional view, respectively of an analyte sensor in accordance with one embodiment of the present disclosure;
- 30 FIG. 5 is a flowchart illustrating ambient temperature compensation routine for determining on-skin temperature information in accordance with one embodiment of the present disclosure;
- 35 FIG. 6 is a flowchart illustrating digital anti-aliasing filtering routing in accordance with one embodiment of the present disclosure;
- 40 FIG. 7 is a flowchart illustrating actual or potential sensor insertion or removal detection routine in accordance with one embodiment of the present disclosure;
- 45 FIG. 8 is a flowchart illustrating receiver unit processing corresponding to the actual or potential sensor insertion or removal detection routine of FIG. 7 in accordance with one embodiment of the present disclosure;
- 50 FIG. 9 is a flowchart illustrating data processing corresponding to the actual or potential sensor insertion or removal detection routine in accordance with another embodiment of the present disclosure;
- 55 FIG. 10 is a flowchart illustrating a concurrent passive notification routine in the data receiver/monitor unit of the data monitoring and management system of FIG. 1 in accordance with one embodiment of the present disclosure;
- 60 FIG. 11 is a flowchart illustrating a data quality verification routine in accordance with one embodiment of the present disclosure;
- 65 FIG. 12 is a flowchart illustrating a rate variance filtering routine in accordance with one embodiment of the present disclosure;
- 70 FIG. 13 is a flowchart illustrating a composite sensor sensitivity determination routine in accordance with one embodiment of the present disclosure;
- 75 FIG. 14 is a flowchart illustrating an outlier data point verification routine in accordance with one embodiment of the present disclosure;
- 80 FIG. 15 is a flowchart illustrating a sensor stability verification routine in accordance with one embodiment of the present disclosure;
- 85 FIG. 16 illustrates analyte sensor code determination in accordance with one embodiment of the present disclosure;
- 90 FIG. 17 illustrates an early user notification function associated with the analyte sensor condition in one aspect of the present disclosure;
- 95 FIG. 18 illustrates uncertainty estimation associated with glucose level rate of change determination in one aspect of the present disclosure;

FIG. 19 illustrates glucose trend determination in accordance with one embodiment of the present disclosure; and

FIG. 20 illustrates glucose trend determination in accordance with another embodiment of the present disclosure.

DETAILED DESCRIPTION

As described in further detail below, in accordance with the various embodiments of the present disclosure, there is provided a method and apparatus for providing data processing and control for use in a medical telemetry system. In particular, within the scope of the present disclosure, there are provided method and system for providing data communication and control for use in a medical telemetry system such as, for example, a continuous glucose monitoring system.

FIG. 1 illustrates a data monitoring and management system such as, for example, analyte (e.g., glucose) monitoring system 100 in accordance with one embodiment of the present disclosure. The subject invention is further described primarily with respect to a glucose monitoring system for convenience and such description is in no way intended to limit the scope of the invention. It is to be understood that the analyte monitoring system may be configured to monitor a variety of analytes, e.g., lactate, and the like.

Analytes that may be monitored include, for example, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketones, lactate, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin. The concentration of drugs, such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, may also be monitored.

The analyte monitoring system 100 includes a sensor 101, a transmitter unit 102 coupled to the sensor 101, and a primary receiver unit 104 which is configured to communicate with the transmitter unit 102 via a communication link 103. The primary receiver unit 104 may be further configured to transmit data to a data processing terminal 105 for evaluating the data received by the primary receiver unit 104. Moreover, the data processing terminal in one embodiment may be configured to receive data directly from the transmitter unit 102 via a communication link which may optionally be configured for bi-directional communication.

Also shown in FIG. 1 is a secondary receiver unit 106 which is operatively coupled to the communication link 103 and configured to receive data transmitted from the transmitter unit 102. Moreover, as shown in the Figure, the secondary receiver unit 106 is configured to communicate with the primary receiver unit 104 as well as the data processing terminal 105. Indeed, the secondary receiver unit 106 may be configured for bi-directional wireless communication with each of the primary receiver unit 104 and the data processing terminal 105. As discussed in further detail below, in one embodiment of the present disclosure, the secondary receiver unit 106 may be configured to include a limited number of functions and features as compared with the primary receiver unit 104. As such, the secondary receiver unit 106 may be configured substantially in a smaller compact housing or embodied in a device such as a wrist watch, for example. Alternatively, the secondary receiver unit 106 may be configured with the same or substantially similar functionality as the primary receiver unit 104, and may be configured to be used in conjunction

with a docking cradle unit for placement by bedside, for night time monitoring, and/or bi-directional communication device.

Only one sensor 101, transmitter unit 102, communication link 103, and data processing terminal 105 are shown in the embodiment of the analyte monitoring system 100 illustrated in FIG. 1. However, it will be appreciated by one of ordinary skill in the art that the analyte monitoring system 100 may include one or more sensor 101, transmitter unit 102, communication link 103, and data processing terminal 105. Moreover, within the scope of the present disclosure, the analyte monitoring system 100 may be a continuous monitoring system, or semi-continuous, or a discrete monitoring system. In a multi-component environment, each device is configured to be uniquely identified by each of the other devices in the system so that communication conflict is readily resolved between the various components within the analyte monitoring system 100.

In one embodiment of the present disclosure, the sensor 101 is physically positioned in or on the body of a user whose analyte level is being monitored. The sensor 101 may be configured to continuously sample the analyte level of the user and convert the sampled analyte level into a corresponding data signal for transmission by the transmitter unit 102. In one embodiment, the transmitter unit 102 is coupled to the sensor 101 so that both devices are positioned on the user's body, with at least a portion of the analyte sensor 101 positioned transcutaneously under the skin layer of the user. The transmitter unit 102 performs data processing such as filtering and encoding on data signals, each of which corresponds to a sampled analyte level of the user, for transmission to the primary receiver unit 104 via the communication link 103.

In one embodiment, the analyte monitoring system 100 is configured as a one-way RF communication path from the transmitter unit 102 to the primary receiver unit 104. In such embodiment, the transmitter unit 102 transmits the sampled data signals received from the sensor 101 without acknowledgement from the primary receiver unit 104 that the transmitted sampled data signals have been received. For example, the transmitter unit 102 may be configured to transmit the encoded sampled data signals at a fixed rate (e.g., at one minute intervals) after the completion of the initial power on procedure. Likewise, the primary receiver unit 104 may be configured to detect such transmitted encoded sampled data signals at predetermined time intervals. Alternatively, the analyte monitoring system 100 may be configured with a bi-directional RF (or otherwise) communication between the transmitter unit 102 and the primary receiver unit 104.

Additionally, in one aspect, the primary receiver unit 104 may include two sections. The first section is an analog interface section that is configured to communicate with the transmitter unit 102 via the communication link 103. In one embodiment, the analog interface section may include an RF receiver and an antenna for receiving and amplifying the data signals from the transmitter unit 102, which are thereafter, demodulated with a local oscillator and filtered through a band-pass filter. The second section of the primary receiver unit 104 is a data processing section which is configured to process the data signals received from the transmitter unit 102 such as by performing data decoding, error detection and correction, data clock generation, and data bit recovery.

In operation, upon completing the power-on procedure, the primary receiver unit 104 is configured to detect the presence of the transmitter unit 102 within its range based

on, for example, the strength of the detected data signals received from the transmitter unit 102 or a predetermined transmitter identification information. Upon successful synchronization with the corresponding transmitter unit 102, the primary receiver unit 104 is configured to begin receiving from the transmitter unit 102 data signals corresponding to the user's detected analyte level. More specifically, the primary receiver unit 104 in one embodiment is configured to perform synchronized time hopping with the corresponding synchronized transmitter unit 102 via the communication link 103 to obtain the user's detected analyte level.

Referring again to FIG. 1, the data processing terminal 105 may include a personal computer, a portable computer such as a laptop or a handheld device (e.g., personal digital assistants (PDAs)), and the like, each of which may be configured for data communication with the receiver via a wired or a wireless connection. Additionally, the data processing terminal 105 may further be connected to a data network (not shown) for storing, retrieving and updating data corresponding to the detected analyte level of the user.

Within the scope of the present disclosure, the data processing terminal 105 may include an infusion device such as an insulin infusion pump or the like, which may be configured to administer insulin to patients, and which may be configured to communicate with the receiver unit 104 for receiving, among others, the measured analyte level. Alternatively, the receiver unit 104 may be configured to integrate an infusion device therein so that the receiver unit 104 is configured to administer insulin therapy to patients, for example, for administering and modifying basal profiles, as well as for determining appropriate boluses for administration based on, among others, the detected analyte levels received from the transmitter unit 102.

Additionally, the transmitter unit 102, the primary receiver unit 104 and the data processing terminal 105 may each be configured for bi-directional wireless communication such that each of the transmitter unit 102, the primary receiver unit 104 and the data processing terminal 105 may be configured to communicate (that is, transmit data to and receive data from) with each other via a wireless communication link. More specifically, the data processing terminal 105 may in one embodiment be configured to receive data directly from the transmitter unit 102 via a communication link, where the communication link, as described above, may be configured for bi-directional communication.

In this embodiment, the data processing terminal 105 which may include an insulin pump, may be configured to receive the analyte signals from the transmitter unit 102, and thus, incorporate the functions of the receiver unit 104 including data processing for managing the patient's insulin therapy and analyte monitoring. In one embodiment, the communication link 103 may include one or more of an RF communication protocol, an infrared communication protocol, a Bluetooth® enabled communication protocol, an 802.11x wireless communication protocol, a Zigbee® transmission protocol, or an equivalent wireless communication protocol which would allow secure, wireless communication of several units (for example, per HIPAA requirements) while avoiding potential data collision and interference.

FIG. 2 is a block diagram of the transmitter of the data monitoring and detection system shown in FIG. 1 in accordance with one embodiment of the present disclosure. Referring to the Figure, the transmitter unit 102 in one embodiment includes an analog interface 201 configured to communicate with the sensor 101 (FIG. 1), a user input 202, and a temperature detection section 203, each of which is

operatively coupled to a transmitter processor 204 such as a central processing unit (CPU).

Further shown in FIG. 2 are a transmitter serial communication section 205 and an RF transmitter 206, each of which is also operatively coupled to the transmitter processor 204. Moreover, a power supply 207 such as a battery is also provided in the transmitter unit 102 to provide the necessary power for the transmitter unit 102. Additionally, as can be seen from the Figure, clock 208 is provided to, among others, supply real time information to the transmitter processor 204.

As can be seen from FIG. 2, the sensor 101 (FIG. 1) is provided four contacts, three of which are electrodes—work electrode (W) 210, guard contact (G) 211, reference electrode (R) 212, and counter electrode (C) 213, each operatively coupled to the analog interface 201 of the transmitter unit 102. In one embodiment, each of the work electrode (W) 210, guard contact (G) 211, reference electrode (R) 212, and counter electrode (C) 213 may be made using a conductive material that is either printed or etched, for example, such as carbon which may be printed, or metal foil (e.g., gold) which may be etched, or alternatively provided on a substrate material using laser or photolithography.

In one embodiment, a unidirectional input path is established from the sensor 101 (FIG. 1) and/or manufacturing and testing equipment to the analog interface 201 of the transmitter unit 102, while a unidirectional output is established from the output of the RF transmitter 206 of the transmitter unit 102 for transmission to the primary receiver unit 104. In this manner, a data path is shown in FIG. 2 between the aforementioned unidirectional input and output via a dedicated link 209 from the analog interface 201 to serial communication section 205, thereafter to the processor 204, and then to the RF transmitter 206. As such, in one embodiment, via the data path described above, the transmitter unit 102 is configured to transmit to the primary receiver unit 104 (FIG. 1), via the communication link 103 (FIG. 1), processed and encoded data signals received from the sensor 101 (FIG. 1). Additionally, the unidirectional communication data path between the analog interface 201 and the RF transmitter 206 discussed above allows for the configuration of the transmitter unit 102 for operation upon completion of the manufacturing process as well as for direct communication for diagnostic and testing purposes.

As discussed above, the transmitter processor 204 is configured to transmit control signals to the various sections of the transmitter unit 102 during the operation of the transmitter unit 102. In one embodiment, the transmitter processor 204 also includes a memory (not shown) for storing data such as the identification information for the transmitter unit 102, as well as the data signals received from the sensor 101. The stored information may be retrieved and processed for transmission to the primary receiver unit 104 under the control of the transmitter processor 204. Furthermore, the power supply 207 may include a commercially available battery.

The transmitter unit 102 is also configured such that the power supply section 207 is capable of providing power to the transmitter for a minimum of about three months of continuous operation after having been stored for about eighteen months in a low-power (non-operating) mode. In one embodiment, this may be achieved by the transmitter processor 204 operating in low power modes in the non-operating state, for example, drawing no more than approximately 1 μA of current. Indeed, in one embodiment, the final step during the manufacturing process of the transmitter unit 102 may place the transmitter unit 102 in the lower power,

non-operating state (i.e., post-manufacture sleep mode). In this manner, the shelf life of the transmitter unit 102 may be significantly improved. Moreover, as shown in FIG. 2, while the power supply unit 207 is shown as coupled to the processor 204, and as such, the processor 204 is configured to provide control of the power supply unit 207, it should be noted that within the scope of the present disclosure, the power supply unit 207 is configured to provide the necessary power to each of the components of the transmitter unit 102 shown in FIG. 2.

Referring back to FIG. 2, the power supply section 207 of the transmitter unit 102 in one embodiment may include a rechargeable battery unit that may be recharged by a separate power supply recharging unit (for example, provided in the receiver unit 104) so that the transmitter unit 102 may be powered for a longer period of usage time. Moreover, in one embodiment, the transmitter unit 102 may be configured without a battery in the power supply section 207, in which case the transmitter unit 102 may be configured to receive power from an external power supply source (for example, a battery) as discussed in further detail below.

Referring yet again to FIG. 2, the temperature detection section 203 of the transmitter unit 102 is configured to monitor the temperature of the skin near the sensor insertion site. The temperature reading is used to adjust the analyte readings obtained from the analog interface 201. The RF transmitter 206 of the transmitter unit 102 may be configured for operation in the frequency band of 315 MHz to 322 MHz, for example, in the United States. Further, in one embodiment, the RF transmitter 206 is configured to modulate the carrier frequency by performing Frequency Shift Keying and Manchester encoding. In one embodiment, the data transmission rate is 19,200 symbols per second, with a minimum transmission range for communication with the primary receiver unit 104.

Referring yet again to FIG. 2, also shown is a leak detection circuit 214 coupled to the guard contact (G) 211 and the processor 204 in the transmitter unit 102 of the data monitoring and management system 100. The leak detection circuit 214 in accordance with one embodiment of the present disclosure may be configured to detect leakage current in the sensor 101 to determine whether the measured sensor data is corrupt or whether the measured data from the sensor 101 is accurate.

FIG. 3 is a block diagram of the receiver/monitor unit of the data monitoring and management system shown in FIG. 1 in accordance with one embodiment of the present disclosure. Referring to FIG. 3, the primary receiver unit 104 includes a blood glucose test strip interface 301, an RF receiver 302, a user input 303, a temperature detection section 304, and a clock 305, each of which is operatively coupled to a receiver processor 307. As can be further seen from the Figure, the primary receiver unit 104 also includes a power supply 306 operatively coupled to a power conversion and monitoring section 308. Further, the power conversion and monitoring section 308 is also coupled to the receiver processor 307. Moreover, also shown are a receiver serial communication section 309, and an output 310, each operatively coupled to the receiver processor 307.

In one embodiment, the test strip interface 301 includes a glucose level testing portion to receive a manual insertion of a glucose test strip, and thereby determine and display the glucose level of the test strip on the output 310 of the primary receiver unit 104. This manual testing of glucose can be used to calibrate sensor 101. The RF receiver 302 is configured to communicate, via the communication link 103 (FIG. 1) with the RF transmitter 206 of the transmitter unit

102, to receive encoded data signals from the transmitter unit 102 for, among others, signal mixing, demodulation, and other data processing. The input 303 of the primary receiver unit 104 is configured to allow the user to enter information into the primary receiver unit 104 as needed. In one aspect, the input 303 may include one or more keys of a keypad, a touch-sensitive screen, or a voice-activated input command unit. The temperature detection section 304 is configured to provide temperature information of the primary receiver unit 104 to the receiver processor 307, while the clock 305 provides, among others, real time information to the receiver processor 307.

Each of the various components of the primary receiver unit 104 shown in FIG. 3 is powered by the power supply 306 which, in one embodiment, includes a battery. Furthermore, the power conversion and monitoring section 308 is configured to monitor the power usage by the various components in the primary receiver unit 104 for effective power management and to alert the user, for example, in the event of power usage which renders the primary receiver unit 104 in sub-optimal operating conditions. An example of such sub-optimal operating condition may include, for example, operating the vibration output mode (as discussed below) for a period of time thus substantially draining the power supply 306 while the processor 307 (thus, the primary receiver unit 104) is turned on. Moreover, the power conversion and monitoring section 308 may additionally be configured to include a reverse polarity protection circuit such as a field effect transistor (FET) configured as a battery activated switch.

The serial communication section 309 in the primary receiver unit 104 is configured to provide a bi-directional communication path from the testing and/or manufacturing equipment for, among others, initialization, testing, and configuration of the primary receiver unit 104. Serial communication section 309 can also be used to upload data to a computer, such as time-stamped blood glucose data. The communication link with an external device (not shown) can be made, for example, by cable, infrared (IR) or RF link. The output 310 of the primary receiver unit 104 is configured to provide, among others, a graphical user interface (GUI) such as a liquid crystal display (LCD) for displaying information. Additionally, the output 310 may also include an integrated speaker for outputting audible signals as well as to provide vibration output as commonly found in handheld electronic devices, such as mobile telephones presently available. In a further embodiment, the primary receiver unit 104 also includes an electro-luminescent lamp configured to provide backlighting to the output 310 for output visual display in dark ambient surroundings.

Referring back to FIG. 3, the primary receiver unit 104 in one embodiment may also include a storage section such as a programmable, non-volatile memory device as part of the processor 307, or provided separately in the primary receiver unit 104, operatively coupled to the processor 307. The processor 307 is further configured to perform Manchester decoding as well as error detection and correction upon the encoded data signals received from the transmitter unit 102 via the communication link 103.

In a further embodiment, the one or more of the transmitter unit 102, the primary receiver unit 104, secondary receiver unit 106, or the data processing terminal/infusion section 105 may be configured to receive the blood glucose value wirelessly over a communication link from, for example, a glucose meter. In still a further embodiment, the user or patient manipulating or using the analyte monitoring system 100 (FIG. 1) may manually input the blood glucose

value using, for example, a user interface (for example, a keyboard, keypad, and the like) incorporated in the one or more of the transmitter unit 102, the primary receiver unit 104, secondary receiver unit 106, or the data processing terminal/infusion section 105.

Additional detailed description of the continuous analyte monitoring system, and it's various components including the functional descriptions of the transmitter are provided in U.S. Pat. No. 6,175,752 issued Jan. 16, 2001 entitled "Analyte Monitoring Device and Methods of Use", and in application Ser. No. 10/745,878 filed Dec. 26, 2003 entitled "Continuous Glucose Monitoring System and Methods of Use", each assigned to the Assignee of the present application, and each of which are incorporated herein by reference for all purposes.

FIGS. 4A-4B illustrate a perspective view and a cross sectional view, respectively of an analyte sensor in accordance with one embodiment of the present disclosure. Referring to FIG. 4A, a perspective view of a sensor 400, the major portion of which is above the surface of the skin 410, with an insertion tip 430 penetrating through the skin and into the subcutaneous space 420 in contact with the user's biofluid such as interstitial fluid. Contact portions of a working electrode 401, a reference electrode 402, and a counter electrode 403 can be seen on the portion of the sensor 400 situated above the skin surface 410. Working electrode 401, a reference electrode 402, and a counter electrode 403 can be seen at the end of the insertion tip 430.

Referring now to FIG. 4B, a cross sectional view of the sensor 400 in one embodiment is shown. In particular, it can be seen that the various electrodes of the sensor 400 as well as the substrate and the dielectric layers are provided in a stacked or layered configuration or construction. For example, as shown in FIG. 4B, in one aspect, the sensor 400 (such as the sensor 101 FIG. 1), includes a substrate layer 404, and a first conducting layer 401 such as a carbon trace disposed on at least a portion of the substrate layer 404, and which may comprise the working electrode. Also shown disposed on at least a portion of the first conducting layer 401 is a sensing layer 408.

Referring back to FIG. 4B, a first insulation layer such as a first dielectric layer 405 is disposed or stacked on at least a portion of the first conducting layer 401, and further, a second conducting layer 409 such as another carbon trace may be disposed or stacked on top of at least a portion of the first insulation layer (or dielectric layer) 405. As shown in FIG. 4B, the second conducting layer 409 may comprise the reference electrode 402, and in one aspect, may include a layer of silver/silver chloride (Ag/AgCl).

Referring still again to FIG. 4B, a second insulation layer 406 such as a dielectric layer in one embodiment may be disposed or stacked on at least a portion of the second conducting layer 409. Further, a third conducting layer 403 which may include carbon trace and that may comprise the counter electrode 403 may in one embodiment be disposed on at least a portion of the second insulation layer 406. Finally, a third insulation layer 407 is disposed or stacked on at least a portion of the third conducting layer 403. In this manner, the sensor 400 may be configured in a stacked or layered construction or configuration such that at least a portion of each of the conducting layers is separated by a respective insulation layer (for example, a dielectric layer).

Additionally, within the scope of the present disclosure, some or all of the electrodes 401, 402, 403 may be provided on the same side of the substrate 404 in a stacked construction as described above, or alternatively, may be provided in a co-planar manner such that each electrode is disposed on

the same plane on the substrate 404, however, with a dielectric material or insulation material disposed between the conducting layers/electrodes. Furthermore, in still another aspect of the present disclosure, the one or more conducting layers such as the electrodes 401, 402, 403 may be disposed on opposing sides of the substrate 404.

Referring back to the Figures, in one embodiment, the transmitter unit 102 (FIG. 1) is configured to detect the current signal from the sensor 101 (FIG. 1) and the skin temperature near the sensor 101, which are preprocessed by, for example, the transmitter processor 204 (FIG. 2) and transmitted to the receiver unit (for example, the primary receiver unit 104 (FIG. 1)) periodically at a predetermined time interval, such as for example, but not limited to, once per minute, once every two minutes, once every five minutes, or once every ten minutes. Additionally, the transmitter unit 102 may be configured to perform sensor insertion detection and data quality analysis, information pertaining to which are also transmitted to the receiver unit 104 periodically at the predetermined time interval. In turn, the receiver unit 104 may be configured to perform, for example, skin temperature compensation as well as calibration of the sensor data received from the transmitter unit 102.

For example, in one aspect, the transmitter unit 102 may be configured to oversample the sensor signal at a nominal rate of four samples per second, which allows the analyte anti-aliasing filter in the transmitter unit 102 to attenuate noise (for example, due to effects resulting from motion or movement of the sensor after placement) at frequencies above 2 Hz. More specifically, in one embodiment, the transmitter processor 204 may be configured to include a digital filter to reduce aliasing noise when decimating the four Hz sampled sensor data to once per minute samples for transmission to the receiver unit 104. As discussed in further detail below, in one aspect, a two stage Kaiser FIR filter may be used to perform the digital filtering for anti-aliasing. While Kaiser FIR filter may be used for digital filtering of the sensor signals, within the scope of the present disclosure, other suitable filters may be used to filter the sensor signals.

In one aspect, the temperature measurement section 203 of the transmitter unit 102 may be configured to measure once per minute the on skin temperature near the analyte sensor at the end of the minute sampling cycle of the sensor signal. Within the scope of the present disclosure, different sample rates may be used which may include, for example, but not limited to, measuring the on skin temperature for each 30 second periods, each two minute periods, and the like. Additionally, as discussed above, the transmitter unit 102 may be configured to detect sensor insertion, sensor signal settling after sensor insertion, and sensor removal, in addition to detecting for sensor—transmitter system failure modes and sensor signal data integrity. Again, this information is transmitted periodically by the transmitter unit 102 to the receiver unit 104 along with the sampled sensor signals at the predetermined time intervals.

Referring again to the Figures, as the analyte sensor measurements are affected by the temperature of the tissue around the transcutaneously positioned sensor 101, in one aspect, compensation of the temperature variations and effects on the sensor signals are provided for determining the corresponding glucose value. Moreover, the ambient temperature around the sensor 101 may affect the accuracy of the on skin temperature measurement and ultimately the glucose value determined from the sensor signals. Accordingly, in one aspect, a second temperature sensor is provided in the transmitter unit 102 away from the on skin temperature sensor (for example, physically away from the tempera-

11

ture measurement section 203 of the transmitter unit 102), so as to provide compensation or correction of the on skin temperature measurements due to the ambient temperature effects. In this manner, the accuracy of the estimated glucose value corresponding to the sensor signals may be attained.

In one aspect, the processor 204 of the transmitter unit 102 may be configured to include the second temperature sensor, and which is located closer to the ambient thermal source within the transmitter unit 102. In other embodiments, the second temperature sensor may be located at a different location within the transmitter unit 102 housing where the ambient temperature within the housing of the transmitter unit 102 may be accurately determined.

Referring now to FIG. 5, in one aspect, an ambient temperature compensation routine for determining the on-skin temperature level for use in the glucose estimation determination based on the signals received from the sensor 101. Referring to FIG. 5, for each sampled signal from the sensor 101, a corresponding measured temperature information is received (510), for example, by the processor 204 from the temperature measurement section 203 (which may include, for example, a thermistor provided in the transmitter unit 102). In addition, a second temperature measurement is obtained (520), for example, including a determination of the ambient temperature level using a second temperature sensor provided within the housing the transmitter unit 102.

In one aspect, based on a predetermined ratio of thermal resistances between the temperature measurement section 203 and the second temperature sensor (located, for example, within the processor 204 of the transmitter unit 102), and between the temperature measurement section 203 and the skin layer on which the transmitter unit 102 is placed and coupled to the sensor 101, ambient temperature compensation may be performed (530), to determine the corresponding ambient temperature compensated on skin temperature level (540). In one embodiment, the predetermined ratio of the thermal resistances may be approximately 0.2. However, within the scope of the present disclosure, this thermal resistance ratio may vary according to the design of the system, for example, based on the size of the transmitter unit 102 housing, the location of the second temperature sensor within the housing of the transmitter unit 102, and the like.

With the ambient temperature compensated on-skin temperature information, the corresponding glucose value from the sampled analyte sensor signal may be determined.

Referring again to FIG. 2, the processor 204 of the transmitter unit 102 may include a digital anti-aliasing filter. Using analog anti-aliasing filters for a one minute measurement data sample rate would require a large capacitor in the transmitter unit 102 design, and which in turn impacts the size of the transmitter unit 102. As such, in one aspect, the sensor signals may be oversampled (for example, at a rate of 4 times per second), and then the data is digitally decimated to derive a one-minute sample rate.

As discussed above, in one aspect, the digital anti-aliasing filter may be used to remove, for example, signal artifacts or otherwise undesirable aliasing effects on the sampled digital signals received from the analog interface 201 of the transmitter unit 102. For example, in one aspect, the digital anti-aliasing filter may be used to accommodate decimation of the sensor data from approximately four Hz samples to one-minute samples. In one aspect, a two stage FIR filter may be used for the digital anti-aliasing filter, which includes improved response time, pass band and stop band properties.

12

Referring to FIG. 6, a routine for digital anti-aliasing filtering is shown in accordance with one embodiment. As shown, in one embodiment, at each predetermined time period such as every minute, the analog signal from the analog interface 201 corresponding to the monitored analyte level received from the sensor 101 (FIG. 1) is sampled (610). For example, at every minute, in one embodiment, the signal from the analog interface 201 is over-sampled at approximately 4 Hz. Thereafter, the first stage digital filtering on the 10 over-sampled data is performed (620), where, for example, a $\frac{1}{6}$ down-sampling from 246 samples to 41 samples is 15 performed, and the resulting 41 samples is further down-sampled at the second stage digital filtering (630) such that, for example, a $\frac{1}{41}$ down-sampling is performed from 41 samples (from the first stage digital filtering), to a single sample. Thereafter, the filter is reset (640), and the routine returns to the beginning for the next minute signal received from the analog interface 201.

While the use of FIR filter, and in particular the use of 20 Kaiser FIR filter, is within the scope of the present disclosure, other suitable filters, such as FIR filters with different weighting schemes or IIR filters, may be used.

Referring yet again to the Figures, the transmitter unit 102 may be configured in one embodiment to periodically perform 25 data quality checks including error condition verifications and potential error condition detections, and also to transmit the relevant information related to one or more data quality, error condition or potential error condition detection to the receiver unit 104 with the transmission of the monitored sensor data. For example, in one aspect, a state machine 30 may be used in conjunction with the transmitter unit 102 and which may be configured to be updated four times per second, the results of which are transmitted to the receiver unit 104 every minute.

In particular, using the state machine, the transmitter unit 102 may be configured to detect one or more states that may indicate when a sensor is inserted, when a sensor is removed 35 from the user, and further, may additionally be configured to perform related data quality checks so as to determine when a new sensor has been inserted or transcutaneously positioned under the skin layer of the user and has settled in the inserted state such that the data transmitted from the transmitter unit 102 does not compromise the integrity of signal processing performed by the receiver unit 104 due to, for 40 example, signal transients resulting from the sensor insertion.

That is, when the transmitter unit 102 detects low or no signal from the sensor 101 which is followed by detected signals from the sensor 101 that is above a given signal, the 45 processor 204 may be configured to identify such transition is monitored signal levels and associate with a potential sensor insertion state. Alternatively, the transmitter unit 102 may be configured to detect the signal level above another predetermined threshold level, which is followed by the 50 detection of the signal level from the sensor 101 that falls below the predetermined threshold level. In such a case, the processor 204 may be configured to associate or identify such transition or condition in the monitored signal levels as a potential sensor removal state.

Accordingly, when either of potential sensor insertion state or potential sensor removal state is detected by the transmitter unit 102, this information is transmitted to the receiver unit 104, and in turn, the receiver unit may be 55 configured to prompt the user for confirmation of either of the detected potential sensor related state. In another aspect, the sensor insertion state or potential sensor removal state may be detected or determined by the receiver unit based on

13

one or more signals received from the transmitter unit 102. For example, similar to an alarm condition or a notification to the user, the receiver unit 104 may be configured to display a request or a prompt on the display or an output unit of the receiver unit 104 a text and/or other suitable notification message to inform the user to confirm the state of the sensor 101.

For example, the receiver unit 104 may be configured to display the following message: "New Sensor Inserted?" or a similar notification in the case where the receiver unit 104 receives one or more signals from the transmitter unit 102 associated with the detection of the signal level below the predetermined threshold level for the predefined period of time, followed by the detection of the signal level from the sensor 101 above another predetermined threshold level for another predefined period of time. Additionally, the receiver unit 104 may be configured to display the following message: "Sensor Removed?" or a similar notification in the case where the receiver unit 104 received one or more signals from the transmitter unit 102 associated with the detection of the signal level from the sensor 101 that is above another predetermined threshold level for another predefined period of time, which is followed by the detection of the signal level from the sensor 101 that falls below the predetermined threshold level for the predefined period of time.

Based on the user confirmation received, the receiver unit 104 may be further configured to execute or perform additional related processing and routines in response to the user confirmation or acknowledgement. For example, when the user confirms, using the user interface input/output mechanism of the receiver unit 104, for example, that a new sensor has been inserted, the receiver unit 104 may be configured to initiate new sensor insertion related routines including, such as, for example, a sensor calibration routine including, for example, calibration timer, sensor expiration timer and the like. Alternatively, when the user confirms or it is determined that the sensor 101 is not properly positioned or otherwise removed from the insertion site, the receiver unit 104 may be accordingly configured to perform related functions such as, for example, stop displaying of the glucose values/levels, or deactivating the alarm monitoring conditions.

On the other hand, in response to the potential sensor insertion notification generated by the receiver unit 104, if the user confirms that no new sensor has been inserted, then the receiver unit 104 in one embodiment is configured to assume that the sensor 101 is in acceptable operational state, and continues to receive and process signals from the transmitter unit 102.

In this manner, in cases, for example, when there is momentary movement or temporary dislodging of the sensor 101 from the initially positioned transcutaneous state, or when one or more of the contact points between sensor 101 and the transmitter unit 102 are temporarily disconnected, but otherwise, the sensor 101 is operational and within its useful life, the routine above provides an option to the user to maintain the usage of the sensor 101, without replacing the sensor 101 prior to the expiration of its useful life. In this manner, in one aspect, false positive indications of sensor 101 failure may be identified and addressed.

For example, FIG. 7 is a flowchart illustrating actual or potential sensor insertion or removal detection routine in accordance with one embodiment of the present disclosure. Referring to the Figure, the current analyte related signal is first compared to a predetermined signal characteristic (710). In one aspect, the predetermined signal characteristic

14

may include one of a signal level transition from below a first predetermined level (for example, but not limited to 18 ADC (analog to digital converter) counts) to above the first predetermined level, a signal level transition from above a second predetermined level (for example, but not limited to 9 ADC counts) to below the second predetermined level, a transition from below a predetermined signal rate of change threshold to above the predetermined signal rate of change threshold, and a transition from above the predetermined signal rate of change threshold to below the predetermined signal rate of change threshold.

In this manner, in one aspect of the present disclosure, based on a transition state of the received analyte related signals, it may be possible to determine the state of the analyte sensor (720), and based on which, the user or the patient may confirm whether the analyte sensor is in the desired or proper position, has been temporarily dislocated, or otherwise, removed from the desired insertion site so as to require a new analyte sensor. A prior signal associated with the analyte level is compared with the current analyte related signal (730). An output data is generated which is associated with the operational state (740).

In this manner, in one aspect, when the monitored signal from the sensor 101 crosses a transition level (for example, from no or low signal level to a high signal level, or vice versa), the transmitter unit 102 may be configured to generate an appropriate output data associated with the sensor signal transition, for transmission to the receiver unit 104 (FIG. 1). Additionally, as discussed in further detail below, in another embodiment, the determination of whether the sensor 101 has crossed a transition level may be determined by the receiver/monitor unit 104/106 based, at least in part on the one or more signals received from the transmitter unit 102.

FIG. 8 is a flowchart illustrating receiver unit processing corresponding to the actual or potential sensor insertion or removal detection routine of FIG. 7 in accordance with one embodiment of the present disclosure. Referring now to FIG. 8, when the receiver unit 104 receives the generated output data from the transmitter unit 102 (810), a corresponding operation state is associated with the received output data (820), for example, related to the operational state of the sensor 101. Moreover, a notification associated with the sensor operation state is generated and output to the user on the display unit or any other suitable output segment of the receiver unit 104 (830). When a user input signal is received in response to the notification associated with the sensor state operation state (840), the receiver unit 104 is configured to execute one or more routines associated with the received user input signal (850).

That is, as discussed above, in one aspect, if the user confirms that the sensor 101 has been removed, the receiver unit 104 may be configured to terminate or deactivate alarm monitoring and glucose displaying functions. On the other hand, if the user confirms that a new sensor 101 has been positioned or inserted into the user, then the receiver unit 104 may be configured to initiate or execute routines associated with the new sensor insertion, such as, for example, calibration procedures, establishing calibration timer, and establishing sensor expiration timer.

In a further embodiment, based on the detected or monitored signal transition, the receiver/monitor unit may be configured to determine the corresponding sensor state without relying upon the user input or confirmation signal associated with whether the sensor is dislocated or removed from the insertion site, or otherwise, operating properly.

FIG. 9 is a flowchart illustrating data processing corresponding to the actual or potential sensor insertion or removal detection routine in accordance with another embodiment of the present disclosure. Referring to FIG. 9, a current analyte related signal is received and compared to a predetermined signal characteristic (910). Thereafter, an operational state associated with an analyte monitoring device such as, for example, the sensor 101 (FIG. 1) is retrieved (920) from a storage unit or otherwise resident in, for example, a memory of the receiver/monitor unit. Additionally, a prior analyte related signal is also retrieved from the storage unit, and compared to the current analyte related signal received (930). An output data is generated which is associated with the operational state (940), and which at least in part is based on the one or more of the received current analyte related signal and the retrieved prior analyte related signal.

Referring again to FIG. 9, when the output data is generated, a corresponding user input command or signal is received in response to the generated output data (950), which may include one or more of a confirmation, verification, or rejection of the operational state related to the analyte monitoring device.

FIG. 10 is a flowchart illustrating a concurrent passive notification routine in the data receiver/monitor unit of the data monitoring and management system of FIG. 1 in accordance with one embodiment of the present disclosure. Referring to FIG. 10, a predetermined routine is executed for a predetermined time period to completion (1010). During the execution of the predetermined routine, an alarm condition is detected (1020), and when the alarm or alert condition is detected, a first indication associated with the detected alarm or alert condition is output concurrent to the execution of the predetermined routine (1030).

That is, in one embodiment, when a predefined routine is being executed, and an alarm or alert condition is detected, a notification is provided to the user or patient associated with the detected alarm or alert condition, but which does not interrupt or otherwise disrupt the execution of the predefined routine. Referring back to FIG. 10, upon termination of the predetermined routine, another output or second indication associated with the detected alarm condition is output or displayed (1040).

More specifically, in one aspect, the user interface notification feature associated with the detected alarm condition is output to the user only upon the completion of an ongoing routine which was in the process of being executed when the alarm condition is detected. As discussed above, when such alarm condition is detected during the execution of a predetermined routine, a temporary alarm notification such as, for example, a backlight indicator, a text output on the user interface display or any other suitable output indication may be provided to alert the user or the patient of the detected alarm condition substantially in real time, but which does not disrupt an ongoing routine.

Within the scope of the present disclosure, the ongoing routine or the predetermined routine being executed may include one or more of performing a finger stick blood glucose test (for example, for purposes of periodically calibrating the sensor 101), or any other processes that interface with the user interface, for example, on the receiver/monitor unit 104/106 (FIG. 1) including, but not limited to the configuration of device settings, review of historical data such as glucose data, alarms, events, entries in the data log, visual displays of data including graphs, lists, and plots, data communication management including RF communication administration, data transfer to the data

processing terminal 105 (FIG. 1), or viewing one or more alarm conditions with a different priority in a preprogrammed or determined alarm or notification hierarchy structure.

In this manner, in one aspect of the present disclosure, the detection of one or more alarm conditions may be presented or notified to the user or the patient, without interrupting or disrupting an ongoing routine or process in, for example, the receiver/monitor unit 104/106 of the data monitoring and management system 100 (FIG. 1).

Referring now back to the Figures, FIG. 11 is a flowchart illustrating a data quality verification routine in accordance with one embodiment of the present disclosure. Referring to FIG. 11, initially the data quality status flags are cleared or initialized or reset (1110). Thereafter, data quality checks or verifications are performed, for example, as described above (1120). Thereafter, data quality flag is generated and associated with the data packet when data quality check has failed (1130). In one aspect, the generated data quality flag may be based on data quality verification such that when the underlying condition being verified is determined to be acceptable, the data quality flag may return a value of zero (or one or more predetermined value). Alternatively, in the case where the underlying condition being verified is determined to be not within the acceptable criteria (or above the acceptable level), the associated data quality flag may return a value of one (or one or more predetermined value associated with the determination of such condition).

Referring to FIG. 11, the data packet including the raw glucose data as well as the data quality flags are transmitted, for example, to the receiver/monitor unit 104/106 for further processing (1140). As described above, the data quality checks may be performed in the transmitter unit 102 (FIG. 1) and/or in the receiver/monitor unit 104/106 in the data monitoring and management system 100 (FIG. 1) in one aspect of the present disclosure.

FIG. 12 is a flowchart illustrating a rate variance filtering routine in accordance with one embodiment of the present disclosure. Referring to FIG. 12, when glucose related data is detected or received (1210), for example, for each predetermined time intervals such as every minute, every five minutes or any other suitable time intervals, a plurality of filtered values based on the received or detected glucose related data is determined (1220). For example, as discussed above, in one aspect, using, for example, an FIR filter, or based on a weighted average, a plurality of filtered values for a 15 minute and two minute glucose related data including the currently received or detected glucose related are determined.

Referring back to FIG. 12, weighting associated with the plurality of filtered values is determined (1230). Thereafter, a rate of change of the glucose level based in part on the detected or received glucose related data is determined as well as a standard deviation of the rate of change based on the glucose related data (1240). Further, a weighted average associated with the current detected or monitored glucose related data is determined based on the plurality of filtered values and the determined standard deviation of the rate of change and/or the rate of change of the glucose level (1250). For example, when the rate of change is determined to be high relative to the rate of change variation, the filtered value based on the two minute data is weighted more heavily. On the other hand, when the rate of change is determined to be low relative to the rate of change variation, the filtered glucose related data includes the one of the plurality of filtered values based on the 15 minute data which is weighted more heavily. In this manner, in one aspect, there

is provided a rate variance filtering approach which may be configured to dynamically modify the weighting function or data filtering to, for example, reduce undesirable variation in glucose related signals due to factors such as noise.

FIG. 13 is a flowchart illustrating a composite sensor sensitivity determination routine in accordance with one embodiment of the present disclosure. Referring to FIG. 13, during scheduled calibration time periods or otherwise manual calibration routines to calibrate the analyte sensor, when a current blood glucose value is received or detected (1310), a current or present sensitivity is determined based on the detected blood glucose value (1320). For example, the current sensitivity may be determined by taking a ratio of the current glucose sensor value and the detected blood glucose value.

Referring to FIG. 13, a prior sensitivity previously determined is retrieved, for example, from the storage unit (1330). In one aspect, the prior sensitivity may include a previous sensitivity determined during a prior sensor calibration event, or may be based on the nominal sensor sensitivity based on the sensor code from manufacturing, for example. Returning again to FIG. 13, a first weighted parameter is applied to the current sensitivity, and a second weighted parameter is applied to the retrieved prior sensitivity (1340). For example, based on the time lapsed between the calibration event associated with the retrieved prior sensitivity value and the current calibration event (associated with the current or received blood glucose value), the first and second weighted parameters may be modified (e.g., increased or decreased in value) to improve accuracy.

Referring back to FIG. 13, based on applying the first and the second weighted parameters to the current sensitivity and the retrieved prior sensitivity, a composite sensitivity associated with the analyte sensor for the current calibration event is determined (1350). For example, using a time based approach, in one embodiment, the sensitivity associated with the analyte sensor for calibration may be determined to, for example, reduce calibration errors or accommodate sensitivity drift.

FIG. 14 is a flowchart illustrating an outlier data point verification routine in accordance with one embodiment of the present disclosure. Referring to FIG. 14, and as discussed in detail above, in determining composite sensitivity associated with the analyte sensor calibration, in one aspect, an outlier data point may be detected and accordingly corrected. For example, in one aspect, two successive sensitivities associated with two successive calibration events for the analyte sensor is compared (1410). If it is determined that the comparison between the two sensitivities are within a predetermined range (1420), the composite sensitivity for the current calibration of the analyte sensor is determined based on the two successive sensitivity values (1430), using, for example, the weighted approach described above.

Referring back to FIG. 14, if it is determined that the comparison of the two successive sensitivities results in the compared value being outside of the predetermined range, then the user may be prompted to enter or provide a new current blood glucose value (for example, using a blood glucose meter) (1440). Based on the new blood glucose value received, an updated or new sensitivity associated with the analyte sensor is determined (1450). Thereafter, the new or updated sensitivity determined is compared with the two prior sensitivities compared (at 1420) to determine whether the new or updated sensitivity is within a predefined range of either of the two prior sensitivities (1460). If it is determined that the new or updated sensitivity of the analyte

sensor is within the predefined range of either of the two prior successive sensitivities, a composite sensitivity is determined based on the new or updated sensitivity and the one of the two prior successive sensitivities within the defined range of which the new or updated sensitivity is determined (1470). On the other hand, if it is determined that the new or updated sensitivity is not within the predefined range of either of the two prior sensitivities, then the routine repeats and prompts the user to enter a new blood glucose value (1440).

FIG. 15 is a flowchart illustrating a sensor stability verification routine in accordance with one embodiment of the present disclosure. Referring to FIG. 15, and as discussed above, between predetermined or scheduled baseline calibration events to calibrate the sensor, the analyte sensor sensitivity stability may be verified, to determine, for example, if additional stability calibrations may be needed prior to the subsequent scheduled baseline calibration event.

For example, referring to FIG. 15, in one embodiment, after the second baseline calibration event to calibrate the analyte sensor, the user may be prompted to provide a new blood glucose value. With the current blood glucose value received (1510), the current sensor sensitivity is determined (1520). Thereafter, the most recent stored sensor sensitivity value from prior calibration event is retrieved (for example, from a storage unit) (1530), and the determined current sensor sensitivity is compared with the retrieved stored sensor sensitivity value to determine whether the difference, if any, between the two sensitivity values are within a predefined range (1540).

Referring back to FIG. 15, if it is determined that the difference between the current and retrieved sensitivity values are within the predefined range, then the stability associated with the sensor sensitivity is confirmed (1550), and no additional calibration is required prior to the subsequent scheduled baseline calibration event. On the other hand, if it is determined that the difference between the current sensitivity and the retrieved prior sensitivity is not within the predefined range, then after a predetermined time period has lapsed (1560), the routine returns to the beginning and prompts the user to enter a new blood glucose value to perform the stability verification routine.

In this manner, in one aspect, the stability checks may be performed after the outlier check is performed, and a new composite sensitivity determined as described above. Accordingly, in one aspect, analyte sensor sensitivity may be monitored as the sensitivity attenuation is dissipating to, among others, improve accuracy of the monitored glucose data and sensor stability.

FIG. 16 illustrates analyte sensor code determination in accordance with one embodiment. Referring to the Figure, a batch of predetermined number of analyte sensors, for example, glucose sensors are selected during the manufacturing process (1610). The batch of predetermined number of glucose sensors may be a set number, or a variable number depending upon other manufacturing or post-manufacturing parameters (for example, such as testing, quality control verification, or packaging).

Referring to FIG. 16, the sensitivity of each selected glucose sensor is determined (1620). For example, in one aspect, in vitro sensitivity determination is performed for each selected glucose sensor to determine the corresponding sensitivity. Thereafter, a variation between the determined sensitivity of each glucose sensor is determined (1630). That is, in one aspect, the determined in vitro sensitivity associated with each selected glucose sensor is compared to a predefined variation tolerance level (1640).

In one aspect, if the variation of the sensitivity is greater than the predefined variation tolerance level for one of the selected glucose sensors in the selected batch of predetermined number of glucose sensors (1660), then the entire batch or lot may be rejected and not used. In another aspect, the rejection of the selected batch of predetermined number of glucose sensors may be based on a predetermined number of sensors within the selected batch that are associated with a sensitivity value that exceeds the predefined variation tolerance level. For example, in a batch of 30 glucose sensors, if 10 percent (or 3 sensors) has sensitivity that exceeds the predefined variation tolerance level, then the entire batch of 30 glucose sensors is rejected and not further processed during the manufacturing routine, for example, for use. Within the scope of the present disclosure, the number of sensors in the selected batch, or the number of sensors within the selected batch that exceeds the predefined variation tolerance level to result in a failed batch may be varied depending upon, for example, but not limited to, sensor manufacturing process, sensor testing routines, quality control verification, or other parameters associated with sensor performance integrity.

Referring back to FIG. 16, if it is determined that the sensitivity of the selected glucose sensors are within the predefined variation tolerance level, a nominal sensitivity is determined for the batch of the predetermined number of glucose sensors (1650). Further, a sensor code is associated with the determined nominal sensitivity for the batch of predetermined number of analyte sensors (1670).

In one aspect, the sensor code may be provided on the labeling for the batch of glucose sensors for use by the patient or the user. For example, in one aspect, the analyte monitoring system may prompt the user to enter the sensor code into the system (for example, to the receiver unit 104/106 FIG. 1) after the sensor has been initially positioned in the patient and prior to the first sensor calibration event. In a further aspect, based on the sensor code, the analyte monitoring system may be configured to retrieve the nominal sensitivity associated with the batch of predetermined number of sensors for, for example, calibration of the transcutaneously positioned glucose sensor.

FIG. 17 illustrates an early user notification function associated with the analyte sensor condition in one aspect of the present disclosure. Referring to FIG. 17, upon detection of the sensor insertion (1710), for example, in fluid contact with the patient or user's analyte (e.g., interstitial fluid), one or more adverse data condition occurrence associated with the patient or the user's analyte level is monitored (1720). Examples of the adverse data condition occurrence may include, for example, a persistent low sensor signal (for example, continuous for a predefined time period), identified data quality flags or identifiers associated with erroneous or potentially inaccurate sensor signal level or sensor condition (for example, dislodged or improperly positioned sensor).

Referring to FIG. 17, when it is determined that the monitored adverse data condition occurrence exceeds a predetermined number of occurrences during a predefined time period (1730), a notification is generated and provided to the user to either replace the sensor, or to perform one or more verifications to confirm, for example, but not limited to, that the sensor is properly inserted and positioned, so the transmitter unit is in proper contact with the sensor (1740).

On the other hand, if the number of adverse data condition occurrence has not occurred during the predefined time period, in one aspect, the routine continues to monitor for the occurrence of such condition during the set time period. In one aspect, the predetermined time period during which the

occurrence of adverse data condition occurrence may be approximately one hour from the initial sensor positioning. Alternatively, this time period may be shorter or longer, depending upon the particular system configuration.

In this manner, in the event that adverse condition related to the sensor is determined and persists for a given time period from the initial sensor insertion, the user or the patient is notified to either replace the sensor or to perform one or more troubleshooting steps to make sure that the components of the analyte monitoring system are functioning properly. Indeed, in one aspect, when an adverse condition related to the sensor is identified early on, the user is not inconvenienced by continuing to maintain the sensor in position even though the sensor may be defective or improperly positioned, or is associated with one or more other adverse conditions that will not allow the sensor to function properly.

FIG. 18 illustrates uncertainty estimation associated with glucose level rate of change determination in one aspect of the present disclosure. Referring to FIG. 18, based on the monitored glucose level from the glucose sensor, a rate of change estimate of the glucose level fluctuation is determined (1810). Further, an estimation of an uncertainty range or level associated with the determined rate of change of the glucose level is determined (1820). That is, in one aspect, a predefined rate of uncertainty determination may be performed, such as for example, a rate of change variance calculation. If the uncertainty determination is within a predetermined threshold level (1830), then an output is generated and/or provided to the user (1840).

For example, when it is determined that the determined uncertainty measure is within the threshold level, the analyte monitoring system may be configured to display or output an indication to the user or the patient, such as a glucose level trend indicator (for example, a visual trend arrow or a distinctive audible alert (increasing or decreasing tone, etc)). On the other hand, if it is determined that the uncertainty measure related to the rate of change estimate exceeds the predetermined threshold, the determined rate of change of glucose level may be rejected or discarded (or stored but not output to the user or the patient). In one aspect, the uncertainty measure may include a predefined tolerance parameter associated with the accuracy of the determined rate of change of the monitored glucose level.

In one aspect, the uncertainty measure or the tolerance level related to the rate of change of monitored glucose level may include, for example, but not limited to, corrupt or erroneous data associated with the monitored glucose level, unacceptably large number of missing data associated with the monitored glucose level, rate of acceleration or deceleration of the monitored glucose level that exceeds a defined or acceptable threshold level, or any other parameters that may contribute to potential inaccuracy in the determined rate of change of the monitored glucose level.

Accordingly, in one aspect, the accuracy of the analyte monitoring system may be maintained by, for example, disabling the output function associated with the rate of change determination related to the monitored glucose level, so that the user or the patient does not take corrective actions based on potentially inaccurate information. That is, as discussed above, in the event when it is determined that the determined uncertainty measure or parameter exceeds an acceptable tolerance range, the output function on the receiver unit 104/106 in the analyte monitoring system 100 may be disabled temporarily, or until the uncertainty mea-

sure of parameter related to the rate of change of the glucose level being monitored is within the acceptable tolerance range.

When the monitored rate of change of the glucose level is steady (or within a defined range) and medically significant with respect to the monitored glucose measurement, a prediction of future or anticipated glucose level may be considered reliable based on the determined rate of change level. However, the monitored glucose level time series is such that the determined rate of change estimate may be less certain.

Accordingly, in one aspect, the present disclosure accounts for the rate of change estimates having varying degrees of certainty. Since clinical treatment decisions may be made based on these estimates, it is important to discount, or not display or output to the user, the determined rate of change estimates with a high degree of uncertainty.

In one aspect, the rate of change value and its uncertainty determine a probability distribution. This distribution may be assumed to be Gaussian, for example. Within the scope of the present disclosure, the uncertainty measure may be calculated in various ways. In one embodiment, it may include a standard deviation determination. Another possibility is to use the coefficient of variation (CV), which is the standard deviation of the rate of change divided by the rate of change. A combination of these uncertainty measures may also be used.

In one aspect, various ranges of rates of change may be combined into bins. For example, bin edges at ± 2 mg/dL and at ± 1 mg/dL may be defined in one embodiment resulting in five bins. Each bin may be represented by a position of a trend arrow indicator, associated with the monitored glucose level. When the rate of change is included in one of the determined bins, the associated trend arrow position may be displayed.

Further, the presence of uncertainty may modify the trend arrow position that is displayed to the user or the patient. In one aspect, a determination that involves the uncertainty measure results in a metric value which may be a simple comparison of the uncertainty value to a predefined threshold. There are also other possible metrics. Another approach may use a different predefined threshold value for each bin.

In one aspect, an unacceptable metric value may cause no trend arrow indicator to be displayed. Alternatively, this condition may be indicated by a change in the characteristics of the display to the user or the patient. For example, the trend arrow indicator may flash, change color, change shape, change size, change length or change width, among others. A further embodiment may include the trend arrow indicator showing no significant rate-of-change. Within the scope of the present disclosure, other user output configurations including audible and/or vibratory output are contemplated.

In one aspect, the uncertainty measure may be characterized a number of ways. One is the standard deviation of the monitored glucose levels over the period in which the rate of change is estimated. Another is the coefficient of variation (CV), which, as discussed above, is the standard deviation of the monitored glucose trend divided by the rate of change value. A further characterization may include a probabilistic likelihood estimate. Yet a further characterization is the output of a statistical filter or estimator such as a Kalman filter. The uncertainty comparison may be based on one of these techniques or a combination of two or more of these techniques. Also, different uncertainty characteristics may be used for different rate-of-change results. For instance, in

one embodiment, a CV formulation may be used for high glucose values and a standard deviation formulation may be used for low glucose values.

FIG. 19 illustrates glucose trend determination in accordance with one embodiment of the present disclosure. Referring to FIG. 19, a current value associated with a monitored glucose level is received (1910). One or more prior values associated with the monitored glucose level (previously stored, for example) is retrieved (1920). With the current and prior values associated with the monitored glucose level, a most recent calibration scale factor is applied to the current and prior values associated with the monitored glucose level (1930). After applying the calibration scale factor to the current and prior values, the trend associated with the monitored glucose level is determined (1940).

In this manner, in one aspect, with the updated calibration of the glucose sensor including a newly determined sensitivity, buffered or stored values associated with the monitored glucose level may be updated using, for example, the updated calibration information, resulting, for example, in revised or modified prior values associated with the monitored glucose level. As such, in one embodiment, stored or buffered values associated with the monitored glucose level may be updated and, the updated values may be used to determine glucose trend information or rate of change of glucose level calculation. In this manner, accuracy of the glucose trend information may be improved by applying the most recent calibration parameters to previously detected and stored values associated with the monitored glucose level, when, for example, the previously detected and stored values are used for further analysis, such as, glucose trend determination or rate of change of glucose level calculation.

FIG. 20 illustrates glucose trend determination in accordance with another embodiment of the present disclosure. Referring to FIG. 20, a current value associated with a monitored glucose level is received (2010). One or more prior values associated with the monitored glucose level (previously stored, for example) is retrieved (2020). With the current and prior values associated with the monitored glucose level, a rate of change estimate of the monitored glucose level is determined (2030). Referring back to FIG. 20, an uncertainty parameter associated with the rate of change estimate is determined (2040).

In one aspect, an uncertainty parameter may be predetermined and programmed into the analyte monitoring system 100 (for example, in the receiver unit 104/106). Alternatively, the uncertainty parameter may be dynamically configured to vary depending upon the number of data available for determination of the glucose level rate of change determination, or upon other programmable parameters that may include user specified uncertainty parameters. Within the scope of the present disclosure, the uncertainty parameter may include the number of acceptable missing or unavailable values when performing the monitored glucose level rate of change estimation. Referring back to FIG. 20, when it is determined that the uncertainty parameter is within an acceptable predetermined tolerance range, the rate of change of the monitored glucose level is determined and output to the user or the patient (2050).

In one embodiment, the uncertainty parameter may be associated with the time spacing of the current and prior values, such that when the rate of change estimation requires a preset number of values, and no more than a predetermined number of values (optionally consecutively, or non consecutively) are unavailable, the rate of change estimation is performed. In this manner, for example, when a large number of values associated with the monitored glucose

level (for example, 5 consecutive one minute data—tolerance range) are unavailable, corrupt or otherwise unusable for purposes of rate of change determination, the uncertainty parameter is deemed to exceed the predetermined tolerance range, and the rate of change calculation may not be performed, or may be postponed.

As discussed, the rate of change in glucose for a patient or a user may be used by glucose monitoring devices to direct glucose trend indicators for display to the patient or the user such that the patient or the user may base treatment decisions not only on the current glucose levels but also on the current direction or change in the glucose level. The rate of change estimate may also be used to project into the future if a predetermined glucose threshold (upper or lower range or limit) is not exceeded within a specific time period based on the current glucose level and rate of change information. Within the scope of the present disclosure, other projection approaches may be based on higher order derivatives of the rate of change, and/or other statistical likelihood formulations that can be contemplated for prediction of a future event.

One approach to determine the rate of change is to calculate the difference between two glucose samples and dividing the result by the time difference between the samples. Another approach may be to fit a time series of glucose readings to a function, such as a polynomial, using techniques such as the least squares techniques. The number of samples and the time period of the samples may impact the accuracy of the rate of change estimate in the form of a trade off between noise reduction properties and lag introduced.

Referring again to the Figures, in one aspect, the transmitter unit **102** may be configured to perform one or more periodic or routine data quality checks or verification before transmitting the data packet to the receiver/monitor unit **104/106**. For example, in one aspect, for each data transmission (e.g., every 60 seconds, or some other predetermined transmission time interval), the transmitter data quality flags in the data packet are reset, and then it is determined whether any data field in the transmission data packet includes an error flag. If one error flag is detected, then in one aspect, the entire data packet may be considered corrupt, and this determination is transmitted to the receiver/monitor unit **104/106**. Alternatively, the determination that the entire data packet is corrupt may be performed by the receiver/monitor unit **104/106**. Accordingly, in one aspect, when at least one data quality check fails in the transmitter data packet, the entire packet is deemed to be in error, and the associated monitored analyte level is discarded, and not further processed by the receiver/monitor unit **104/106**.

In another aspect, the data quality check in the transmitter unit **102** data packet may be performed so as to identify each error flag in the data packet, and those identified error flag are transmitted to the receiver/monitor unit **104/106** in addition to the associated monitored analyte level information. In this manner, in one aspect, if the error flag is detected in the transmitter data packet which is not relevant to the accuracy of the data associated with the monitored analyte level, the error indication is flagged and transmitted to the receiver/monitor unit **104/106** in addition to the data indicating the monitored analyte level.

In one aspect, examples of error condition that may be detected or flagged in the transmitter unit **102** data packet include sensor connection fault verification by, for example, determining, among others, whether the counter electrode voltage signal is within a predetermined range, resolution of the data associated with the monitored analyte level, trans-

mitter unit temperature (ambient and/or on-skin temperature) out of range, and the like. As discussed above, the data quality check in the transmitter unit **102** may be performed serially, such that detection of an error condition or an error flag renders the entire data packet invalid or deemed corrupt. In this case, such data is reported as including error to the receiver/monitor unit **104/106**, but not used to process the associated monitored analyte level. In another aspect, all data quality fields in the data packet of the transmitter unit **102** may be checked for error flags, and if there are error flags detected, the indication of the detected error flags is transmitted with the data packet to the receiver/monitor unit **104/106** for further processing.

In one embodiment, on the receiver/monitor unit **104/106** side, for each periodic data packet received (for example every 60 seconds or some other predetermined time interval), the receiver/monitor unit **104/106** may be configured to receive the raw glucose data including any data quality check flags from the transmitter unit **102**, and to apply temperature compensation and/or calibration to the raw data to determine the corresponding glucose data (with any data quality flags as may have been identified). The unfiltered, temperature compensated and/or calibrated glucose data is stored along with any data quality flags in a FIFO buffer (including, for example, any invalid data identifier). Alternatively, a further data quality check may be performed on the temperature compensated and calibrated glucose data to determine the rate of change or variance of the measured glucose data. For example, in one embodiment, a high variance check or verification is performed on 30 minutes of glucose data stored in the FIFO buffer. If it is determined that the rate of variance exceeds a predetermined threshold, then the data packet in process may be deemed invalid. On the other hand, if the rate of variance does not exceed the predetermined threshold, the results including the glucose data and any associated validity or error flags are stored in the FIFO buffer.

Thereafter, the data processing is performed on the stored data to determine, for example, the respective glucose level estimation or calculation. That is, the stored data in the FIFO buffer in one embodiment is filtered to reduce unwanted variation in signal measurements due to noise or time delay, among others. In one aspect, when the rate of change or variance of glucose data stored in the FIFO buffer, for example, is within a predetermined limit, the glucose measurements are filtered over a 15 minute period. On the other hand, if it is determined that the rate of change is greater than the predetermined limit, a more responsive 2 minute filtering is performed. In one aspect, the filtering is performed for each 60 second glucose data. In this manner, in one embodiment, a rate variance filter is provided that may be configured to smooth out the variation in the glucose measurement when the glucose level is relatively stable, and further, that can respond quickly when the glucose level is changing rapidly. The rate variance filter may be implemented in firmware as an FIR filter which is stable and easy to implement in integer-based firmware, for example, implemented in fixed point math processor.

In one embodiment, for each 60 second glucose data received, two filtered values and two additional parameters are determined. That is, using an FIR filter, for example, a weighted average for a 15 minute filtered average glucose value and a 2 minute average filtered glucose value are determined. In addition, a rate of change based on 15 minutes of data as well as a standard deviation associated with the rate estimate is determined. To determine the final filtered glucose value for output and/or display to the user,

a weighted average of the two determined filtered glucose values is determined, where when the rate of change of the glucose values is high, then weighting is configured to tend towards the 2 minute filtered value, while when the rate of change of the glucose value is low the weighting tends towards the 15 minute filtered value. In this manner, when the rate of change is high, the 2 minute filtered value is weighted more heavily (as the 15 minute filtered average value potentially introduces lag, which at higher rates of change, likely results in large error).

Referring back, during the calibration routine, in one embodiment, when the discrete blood glucose value is received for purposes of calibration of the glucose data from the sensor 101 (FIG. 1), the processing unit of the receiver/monitor unit 104/106 is configured to retrieve from the FIFO buffer two of the last five valid transmitter data packets that do not include any data quality flags associated with the respective data packets. In this manner, in one aspect, the calibration validation check may be performed when the blood glucose value is provided to the receiver/monitor unit 104/106 determined using, for example, a blood glucose meter. In the event that two valid data packets from the last five data packets cannot be determined, the receiver/monitor unit 104/106 is configured to alarm or notify the user, and the calibration routine is terminated.

On the other hand, if the calibration validation check is successful, the sensitivity associated with the sensor 101 (FIG. 1) is determined, and its range verified. In one aspect, if the sensitivity range check fails, again, the receiver/monitor unit 104/106 may be configured to alarm or otherwise notify the user and terminate the calibration routine. Otherwise, the determined sensitivity is used for subsequent glucose data measurement and processing (until a subsequent calibration is performed).

Referring back to the Figures, in one aspect, determination of optimal sensitivity evaluates one or more potential error sources or conditions present in blood glucose value for calibration and the potential sensitivity drift. Accordingly, using a weighted average of the current sensitivity determined for calibration and previously determined sensitivity, the sensitivity accuracy may be optimized. For example, in one embodiment, a weighted average of the two most recent sensitivities determined used for calibration may be used to determine a composite sensitivity determination to improve accuracy and reduce calibration errors. In this aspect, earlier blood glucose values used for calibration are discarded to accommodate for sensitivity drift. In one embodiment, the number of blood glucose values used for determining the weighted average, and also, the weighting itself may be varied using one or more approaches including, for example, a time based technique.

For example, for each sensor calibration routine, the sensitivity derived from the current blood glucose value from the current blood glucose test and the stored sensitivity value associated with the most recent prior stored blood glucose value may be used to determine a weighted average value that is optimized for accuracy. Within the scope of the present disclosure, as discussed above, the weighting routine may be time based such that if the earlier stored blood glucose value used for prior calibration is greater than a predetermined number of hours, then the weighting value assigned to the earlier stored blood glucose may be less heavy, and a more significant weighting value may be given to the current blood glucose value to determine the composite sensitivity value.

In one embodiment, a lookup table may be provided for determining the composite sensitivity determination based

on a variable weighting average which provides a non-linear correction to reduce errors and improve accuracy of the sensor sensitivity.

The determined composite sensitivity in one embodiment 5 may be used to convert the sensor ADC counts to the corresponding calibrated glucose value. In one aspect, the composite sensitivity determined may be used to minimize outlier calibrations and unstable sensitivity during, for example, the initial use periods. That is, during the data 10 validation routines, an outlier check may be performed to determine whether the sensitivity associated with each successive calibration is within a predetermined threshold or range.

For example, the sensor 101 (FIG. 1) may require a 15 predetermined number of baseline calibrations during its use. For a five day operational lifetime of a sensor, four calibrations may be required at different times during the five day period. Moreover, during this time period, additional stability related calibrations may be required if the 20 sensor sensitivity is determined to be unstable after the second baseline calibration is performed, for example, at the 12th hour (or other suitable time frame) of the sensor usage after the initial calibration within the first 10 hours of sensor deployment.

25 In one aspect, during the outlier check routine, it is determined whether the sensitivity variance between two successive calibrations is within a predetermined acceptable range. If it is determined that the variance is within the predetermined range, then the outlier check is confirmed, 30 and a new composite sensitivity value is determined based on a weighted average of the two sensitivity values. As discussed above, the weighted average may include a time based function or any other suitable discrete weighting parameters.

If on the other hand, the variance between the two 35 sensitivities is determined to be outside of the predetermined acceptable range, then the second (more recent) sensitivity value is considered to be an outlier (for example, due to ESA, change in sensitivity or due to bad or erroneous blood 40 glucose value), and the user is prompted to perform another fingerstick testing to enter a new blood glucose value (for example, using a blood glucose meter). If the second current sensitivity associated with the new blood glucose value is determined to be within the predetermined acceptable range 45 from the prior sensitivity, then the earlier current sensitivity value is discarded, and the composite sensitivity is determined based on applying a weighting function or parameter on the prior sensitivity value, and the second current sensitivity value (discarding the first current sensitivity value 50 which is outside the predetermined acceptable range and considered to be an outlier).

On the other hand, when the second current sensitivity value is determined to be within the predetermined acceptable range of the first current sensitivity value, but not within 55 the predetermined acceptable range of the prior sensitivity value (of the two successive calibrations described above), then it is determined in one embodiment that a sensitivity shift, rather than an outlier, has occurred or is detected from the first current sensitivity value to the second current sensitivity value. Accordingly, the composite sensitivity 60 may be determined based, in this case, on the first and second current sensitivity values (and discarding the prior sensitivity).

If, for example, the second current sensitivity value is 65 determined to be outside the predetermined range of both of the two successive sensitivities described above, then the user in one embodiment is prompted to perform yet another

blood glucose test to input another current blood glucose value, and the routine described above is repeated.

Furthermore, in accordance with another aspect, the determination of the sensitivity variance between two successive calibrations are within a predetermined acceptable range may be performed prior to the outlier check routine.

Referring to the Figures, during the period of use, as discussed above, the sensor 101 (FIG. 1) is periodically calibrated at predetermined time intervals. In one aspect, after the second baseline calibration (for example, at 12th hour of sensor 101 transcutaneously positioned in fluid contact with the user's analyte), sensor sensitivity stability verifications may be performed to determine whether, for example, additional stability calibrations may be necessary before the third baseline calibration is due. In one aspect, the sensitivity stability verification may be performed after the outlier checks as described above is performed, and a new composite sensitivity is determined, and prior to the third scheduled baseline calibration at the 24th hour (or at another suitable scheduled time period).

That is, the sensor sensitivity may be attenuated (e.g., ESA) early in the life of the positioned sensor 101 (FIG. 1), and if not sufficiently dissipated by the time of the first baseline calibration, for example, at the 10th hour (or later), and even by the time of the second calibration at the 12th hour. As such, in one aspect, a relative difference between the two sensitivities associated with the two calibrations is determined. If the determined relative difference is within a predefined threshold or range (for example, approximately 26% variation), then it is determined that the sufficient stability point has reached. On the other hand, if the relative difference determined is beyond the predefined threshold, then the user is prompted to perform additional calibrations at a timed interval (for example, at each subsequent 2 hour period) to determine the relative difference in the sensitivity and compared to the predefined range. This may be repeated for each two hour interval, for example, until acceptable stability point has been reached, or alternatively, until the time period for the third baseline calibration is reached, for example, at the 24th hour of sensor 101 (FIG. 1) use.

In this manner, in one aspect, the stability verification may be monitored as the sensitivity attenuation is dissipating over a given time period. While the description above is provided with particular time periods for baseline calibrations and additional calibration prompts for stability checks, for example, within the scope of the present disclosure, other time periods or calibration schedule including stability verifications may be used. In addition, other suitable predefined threshold or range of the relative sensitivity difference to determine acceptable attenuation dissipation other than approximately 26% may be used. Moreover, as discussed above, the predetermined calibration schedule for each sensor 101 (FIG. 1) may be modified from the example provided above, based on, for example, the system design and/or sensor 101 (FIG. 1) configuration.

Additionally, in one aspect, the user may be prompted to perform the various scheduled calibrations based on the calibration schedule provided. In the case where the scheduled calibration is not performed, in one embodiment, the glucose value determination for user display or output (on the receiver/monitor unit 104/106, for example) based on the received sensor data may be disabled after a predetermined time period has lapsed. Further, the glucose value determination may be configured to resume when the prompted calibration is successfully completed.

In a further aspect, the scheduled calibration timing may be relative to the prior calibration time periods, starting with

the initial sensor positioning. That is, after the initial transcutaneous positioning of the sensor 101 (FIG. 1) and the scheduled time period has elapsed to allow the sensor 101 to reach a certain stability point, the user may be prompted to 5 perform the first baseline calibration as described above (for example, at the 10th hour since the initial sensor placement). Thereafter, in the case when the user waits until the 11th hour to 10 perform the initial baseline calibration, the second scheduled calibration at the 12th hour, for example, may be performed at the 13th hour, so that the two hour spacing 15 between the two calibrations are maintained, and the second calibration timing is based on the timing of the first successful baseline calibration performed. In an alternate embodiment, each scheduled calibration time period may be 20 based on the timing of the initial sensor positioning. That is, rather than determining the appropriate subsequent calibration time periods based on the prior calibration performed, the timing of the scheduled calibration time periods may be made to be absolute and based from the time of the initial sensor placement.

Furthermore, in one aspect, when the scheduled calibration is not performed at the scheduled time periods, the glucose values may nevertheless be determined based on the sensor data for display to the user for a limited time period 25 (for example, for no more than two hours from when the scheduled calibration time period is reached). In this manner, a calibration time window may be established or provided to the user with flexibility in performing the scheduled calibration and during which the glucose values are determined 30 for output display to the user, for example. In one aspect, if within the calibration time window, the scheduled calibrations are not performed, the glucose values may be deemed in error, and thus not provided to the user or determined until the calibration is performed.

For example, after the initial successful baseline calibration at the 10th hour, for example, or at any other suitable scheduled initial baseline calibration time, glucose values are displayed or output to the user and stored in a memory. Thereafter, at the next scheduled calibration time period (for 40 example, at the 12th hour), the user may be prompted to perform the second calibration. If the user does not perform the second calibration, a grace period of two hours, for example, is provided during which valid glucose values are 45 provided to the user (for example, on the display unit of the receiver/monitor unit 104/106) based on the prior calibration parameters (for example, the initial baseline calibration performed at the 10th hour). However, if the second calibration is still not performed after the grace period, in one aspect, no additional glucose values are provided to user, 50 and until the scheduled calibration is performed.

In still another aspect, the user may supplement the scheduled calibrations, and perform manual calibration based on the information that the user has received. For example, in the case that the user determines that the 55 calibration performed and determined to be successful by the receiver/monitor unit 104/106, for example, is not sufficiently accurate, rather than replacing the sensor, the user may recalibrate the sensor even if the scheduled calibration time has not been reached. For example, based on a blood 60 glucose test result, if the determined blood glucose level is not close to or within an acceptable range as compared to the sensor data, the user may determine that additional calibration may be needed.

Indeed, as the sensitivity value of a given sensor tends to 65 stabilize over time, a manual user forced calibration later in the sensor's life may provide improved accuracy in the determined glucose values, as compared to the values based

on calibrations performed in accordance with the prescribed or predetermined calibration schedule. Accordingly, in one aspect, additional manual calibrations may be performed in addition to the calibrations based on the predetermined calibration schedule.

In a further aspect, user notification functions may be programmed in the receiver/monitor unit **104/106**, or in the transmitter unit **102** (FIG. 1) to notify the user of initial conditions associated with the sensor **101** (FIG. 1) performance or integrity. That is, alarms or alerts, visual, auditory, and/or vibratory may be configured to be triggered when conditions related to the performance of the sensor are detected. For example, during the initial one hour period (or some other suitable time period) from the sensor insertion, in the case where data quality flags/conditions (described above) are detected, or in the case where low or no signal from the sensor is detected from a given period of time, an associated alarm or notification may be initiated or triggered to notify the user to verify the sensor position, the sensor contacts with the transmitter unit **102** (FIG. 1), or alternatively, to replace the sensor with a new sensor. In this manner, rather than waiting a longer period until the acceptable sensor stability point has been reached, the user may be provided at an early stage during the sensor usage that the positioned sensor may be defective or has failed.

In addition, other detected conditions related to the performance of the sensor, calibration, and detected errors associated with the glucose value determination may be provided to the user using one or more alarm or alert features. For example, when the scheduled calibration has been timely performed, and the grace period as described above has expired, in one embodiment, the glucose value is not processed for display or output to the user anymore. In this case, an alarm or alert notifying the user that the glucose value cannot be calculated is provided so that the user may timely take corrective actions such as performing the scheduled calibration. In addition, when other parameters that are monitored such as the temperature, sensor data, and other variables that are used to determine the glucose value, include error or otherwise is deemed to be corrupt, the user may be notified that the associated glucose value cannot be determined, so that the user may take corrective actions such as, for example, replacing the sensor, verifying the contacts between the sensor and the transmitter unit, and the like.

In this manner, in one embodiment, there is provided an alarm or notification function that detects or monitors one or more conditions associated with the glucose value determination, and notifies the user of the same when such condition is detected. Since the alarms or notifications associated with the glucose levels (such as, for example, alarms associated with potential hyperglycemic, hypoglycemic, or programmed trend or rate of change glucose level conditions) will be inactive if the underlying glucose values cannot be determined, by providing a timely notification or alarm to the user that the glucose value cannot be determined, the user can determine or be prompted/notified that these alarms associated with glucose levels are inactive.

In one aspect of the present disclosure, glucose trend information may be determined and provided to the user, for example, on the receiver/monitor unit **104/106**. For example, trend information in one aspect is based on the prior monitored glucose levels. When calibration is performed, the scaling used to determine the glucose levels may change. If the scaling for the prior glucose data (for example, one minute prior) is not changed, then in one aspect, the trend determination may be deemed more error prone. Accordingly, in one aspect, to determine accurate and

improved trend determination, the glucose level determination is performed retrospectively for a 15 minute time interval based on the current glucose data when each successive glucose level is determined.

That is, in one aspect, with each minute determination of the real time glucose level, to determine the associated glucose trend information, the stored past 15 minute data associated with the determined glucose level is retrieved, including the current glucose level. In this manner, the buffered prior glucose levels may be updated with new calibration to improve accuracy of the glucose trend information.

In one aspect, the glucose trend information is determined based on the past 15 minutes (or some other predetermined time interval) of glucose data including, for example, the current calibration parameter such as current sensitivity. Thereafter, when the next glucose data is received (at the next minute or based on some other timed interval), a new sensitivity is determined based on the new data point associated with the new glucose data. Also, the trend information may be determined based on the new glucose data and the past 14 minutes of glucose data (to total 15 minutes of glucose data). It is to be noted that while the trend information is determined based on 15 minutes of data as described above, within the scope of the present disclosure, other time intervals may be used to determine the trend information, including, for example, 30 minutes of glucose data, 10 minutes of glucose data, 20 minutes of glucose data, or any other appropriate time intervals to attain an accurate estimation of the glucose trend information.

In this manner, in one aspect of the present disclosure, the trend information for the historical glucose information may be updated based on each new glucose data received, retrospectively, based on the new or current glucose level information, and the prior 14 glucose data points (or other suitable number of past glucose level information). In another aspect, the trend information may be updated based on a select number of recent glucose level information such that, it is updated periodically based on a predetermined number of determined glucose level information for display or output to the user.

In still another aspect, in wireless communication systems such as the data monitoring and management system **100** (FIG. 10), the devices or components intended for wireless communication may periodically be out of communication range. For example, the receiver/monitor unit **104/106** may be placed out of the RF communication range of the transmitter unit **102** (FIG. 1). In such cases, the transmitted data packet from the transmitter unit **102** may not be received by the receiver/monitor unit **104/106**, or due to the weak signaling between the devices, the received data may be invalid or corrupt. In such cases, while there may be missing data points associated with the periodically monitored glucose levels, the trend information may be nevertheless determined, as the trend information is determined based on a predetermined number of past or prior glucose data points (for example, the past 15 minutes of glucose data).

That is, in one aspect, even if there are a certain number of glucose data points within the 15 minute time frame that may be either not received by the receiver/monitor unit **104/106**, or alternatively be corrupt or otherwise invalid due to, for example, weakness in the communication link, the trend information may be determined. For example, given the 15 minutes of glucose data, if three or less non consecutive data points are not received or otherwise corrupt, the receiver/monitor unit **104/106** may determine the glucose trend information based on the prior 12 glucose data points

31

that are received and considered to be accurate. As such, the features or aspects of the analyte monitoring system which are associated with the determined trend information may continue to function or operate as programmed.

That is, the projected alarms or alerts programmed into the receiver/monitor unit **104/106**, or any other alarm conditions associated with the detection of impending hyperglycemia, impending hypoglycemia, hyperglycemic condition or hypoglycemic condition (or any other alarm or notification conditions) may continue to operate as programmed even when there are a predetermined number or less of glucose data points. However, if and when the number of missing glucose data points exceed the tolerance threshold so as to accurately estimate or determine, for example, the glucose trend information, or any other associated alarm conditions, the display or output of the associated glucose trend information or the alarm conditions may be disabled.

For example, in one aspect, the glucose trend information and the rate of change of the glucose level (which is used to determine the trend information) may be based on 15 minute data (or data based on any other suitable time period) of the monitored glucose levels, where a predetermined number of missing data points within the 15 minutes may be tolerated. Moreover, using least squares approach, the rate of change of the monitored glucose level may be determined to estimate the trend, where the monitored glucose data is not evenly spaced in time. In this approach, the least squares approach may provide an uncertainty measure of the rate of change of the monitored glucose level. The uncertainty measure, in turn, may be partially dependent upon the number of data points available.

Indeed, using the approaches described above, the trend information or the rate of change of the glucose level may be estimated or determined without the need to determine which data point or glucose level is tolerable, and which data point is not tolerable. For example, in one embodiment, the glucose data for each minute including the missing data is retrieved for a predetermined time period (for example, 15 minute time period). Thereafter, least squares technique is applied to the 15 minute data points. Based on the least squares (or any other appropriate) technique, the uncertainty or a probability of potential variance or error of the rate of glucose level change is determined. For example, the rate of change may be determined to be approximately 1.5 mg/dL/minute+/-0.1 mg/dL/minute. In such a case, the 0.1 mg/dL/minute may represent the uncertainty information discussed above, and may be higher or lower depending upon the number of data points in the 15 minutes of data that are missing or corrupt.

In this manner, in one aspect, the glucose trend information and/or the rate of change of monitored glucose level may be determined based on a predefined number of past monitored glucose level data points, even when a subset of the predefined number of past monitored glucose level data points are missing or otherwise determined to be corrupt. On the other hand, when the number of past glucose level data points based on which the glucose trend information is determined, exceeds the tolerance or acceptance level, for example, the display or output of the glucose trend information may be disabled. Additionally, in a further aspect, if it is determined that the underlying data points associated with the monitored glucose level based on which the trend information is determined, includes uncertainty or error factor that exceeds the tolerance level (for example, when there are more than a predetermined number of data points which deviate from a predefined level), the receiver/monitor

32

unit **104/106**, for example, may be configured to disable or disallow the display or output of the glucose trend information.

For example, when the 15 minute glucose data including the current glucose level as well as the past 14 minutes of glucose level data is to be displayed or output to the user, and the determined rate variance of the 15 data points exceeds a preset threshold level (for example, 3.0), the glucose trend information display function may be disabled. In one aspect, the variance may be determined based on the square function of the standard deviation of the 15 data points. In one aspect, this approach may be performed substantially on a real time basis for each minute glucose data. Accordingly, as discussed above, the glucose trend information may be output or displayed substantially in real time, and based on each new glucose data point received from the sensor/transmitter unit.

Additionally, when it is determined that the 15 data points (or any other suitable number of data points for determining glucose trend information, for example), deviate beyond a predetermined tolerance range, in one aspect, the 15 minute data may be deemed error prone or inaccurate. In this case, rather than outputting or displaying glucose trend information that may be erroneous, the receiver/monitor unit **104/106** may be configured to display the output or display function related to the output or display of the determined glucose trend information. The same may apply to the output or display of projected alarms whose estimates may be based in part, on the determined trend information. Accordingly, in one aspect, there may be instances when the projected alarm feature may be temporarily disabled where the underlying monitored glucose data points are considered to include more than acceptable levels of uncertainty or error.

In a further aspect, it is desired to determine an estimate of sensor sensitivity, and/or a range of acceptable or reasonable sensitivity. For example, during determination or verification of the glucose rate of change prior to calibration, the estimated sensor sensitivity information is necessary, for example, to determine whether the rate of change is within or below an acceptable threshold level, and/or further, within a desired range. Moreover, when determining whether the sensor sensitivity is within an acceptable or reasonable level, it may be necessary to ascertain a range of reasonable or acceptable sensitivity—for example, a verification range for the sensitivity value for a given sensor or batch of sensors.

Accordingly, in one aspect, during sensor manufacturing process, a predetermined number of sensor samples (for example, 16 samples) may be evaluated from each manufacturing lot of sensors (which may include, for example, approximately 500 sensors) and the nominal sensitivity for each lot (based, for example, on a mean calculation) may be determined. For example, during the manufacturing process, the predetermined number of sensors (for example, the 16 sensors) are sampled, and the sensitivity of each sampled sensor is measured in vitro. Thereafter, a mean sensitivity may be determined as an average value of the 16 sampled sensor's measured sensitivity, and thereafter, the corresponding sensor code is determined where the determined mean sensitivity falls within the preassigned sensitivity range. Based on the determined sensor code, the sensor packaging is labeled with the sensor code.

For example, each sensor code value (e.g., **105, 106, 107** or any suitable predetermined number or code) may be preassigned a sensitivity range (For example, code **105: S1-S2**, code **106: S2-S3**, and code **107: S3-S4**), where each sensitivity range (e.g., **S1-S2**, or **S2-S3**, or **S3-S4**) is approximately over a 10 percent increment (for example, **S1**

33

is approximately 90% of S2). Also, each sensor code (e.g., 105, 106, 107, etc.) is assigned a nominal sensitivity value (Sn) that is within the respective preassigned sensitivity range.

Referring back, when the user inserts the sensor or positions the sensor transcutaneously in place, the receiver/monitor unit 104/106 in one embodiment prompts the user to enter the associated sensor code. When the user enters the sensor code (as derived from the sensor packing label discussed above), the receiver/monitor unit 104/106 is configured to retrieve or look up the nominal sensitivity associated with the user input sensor code (and the nominal sensitivity which falls within the preassigned sensitivity range associated with that sensor code, as described above). Thereafter, the receiver/monitor unit 104/106 may be configured to use the sensor code in performing associated routines such as glucose rate of change verification, data quality checks discussed above, and/or sensor sensitivity range acceptability or confirmation.

In a further aspect, the sensor codes may be associated with a coefficient of variation of the predetermined number of sampled sensors discussed above in addition to using the mean value determined as discussed above. In one embodiment, the coefficient of variation may be determined from the predetermined number of sampled sensors during the manufacturing process. In addition, the mean response time of the sampled sensors may be used by separately measuring the predetermined number of sampled sensors which may be used for lag correction adjustments and the like.

In this manner, in one aspect, the manufacturing process control described above ensures that the coefficient of variation of the sampled sensors is within a threshold value. That is, the value of the nominal sensitivity is used to determine a sensor code, selected or looked up from a predetermined table, and that is assigned to the sensors from the respective sensor lot in manufacturing. The user then enters the sensor code into the receiver/monitor unit that uses the sensor code to determine the glucose rate of change for purposes of data quality checking, for example, and also to determine validity or reasonableness of the sensitivity that is determined.

In one embodiment a method may comprise receiving a plurality of signals associated with a monitored analyte level detected by an in vivo sensor for a predetermined time period, comparing each of the plurality of the received signals to a predefined signal range, and modifying a parameter associated with a trend information determined based on comparing the plurality of the received signals to the predefined signal range.

The plurality of signals may be substantially evenly temporally spaced within the predetermined time period.

The predefined signal range may define a valid signal range.

The trend information may be based on the plurality of signals and provide a prospective direction of the monitored analyte level.

Modifying the parameter associated with the trend information may include disabling output of the trend information.

The trend information output may be disabled when a predetermined number of the plurality of the received signals are outside the predefined signal range.

In one embodiment, an apparatus may comprise a communication unit configured to receive a plurality of signals associated with a monitored analyte level using an in vivo analyte sensor for a predetermined time period, and a data processing unit coupled to the communication unit, and configured to compare each of the plurality of the received

34

signals to a predefined signal range, and modify a parameter associated with a trend information determined based on comparing the plurality of the received signals to the predefined signal range.

5 The plurality of signals may be substantially evenly temporally spaced within the predetermined time period.

The predefined signal range may define a valid signal range.

10 The trend information may be based on the plurality of signals and provide a prospective direction of the monitored analyte level.

The data processing unit may be configured to disable output of the trend information.

15 The data processing unit may be configured to disable the trend information output when a predetermined number of the plurality of the received signals are outside the predefined signal range.

The trend information may include a projected alarm.

20 One aspect may include an output unit coupled to the data processing unit.

The output unit may be configured to present one or more of a visual, an audible or a vibratory output associated with the trend information.

25 The trend information may include a projected alarm.

The analyte sensor may be a glucose sensor.

30 In one embodiment, a method may comprise receiving a signal associated with a monitored analyte level of an individual from an in vivo analyte sensor, retrieving at least one previously stored signal associated with the monitored analyte level of the individual, determining a tolerance parameter associated with a rate of change of the monitored analyte level based on the received signal and the retrieved at least one previously stored signal, comparing the tolerance parameter to a predetermined threshold value, and generating an output data based on the result of the comparison.

35 One aspect may include retrieving the previously stored signal, which includes retrieving a predetermined number of previously stored signals associated with the monitored analyte level.

40 The tolerance parameter may include an uncertainty value associated with the rate of change of the monitored analyte level based on a least squares determination.

45 The generated output data may include a command to prevent the output of a projected alarm information when the tolerance parameter exceeds the predetermined threshold value.

50 The generated output data may include a command to prevent the output of a monitored analyte level trend information when the tolerance parameter exceeds the predetermined threshold value.

55 In one embodiment, an analyte monitoring device may comprise a processing unit configured to receive a signal associated with a monitored analyte level of an individual from an in vivo analyte sensor; the processing unit further configured to retrieve at least one previously stored signal associated with the monitored analyte level of the individual, determine a tolerance parameter associated with a

60 rate of change of the monitored analyte level based on the received signal and the retrieved at least one previously stored signal, compare the tolerance parameter to a predetermined threshold value, and to generate an output data based on the result of the comparison.

65 The processing unit may be configured to retrieve a predetermined number of previously stored signals associated with the monitored analyte level.

35

The tolerance parameter may include an uncertainty value associated with the rate of change of the monitored analyte level based on a least squares determination.

The generated output data may include a command to prevent the output of a projected alarm information when the tolerance parameter exceeds the predetermined threshold value.

The generated output data may include a command to prevent the output of a monitored analyte level trend information when the tolerance parameter exceeds the predetermined threshold value.

One aspect may include an output unit operatively coupled to the processing unit, the output unit configured to output the generated output data.

The output data may include one or more of a graphical display, a text display, an audible output, or a vibratory output.

Various other modifications and alterations in the structure and method of operation of this invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. It is intended that the following claims define the scope of the present disclosure and that structures and methods within the scope of these claims and their equivalents be covered thereby.

What is claimed is:

- 1.** A glucose monitoring device, comprising:
 - a data communication unit comprising a RF transmitter, the data communication unit configured to wirelessly receive sensor data generated by an in vivo glucose sensor when the sensor is positioned in contact with biofluid under a skin surface of a user, the sensor data being indicative of a monitored glucose level of the user and one or more uncertainty indicators corresponding to uncertain conditions detected during measurement;
 - one or more memories configured to store the received data;
 - a data processing unit comprising one or more processors, the data processing unit operatively coupled to the data communication unit and the one or more memories, the data processing unit configured to:
 - obtain the monitored glucose level from the sensor data;
 - determine one or more data points over a period of time based on the sensor data and the one or more uncertainty indicators;
 - determine an uncertainty parameter using a number of the uncertainty indicators received over the period of time; and
 - determine glucose trend information corresponding to the monitored glucose level when the uncertainty parameter indicates that the number of the one or more uncertainty indicators received over the period of time are less than a predetermined amount; and
 - one or more output units of the glucose monitoring device configured to output one or more notifications upon detection of one or more alarm conditions associated with the one or more uncertainty indicators exceeding a predetermined threshold level.
- 2.** The device of claim 1, wherein the biofluid is interstitial fluid.
- 3.** The device of claim 1, wherein the data communication unit is configured to wirelessly receive the sensor data

36

corresponding to the monitored glucose level using a communication protocol, the communication protocol comprising at least one of an RF communication protocol, an infrared communication protocol, an 802.11x wireless communication protocol, or an IEEE 802.15.4-based protocol such as ZIGBEE transmission protocol.

4. The device of claim 1, wherein the one or more uncertainty indicators comprise one or more missing or unavailable values in one or more data fields of the sensor data.

5. The device of claim 1, wherein the data processing unit is configured to postpone determining the glucose trend information when the one or more uncertainty indicators are less than the predetermined amount.

6. The device of claim 1, wherein the in vivo glucose sensor comprises a plurality of electrodes including a working electrode comprising a glucose-responsive enzyme bonded to a polymer disposed on the working electrode.

7. The device of claim 6, wherein the glucose-responsive enzyme is chemically bonded to the polymer disposed on the working electrode.

8. The device of claim 6, wherein the working electrode comprises a mediator bonded to the polymer disposed on the working electrode.

9. The device of claim 8, wherein the mediator is cross-linked with the polymer disposed on the working electrode.

10. The device of claim 1, wherein the one or more output units are configured to, upon detection of the one or more alarm conditions, output the one or more notifications concurrent to execution of a predetermined routine, wherein the predetermined routine is a process by the data processing unit that is ongoing at the time of detection of the one or more alarm conditions.

11. The device of claim 1, wherein the one or more output units are configured to, upon detection of the one or more alarm conditions, output the one or more notifications concurrent to execution of a predetermined routine and output one or more notifications after a termination of the predetermined routine, wherein the predetermined routine is a process by the data processing unit that is ongoing at the time of detection of the one or more alarm conditions.

12. The device of claim 1, wherein the one or more output units are configured to, upon detection of the one or more alarm conditions, output the one or more notifications indications after a termination of the predetermined routine, wherein the predetermined routine is a process by the data processing unit that is ongoing at the time of detection of the one or more alarm conditions.

13. The device of claim 1, wherein the one or more notifications, associated with the one or more corresponding alarm conditions, are assigned and viewed with different priorities in a predetermined notification hierarchy structure.

14. The device of claim 1, wherein the determination of the one or more data points over the period of time is further based on at least one calibration factor from a calibration event.

15. The device of claim 1, wherein the one or more uncertainty indicators comprises a rate variance of the one or more data points.

16. The device of claim 1, wherein the one or more uncertainty indicators comprises a number of the one or more data points deviating beyond a predetermined tolerance range.

17. The device of claim 1, wherein the one or more notifications are disabled.

37

18. A glucose monitoring system, comprising:
 an in vivo glucose sensor configured to be positioned in contact with biofluid under a skin surface and to generate sensor data, the sensor data being indicative of a monitored glucose level and one or more uncertainty indicators corresponding to uncertain conditions detected during measurement;
 a transmitter unit operatively coupled to the in vivo glucose sensor to receive the sensor data; and
 a receiving device communicatively coupled to the transmitter unit, the receiving device comprising:
 a data communication unit comprising a RF transmitter, the data communication unit configured to wirelessly receive the sensor data;
 one or more memory memories configured to store the sensor data; and
 a data processing unit comprising one or more processors, the data processing unit operatively coupled to the data communication unit and the one or more memories, the data processing unit configured to:
 determine the monitored glucose level from the sensor data;
 determine one or more data points over a period of time based on the sensor data and the one or more uncertainty indicators;
 determine an uncertainty parameter using a number of the one or more uncertainty indicators received over the period of time;
 determine glucose trend information corresponding to the monitored glucose level when the uncertainty parameter indicates that the number of the one or more uncertainty indicators received over the period of time are less than a predetermined amount; and
 one or more output units of the receiving device configured to output one or more notifications upon detection of one or more alarm conditions associated with the one or more uncertainty indicators exceeding a predetermined threshold level.

19. The system of claim **18**, wherein the biofluid is interstitial fluid.

20. The system of claim **18**, wherein the data communication unit is configured to wirelessly receive the sensor data corresponding to the monitored glucose level using a communication protocol, the communication protocol being one of an RF communication protocol, an infrared communication protocol, or an 802.11x wireless communication protocol, or an IEEE 802.15.4-based protocol such as ZIGBEE transmission protocol.

21. The system of claim **18**, wherein the one or more uncertainty indicators comprise one or more missing or unavailable values in one or more data fields of the sensor data.

22. The system of claim **18**, wherein the data processing unit is configured to postpone determining the glucose trend

38

information when the one or more uncertainty indicators are less than the predetermined amount.

23. The system of claim **18**, wherein the in vivo glucose sensor comprises a plurality of electrodes including a working electrode comprising a glucose-responsive enzyme bonded to a polymer disposed on the working electrode.

24. The system of claim **23**, wherein the glucose-responsive enzyme is chemically bonded to the polymer disposed on the working electrode.

25. The system of claim **23**, wherein the working electrode comprises a mediator bonded to the polymer disposed on the working electrode.

26. The system of claim **25**, wherein the mediator is crosslinked with the polymer disposed on the working electrode.

27. The system of claim **18**, wherein the one or more output units are configured to, upon detection of the one or more alarm conditions, output the one or more notifications concurrent to execution of a predetermined routine, wherein the predetermined routine is a process by the data processing unit that is ongoing at the time of detection of the one or more alarm conditions.

28. The system of claim **18**, wherein the one or more output units are configured to, upon detection of the one or more alarm conditions, output the one or more notifications concurrent to execution of a predetermined routine and output one or more notifications after a termination of the predetermined routine, wherein the predetermined routine is a process by the data processing unit that is ongoing at the time of detection of the one or more alarm conditions.

29. The system of claim **18**, wherein the one or more output units are configured to, upon detection of the one or more alarm conditions, output the one or more notifications indications after a termination of the predetermined routine, wherein the predetermined routine is a process by the data processing unit that is ongoing at the time of detection of the one or more alarm conditions.

30. The system of claim **18**, wherein the one or more notifications, associated with the one or more corresponding alarm conditions, are assigned and viewed with different priorities in a predetermined notification hierarchy structure.

31. The system of claim **18**, wherein the determination of the one or more data points over the period of time is further based on at least one calibration factor from a calibration event.

32. The system of claim **18**, wherein the one or more uncertainty indicators comprises a rate variance of the one or more data points.

33. The system of claim **18**, wherein the one or more uncertainty indicators comprises a number of the one or more data points deviating beyond a predetermined tolerance range.

34. The system of claim **18**, wherein the one or more notifications are disabled.

* * * * *